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Family history, reproductive factors, hormonal exposures, and subjective immunohistochemical evaluations of in situ lesions, and to a lesser extent age, remain the best clinical
predictors of an individual’s risk of developing breast cancer. Identification of early markers
predictive of impending invasive breast cancer from in situ carcinoma is a long-term goal. The
latent mammary cancer transgenic mouse model of human breast cancer, C57BL/6JTg(WapTAg)1Knw (Waptag1), develops characteristic stages of tumorigenesis in a highly
predictable manner: atypical hyperplasia advances to ductal carcinoma in situ (DCIS), which
progresses to papillary adenocarcinomas and/or solid, invasive tumors. Microarray analyses of
whole mammary glands and tumors across these stages, to detect transcriptional changes
throughout tumorigenesis, revealed marked, phased stage-specific changes. In contrast, results
from the laser capture microdissected tumor cells depict a moderately constant characteristic
tumorigenic profile, irrespective of stage. Evaluation of differences in whole glands with those of
microdissected samples suggests that paracrine signaling between tumor and stromal cells
substantially alters the tumor microenvironment, early in progression. Strikingly, comparison of
statistically significant microarray results between Waptag1 DCIS and human DCIS revealed 2,097
overlapping early transcriptional changes. When compared with species-specific controls, common
abundant early gene alterations were associated with cell cycle, cell division, and DNA replication
Gene Ontology categories, with a notable decrease in genes involved in aerobic energy
metabolism, and significant increased transcription of retrotransposons and chromosome

modification genes. Based on these initial experimental results, retrotransposons were identified
as a potential marker for testing in several mouse models and in biopsies derived from breast
cancer patients. Analysis of data from five independent mouse models of mammary cancer and
five human breast cancer datasets revealed over expression of retrotransposons, mainly Class I
and Class II LTR elements, as well as LINEs and SINEs, when compared with normal samples.
Cross-species comparison of gene expression profiles suggests epigenetic alterations and
chromatin remodeling changes coincide with retrotransposon over expression. Through validation
of such mutual human and mouse changes in gene expression, these novel putative markers may
allow earlier detection and therapeutic intervention, possibly reducing the incidence of invasion and
metastases in patients with breast cancer.
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Chapter 1
INTRODUCTION
1.1. Tumor Progression
Within a conducive environment, malignant cells arise as a consequence of multiple germline
and somatic mutations over time. As cells accumulate mutations, they clonally expand1 until a
significant population of neoplastic cells results in a detectable lesion7-10. Progression from the
primary lesion to invasive and/or metastatic cancer requires additional molecular changes,
including loss of cell-cell adhesion, access to the blood stream, ability to embolize, and a
microenvironment favoring growth at the distant site. Several classical ‘Hallmarks of Cancer’ are
considered the minimum requirements for progression: growth signaling independence;
resistance to anti-growth signals; escape from apoptosis; continuous angiogenesis; uncontrolled
replication/division; tissue invasion/metastasis11. A seventh hallmark of cancer, deregulation of
metabolic pathways, has also been proposed as a necessity for tumorigenesis12-20,21. Dysfunction
of over a dozen tumor suppressor genes and activation of numerous oncogenes and their related
pathways are associated with cancer. Although the initiation, mechanisms and pathways may
differ among cells, tissues, and species it is the acquisition of specific combinations of capabilities
within tumor cells (or in the surrounding stroma) which characterizes cancer as a life-threatening
disease.
1.2. Human Breast Carcinogenesis
Environmental factors, genetic, genomic, and epigenetic alterations are all possible causes of
cancer. Identification of early indicators of impending invasive breast cancer from carcinoma in
situ biopsy material is one of the current challenges facing the research community. Despite
technological breakthroughs and numerous research discoveries made over the last 30 years, the
best predictors of a woman’s risk of developing breast cancer remain family history, reproductive
factors, and hormonal exposure, as well as age, to a lesser extent. Poor prognosis for human
breast cancer has been based on lymph node assessment and subjective immunohistochemical
evaluation of molecular changes in biopsied samples: for example, lack of estrogen receptor
expression (ER-); abundant epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia
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viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (ERBB2/HER2/NEU)
expression (HER2+); lack of tumor suppressor p53 (TP53); and expression of the
myelocytomatosis (MYC) oncogene. At the transcript level, the following genes are frequently
down-regulated in human cancers, to initiate, promote, and/or enhance tumorigenesis: tumor
suppressors, such as TP53 or retinoblastoma (RB1); cyclin dependent kinase, CDKN2A (also
known as p19/INK4A); adenomatosis polyposis coli (APC); and phosphatase and tensin homolog
(PTEN). However, a ‘one gene at a time’ approach, based on results from developed tumors,
does not sufficiently predict whether an early lesion will become invasive. To identify and validate
potentially valuable markers for early pre-cancer progression, detection methods have to be
affordable and easy to perform. Earlier detection and diagnosis of pre-malignant lesions and
carcinoma in situ, may prevent the high incidence of progression to invasive cancer and
subsequent metastases.
Large scale gene expression profiles have provided valuable genetic markers of carcinoma in
situ, invasive and non-invasive human breast cancers, and predictors of relapse/recurrence and
metastases. However, such studies are challenging in human patients because of difficulty in
obtaining samples at early stages of tumorigenesis, insufficient quantities of quality samples, and
the heterogeneity of each specimen, especially among genetically diverse ethnic populations with
unique environmental surroundings. The majority of human breast cancer studies focus on
advanced tumors, with only a few analyses of in situ stages of breast carcinogenesis22-34.
In the last six years, at least two independent laboratories have developed panels for analysis
of 14-76 human transcripts predictive of clinical prognosis, based on gene expression analyses,
in an attempt to offer more personalized diagnosis and an affordable, less-subjective evaluation
of human breast cancer35-37. In fact, two of these, OncoTypeDXTM, an RT-PCR platform, and
MammaPrintR, a microarray-based platform, are commercially available to clinicians38-40.
However, markers to predict whether carcinoma in situ of the breast will progress to invasive
cancer or metastatic disease are lacking. Furthermore, the underlying cause for some women
with ductal carcinoma in situ to suffer relapse after surgery, while others do not, requires years of
investigation and remains largely unknown. For these reasons, identification of early changes
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that may be predictive of progression to invasion in mouse mammary tumorigenesis, with followup in human carcinogenesis, is the ultimate goal of this thesis research.
1.3. The Experimental Hypothesis
The foundation of this thesis is based on the hypothesis that a reliable early marker of
tumorigenesis is epigenetic deregulation of retrotransposons and their robust transcriptional
activation within the early stages of tumor progression in mouse and human mammary cancers.
To investigate this hypothesis, a comprehensive survey of retrotransposon expression was
undertaken using microarray data from a mouse model of mammary cancer, Waptag1. Whole
mammary glands and tumors or microdissected epithelial tumor cells from lesions of DCIS and
mammary tumors taken from multiparous Waptag1 females were compared with control whole
glands or microdissected C57BL/6J normal mammary cells, respectively. Target sequences from
all microarray platforms were interrogated for retrotransposons. Additionally, an investigation of
retrotransposons in tumors in five mouse models of mammary cancer, as well as in five datasets
from human hyperplasia, in situ carcinoma and breast cancer, was performed by in silico mining
of publicly available expression data, to compare with results from Waptag1.
1.4. Mouse Models of Mammary Cancer
Although no one mouse model completely recapitulates all aspects of any subtype of human
breast cancer, genetically engineered mice that model important aspects of human cancers are
invaluable. Mouse models assist in the elucidation of pathways involved in normal development
and disease, discovery of novel markers for eelier detection of cancer and as potential candidates
for diagnostic trials, and efficacy testing of new targeted therapeutics. Several laboratories have
developed key mouse models to facilitate the study of mammary cancer41-56. The bulk of this
thesis will detail primarily one mouse model, Waptag1, however, several mouse models were
utilized to a lesser extent as well and therefore, they will briefly be discussed below.
FVB/N-Tg(WapMyc)212Bri/J (Myc) hemizygous transgenic mice, containing the
myelocytomatosis oncogene (c-myc), driven by the whey acidic protein promoter, develop
mammary tumors (of several histotypes) at about 6 months of age in mated females55. Virgin
female Myc mice develop mammary tumors around 250 days, median 8.3 months of age
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(Fancher K et.al., future publication), and lung metastases are observed in about 20% of all
females55 (Fancher K et.al., future publication). Among several mammary tumor types observed
in Myc mice, the glandular carcinoma with epithelial to mesenchymal transition (EMT) provides a
unique mouse model of EMT, a feature observed in human breast cancer as well57. Human
tumors with EMT show genomic amplification of MYC58. Myc transgenic mice provide a system
to study late-stage mammary tumor progression in a well characterized mouse model.
FVB.Cg-Tg(Wnt1)1Hev/J, or Wnt1 transgenic mice contain the wingless-related MMTV
integration site 1 (Wnt1 or int-1) oncogene driven by the mouse mammary tumor virus (MMTV)
promoter. WNT1 is a secreted protein and a ligand for frizzled receptors. Several Wnt signaling
pathways have been discovered and are current subjects of active research. Wnt1 was first
discovered as a proto-oncogene when it was the target of MMTV insertion into the genome59; the
retrovirus MMTV integration enhanced Wnt1 expression within the mammary gland epithelial cells
and subsequently mammary tumors developed42. Wnt1 transgenic mice develop early
hyperplasia through late tumor progression including metastases60,61. Similar to Myc mice, Wnt1
virgin females can develop mammary tumors, but parous females present tumors with a shorter
latency60,62. Tumors appear as early as 90 or as late as 210 days of age in hemizygous females,
with a median age of death at 133 days of age in virgin females60,62 and (Fancher K et.al., future
publication).
Neu transgenic mice [FVB/N-Tg(MMTVneu)202Mul/J], express an unactivated, wild-type rat
Neu gene in the mammary glands, salivary glands, thymus, spleen, and lungs. Neu, also known
as ErbB2 and HER2, is a member of the epidermal growth factor receptor family of type I receptor
tyrosine kinases (RTKs). NEU phosphorylation leads to aberrant increased RTK activity,
primarily within the mammary glands, which ultimately results in metastatic mammary cancer.
The median age of tumor onset is 205 days with 72% of mice showing lung metastases at about
8 months of age44,45. Amplification of HER2/ERBB2/NEU occurs in ~25% of human lymph nodepositive breast cancer and is correlated with undesirable nuclear grade63-65.
In Trp53 mutant mice [FVB.129S2(B6)-Trp53tm1Tyj/J], the targeted mutation deletes exons 2-6
of the endogenous mouse Trp53 gene and replaces it with a neomycin cassette, thereby creating
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a null allele41. Although Trp53 null mice develop lymphomas, heterozygous knockout (+/-)
females regularly develop mammary tumors at approximately 300 days of age 41. When Trp53
(+/-) mice are combined with another transgenic mouse mammary tumor model, double mutant
mice exhibit accelerated tumor onset and shortened life span, compared with single transgenics
(Fancher K et.al., future publication and66-72). TP53 is the most frequently mutated gene in breast
cancer and, indeed, in most human cancers67,73.
PyMT mice [FVB/N-Tg(MMTV-PyVT)634Mul], containing the oncogenic polyoma virus middle
T-antigen driven by the MMTV long terminal repeat, also develop early hyperplasia through late
tumor progression, including a high percentage of metastatic tumors43. Virgins, breeders, and
males present with multiple mammary adenocarcinomas as early as 35 days of age43. The PyMT
transgene enhances phosphatidylinositol 3-kinase pathway signaling, which eventually leads to
uncontrolled cell cycling74.
C57BL/6J-Tg(WapTAg)1Knw (Waptag1) mice, which express the early region of Simian Virus
40 Tumor-antigen (SV40 Tag), under the control of the whey acidic protein (WAP) promoter
within the genetically-defined C57BL/6J inbred background50, were chosen as a model system for
this study. The hormone-responsive WAP promoter drives expression during late pregnancy
through mid lactation, coincident with endogenous WAP expression75, in the mammary gland
luminal epithelial cells in Waptag150. Waptag1 parity-induced tumors develop late in the life of
multiparous females, allowing for evaluation of early stages of cancer progression: atypical cells
appear in visually normal mammary tissue and multiple stages of ductal carcinoma in situ (DCIS)
progress into mammary tumors of one or more histological subtypes. Histologically, Waptag1
early DCIS and papillary adenocarcinomas resemble human DCIS and human papillary breast
tumors50. Genetically, two of the most common genes mutated in human breast cancer, TP53
and RB173, would be predicted to show abrogated function in Waptag1. Similarly, two other
human cancer genes, FBW7 a member of the ubiquitination apparatus76, and a mitotic spindle
checkpoint protein, BUB177, should show similar altered expression in Waptag1 females.
Cytogenetically, genomic instability, including aneuploidy which is frequently seen in human
breast cancer is a consequence of SV40 tumorigenesis78. Chromosomes 9 and 16 are frequently
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deleted in SV40 Tag-induced mouse tumors; these regions are syntenic with human
chromosomes 3p21, 3q, 6q12, 15q24, and 22q, several of which undergo deletion in human
cancers79,80.
Extrintistic factors, such as transgene integration site, genetic background, and copy
number, can dramatically affect SV40-transgene tumorigenic phenotype. In sharp contrast to
homozygous Waptag1 multiparous females, which develop mammary tumors around 12 months
of age, hemizygous virgin or mated females generated from the same construct (WAP-SV-T on
the outbred NMRI genetic background), show earlier tumor onset46-48. In addition, the WAP-SV-T
females are unable to suckle or feed their young46-48. Female mice from a second founder line
from the Knowles laboratory, [C57BL/6J-Tg(WapTAg)3Knw/J, Waptag3], did not suckle their
pups, or routinely develop mammary tumors. Instead, Waptag3 males and females developed
osteosarcomas of the os petrosum, as well as adrenal adenocarcinomas at about 6 months of
age50. Together these findings suggest the WAP promoter may be leaky and that transgene
integration site and environmental dissimilarities can change the rate and location of tumor
formation. Additionally, variation in transgene copy number and genetic background undoubtedly
play a role in the phenotypic differences among these three strains.
1.5. In Situ Carcinoma Studies in Vivo
One of the primary goals of these experiments was to characterize ductal carcinoma in situ,
(DCIS) in mouse models as it has been a limited area of study. Although over-expression of
Wnt1 is not a common occurrence in human breast carcinogenesis, the MMTV-Wnt1 mouse
model has been used to investigate universal transcriptional changes in DCIS42,61. The MMTVPyMT mouse model develops an early onset DCIS, which rapidly progresses to multiple
mammary tumors43, which may hinder characterization of the early stages. Some transgenic
mouse models expressing SV40 Tumor antigen in the mammary gland epithelial cells develop
DCIS that progresses to multiple mammary tumors, which resemble stages of human breast
carcinogenesis46-50,78. Each model, developed independently from the same construct and
characterized on different genetic backgrounds, offers unique opportunities for in vivo studies of
DCIS and progression to invasive cancer. Unfortunately, only one of these models is well
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described and publicly available, C57BL/6J-Tg(WapTAg)1Knw. The Waptag1 mouse model
(detailed within) has been extensively characterized using histology50 and microarray analysis.
Here, Waptag1 changes during tumor progression have been compared directly with those of
human DCIS with progression to invasive cancer (Chapter 4). Finally, although previously used
to study metastatic progression, mouse models which offer inducible and reversible oncogene
activation may be useful early models in the future as well81-84.
1.6. SV40 Tumor Antigen (SV40 Tag)
Transgenic mouse models that over express oncogenes, such as Simian Virus 40 Tumor
Antigen (SV40 Tag), provide a means to study multiple stages of tumor progression within
genetically-defined inbred backgrounds. Numerous mouse models exploit the oncogenic
potential of different SV40 Tag regions providing the research community with models of human
cancers, including osteosarcomas, insulinomas, hepatocellular carcinoma, kidney and choroid
plexus tumors, lymphomas, mesotheliomas, mammary carcinoma, and others (for review85).
Simian Virus 40 is a member of the Polyomaviridae family of DNA viruses; its natural host is
the rhesus macaque monkey, where it lives in kidney cells for an indefinite length of time. The
virus was first discovered as a contaminant of the poliovirus vaccine when ‘vacuolar cytopathatic
changes’ were seen in cultures of African green monkey cells86. A short time later, two groups
revealed that injection of SV40 produced tumors in newborn hamsters87,88. Consequently, SV40
Tag oncoproteins have been shown to induce a wide variety of neoplasms.
The early region of SV40 Tag encodes three unique proteins: Large Tag (708 amino acids
[aa]), small tag (174 aa) and 17K, the mini-tag (135 aa). SV40 Tag is capable of transforming
host cells through the actions of two of its early proteins, Large Tag and small tag, although the
contribution to transformation of 17K tag remains largely undefined. Large Tag and small tag
proteins bind a plethora of host cell proteins, altering their normal function, either through
inhibition or stimulation. Three SV40 Large Tag domains (J, Rb, and Trp53) and one additional
small tag domain (Pp2a), as well as the proteins which bind those SV40 Tag domains, are
involved in transformation; the requirement of domains depends upon cell type, environment,
and/or genetic background. In some systems, the N-terminal 127 amino acids of SV40 Tag were
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sufficient for transformation and progression to hepatic or pancreatic tumorigenesis89-92, implying
that the C-terminal, Trp53 domain was not required in these cell types.
SV40 Tag binds to and stimulates HSPA8 activity. All three SV40 Tumor antigen proteins
function as co-chaperone DNA J proteins and bind the DnaK chaperone HSPA8 (formerly
HSC70), a homolog of heat shock protein 7090,93. Binding of SV40 Tag’s N-terminal J-domain to
HSPA8 is ATP-dependent and stimulates HSPA8’s ATPase activity94. Following activation,
conformational changes occur (in HSPA8, SV40 Tag and the bound substrate) which permit
chaperone activities such as: protein folding/unfolding, protein transport (import/export of host
cell proteins across ER and mitochondrial membranes), and dissociation of multimeric protein
complexes, such as E2F- RBL2 (formerly p130)95. In summary, SV40 Tag’s J domain- HSPA8
complex is essential for transformation, viral DNA synthesis, and activation of transcription90. The
SV40 Tag-HSPA8 complex promotes additional transformation events: 1) association of
retinoblastoma family proteins with SV40 Tag96; 2) phosphorylation and degradation of
substrates90; 3) inhibition of apoptosis97.
SV40 Tag binds the retinoblastoma family proteins to inactivate them. Retinoblastoma (RB)
family members, RB1, RBL1 (p107) and RBL2 (p130), normally form a complex with transcription
factors such as E2F, MYOD1, PAX3, and ABL1 (c-Abl), repressing their transcriptional activation
capabilities. In the presence of ATP, the SV40Tag-RB and SV40Tag-HSPA8 protein complexes
disrupt RBL2-E2F, and RBL1-E2F associations. This liberates E2F to activate transcription of
target genes which promotes cell cycle progression, DNA synthesis/replication, and nucleotide
metabolism77,95. In addition, SV40 Tag simultaneously blocks the activity of tumor suppression
genes, such as Trp53, at a molecular level.
SV40 Tag complexes with TRP53, inhibiting its normal functions: 1) to act as a gate-keeper
and prevent cell cycle progression during conditions of DNA damage, synthesis of viral DNA, or
other genotoxic stress; 2) activate genes involved in cell cycle regulation, DNA repair, metabolism
and apoptosis. SV40 Tag proteins inhibit Trp53-mediated activities in multiple ways, including
several pathways independent from direct TRP53 binding98,99. Although the mechanism is
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currently unknown, SV40 Tag proteins can inhibit apoptosis and override Trp53-mediated growth
suppression98-101.
CREBBP and EP300 proteins associate with SV40 Tag to either inhibit or stimulate their
function. The proteins EP300 (formerly p300) and cyclic AMP-response element binding protein
(CREB-Binding Protein, CREBBP or CBP), are structurally and functionally similar; both function
as transcriptional co-factors and acetyltransferases; either protein can bind to TRP53 to enhance
its transcriptional activation, through acetylation of TRP53 and/or histone acetylation at the
promoter of Trp53-mediated genes77,102,103. CREBBP also acetylates SV40 Tag at lysine 697
(K697) in a TRP53-independent manner90,103,104. Thus, acetylation of SV40 Tag may promote or
disrupt its associations with other host proteins thereby affecting protein stability, localization,
interactions with other proteins, and/or interactions with DNA during chromatin remodeling.
The cellular consequence of SV40 Tag binding to CREBBP/EP300 proteins is currently an
unresolved issue. It is not clear if SV40 Tag binding to CREBBP/EP300 proteins inhibits or
stimulates normal function. Some researchers suggest that the SV40 Tag-EP300 association is
inhibitory; Tag alters EP300’s phosphorylation state, rendering it inactive, especially its TRP53mediated co-activation of transcription90,104,105. Others suggest that SV40 Tag increases
CREBBP’s acetyltransferase activity, enhancing it for its own viral needs103,106, such as increasing
E2F-mediated transcriptional activation. SV40 Tag may bind different family members (EP300,
CREBBP, or EP400), one to inhibit, another to stimulate; post-translational modifications may
influence binding with SV40 Tag with CREBBP/EP300 proteins.
SV40 binds host cell proteins, such as FBW7, CUL7, BUB1, and NBS1 to inhibit their normal
function. Fbw7, F-box and WD-40 domain protein 7, archipelago homolog (Drosophila), is a
human tumor suppressor and a member of the ubiquitination apparatus. When bound by SV40
Tag, FBW7 is relocalized to the nucleoplasm, thereby inhibiting the degradation of proteins
needed for cell cycle progression76. CUL7/p185/p193 is part of the E3 ubiquitin ligase complex
and is part of a scaffold complex that marks no-longer needed proteins for degradation by the
proteosome. SV40 Tag inactivates FBW7 and CUL7 to promote growth, probably through
increasing the longevity of proteins, resulting in enhanced transformation and tumorigenesis104.
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Bub1, budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae), encodes a mitotic
spindle checkpoint protein, and is found mutated in human colorectal cancer and leukemia77. The
SV40 Tag-BUB1 interaction may contribute to SV40 Tag-induced transformation, aneuploidy,
and/or genomic instability107. Alongside MRE11A and RAD50, Nijmegen breakage syndrome
protein 1 (NBS1) forms the MRN complex involved in double-strand break repair. The SV40 TagNBS1 association reinitiates DNA replication regardless of the need for DNA repair, thereby
contributing to genomic instability77,108.
SV40Tag binds SP1, enhancing its activity. Sp1 encodes stimulating protein 1, a
ubiquitously expressed transcription factor that binds the GC-box motif within the promoters of
many genes. The SV40 Tag-SP1 complex may enhance Sp1-mediated transcriptional
activation109.
SV40 Tag supports other functions, needed for its own viral replication, which may enhance
transformation towards tumorigenesis, such as the following: 1) ATPase activity, which provides
energy for DNA unwinding; 2) helicase activity, for unwinding (or rewinding) DNA; 3)
transactivation of promoters to supply needed molecules for entry into S phase, such as Ccna1
and Ccna2, as well as those for cell cycle progression; 4) loose transactivation of Pol I, II, and
III77,85.
SV40 small t-antigen (tag) binds to and inhibits PP2A. Protein phosphatase 2a, encoded by
the Pp2a gene, is a trimeric protein complex whose normal function is to phosphorylate and
inactivate kinases (and other proteins) involved in cell cycle and mitotic checkpoints, apoptosis,
signal transduction, and cytoskeletal organization110-113. SV40 tag inhibits PP2A’s phosphatase
activity, which leaves kinases, such as PRKACA/PKA, MAPK1/ERK, AKT1, PIK3/PI3K,
MAP2K1/MEK1, as well as the Na+/H+ antiporter SLC9A1, and BCL2 constitutively
activated110,111,113. The SV40 tag/PP2A complex promotes increased cell migration and cell
spreading via increased paxillin in the cell110,113. Taken altogether, the SV40 tag-PP2A
interaction contributes to tumorigenesis through constitutive activation (via lack of deactivation) of
kinases, cell cycle proteins, and apoptotic factors.
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SV40 is not naturally found in the human population, to our knowledge. However, some
percentage of Americans were accidentally infected with live SV40 virus in their polio
vaccinations in the 1960s (for review 85). Moreover, the effects of SV40 Tag oncoproteins mimic
many aspects of human cancers: continued activation of SV40 Tag over time results in at least
three major cancer phenotypes. First, loss of cell cycle and mitotic checkpoints (due to SV40
Tag’s association with TRP53, RB1, BUB1, NBS1, and PP2A) leads to uninhibited and
autonomous growth77,85,90,102,107,110-115. Second, loss of initiation of at least one apoptotic pathway
and anti-apoptotic signals (through SV40 Tag’s interaction with TRP53 and PP2A) results in
survival of abnormal cells97-102,110,111,113,114. Third, loss of a DNA repair mechanism (via NBS1 and
TRP53) leads to genomic instability107,108. Finally, sequestering of ubiquitination machinery
(CUL7 and FBW7) by SV40 Tag prevents degradation of critical proteins76,104,116, and recruitment
of transcriptional co-activators (HSPA8, SP1, CREBBP/EP300) enhances the aforementioned
effects90,103-106,109. In summary, the many functions of SV40 Tag proteins ultimately cause cancer
with many features that imitate human cancers characteristics.
1.7. Chromatin Remodeling, Retrotransposons and Cancer
Deregulation of gene expression is an early step in neoplastic transformation. Given the
close link with chromatin structure and operation, it is not surprising that abnormal expression of
many cellular genes goes hand in hand with epigenetic changes, such as DNA methylation and
histone modifications. Dysfunction of chromatin remodeling processes coupled with aberrant
gene expression and genomic instability are contributing factors in cancer.
Uncharacteristic DNA methylation patterns are frequently associated with malignancy in
humans117. Both genomic DNA hypomethylation and hypermethylation have been causally linked
with carcinogenesis. For example, targeted mutant mice hypomorphic/null for Dnmt1, develop
thymic lymphomas at 4-8 months of age and display chromosomal aberrations, suggesting that
genome-wide hypomethylation can lead to tumor formation118. On the other hand, the CpG island
within Sfn, a gene encoding a cell cycle checkpoint regulator 14-3-3 σ, is hypermethylated and
silenced in human breast cancer119. Thus, the effect of DNA methylation on oncogenesis can
depend on locus-specific factors as well as the global DNA methylation status.

11

Generally, histone modifications, such as acetylation or demethylation are associated with
open chromatin structure, allowing transcriptional apparatus access to the underlying DNA.
Conversely, heterochromatin is associated with silenced DNA, due to histone H3 tri-methylation
at lysine 9 (tri-meH3K9); moreover, mono-, di-, or tri-methylation at K9 may trigger methylation of
the associated DNA, which then may recruit histone deacetylases, resulting in hypoacetylated
lysines along histone tails120. In mammals, the histone methyltransferases SUV39H1/SUV39H2
are responsible for tri-meH3K9; this modification is recognized by heterochromatin protein
chromobox homolog 5 (CBX5/HP1 or other chromobox family member), which binds to
SUV39H1/SUV39H2 and recruits DNA methyltransferases, such as DNMT3B, that methylate the
cytosine within CpG dinucleotides121. Subsequently, methylated cytosines cause the methyl
binding protein MECP2 to bind to DNA and together with a DNMT3 family member, recruit
histone deacetylases (such as HDAC1) to histones H3 and H4122.
When considering both active and inactive chromatin modifications, histone tails contain
lysines which may be methylated, ubiquitinated, or acetylated and phosphorylatable threonines
and serines. In addition to mono-, di-, or tri-methylation at K9, H4 tri-methylation at K20 occurs
independently via SUV420H2 methyltransferase, and this epigenetic modification is thought to be
directed by CBX5 (formerly HP1), rather than CBX5 being recruited first123. Phosphorylation at
serine 10 of histone H3 by the mitotic aurora B kinase (AURKB), which occurs during M phase of
the cell cycle, results in the dissociation of CBX5 from heterochromatin, but leaves tri-meH3K9
unaltered (see below)124,125. Serine phosphorylation-induced blocking of CBX5 binding has also
been identified in linker histone variant H1.4, in which methylated K26 binds CBX5, but
subsequent phosphorylation of S27 inhibits CBX5 binding126. Finally, many lysines are flanked by
a serine or threonine, suggesting that this mechanism of control may be even more diverse than
previously thought127,128.
The current model of protein-DNA interactions and histone modifications is as follows:
locally, if there is no promoter CpG methylation, nor MECP2 family member, HDAC, or inhibitory
protein complex bound, then transcription factor complexes, containing histone acetyltransferases
can bind to promoters (containing their consensus motif), acetylate lysines along histone H3 and
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H4 tails, which allows a more open chromatin formation such that the ‘holo’ RNA Pol II complex
may bind and initiate transcription. Genes expressed in one system but repressed in another,
such as the estrogen receptors (Esr1/Esr2) and Hoxd4, provide examples of local active or
inactive chromatin states129,130. Alternatively, others theorize that initially global opening of
chromatin occurs (i.e. within open chromatin fibers) and then local epigenetic modifications, such
as histone acetylation, are necessary for gene transcription131-133.
Repetitive sequences, such as retrotransposons (or transposable elements), are generally
located within regions of heterochromatin and therefore normally are transcriptionally silenced by
epigenetic mechanisms, such as DNA and histone methylation, and deacetylation of
histones120,134-136. A few reports detail the methylation status of retrotransposons in cancer,
however, evidence for this as a pre-malignant occurrence is lacking. Thus, elevated expression
of transposable elements in cancer may reflect alterations in the epigenetic backbone of the
genome. Elevated levels of retrotransposon expression are found in a number of human cancers
and are often associated with genomic rearrangements. Gene deletions, amplifications,
conversions, or translocations as well as disruption of normal gene function may be a
consequence of homologous recombination at retrotransposon ‘hot spots’137.
Retrotransposons are a distinct type of very abundant, repetitive genetic elements able to
propagate themselves within a genome and are ubiquitous components of genomes in most
eukaryotic organisms. In mammals, 40-50% of genomes consist of retrotransposons or their
‘remnants’, i.e. phylogenetically older insertions no longer capable of propagation138,139. Although
they are transcribed by the host cell, their mode of propagation is through an RNA-intermediate,
which is reverse transcribed and integrated into the genome, thus increasing their copy number.
Approximately one-tenth of retrotransposons resemble retroviruses in that they are flanked by
Long Terminal Repeats (LTRs), while the majority of retroelements are non-LTR
retrotransposons, Long and Short Interspersed Nuclear Elements (LINEs and SINEs)139. LINEs
contain two open reading frames and the ability to retro-transpose, unlike SINEs which are ‘nonautonomous’ and may transpose and integrate using the protein machinery of LINEs, or rarely,
other elements. Some LTR retrotransposons, such as endogenous retroviruses, are closely
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related to, and originate from infectious retroviruses; however, most LTR retrotransposons have
evolved to be non-infectious parasites. One distinction between certain transposable elements is
their preference for GC-rich genomic regions (SINEs) or GC-poor locations (LINEs and LTR
elements)140. Endogenous LTR retroviruses usually contain genes which encode: 1) the viral
particle (gag gene) in which reverse transcription takes place; 2) the enzymes protease,
integrase, and reverse transcriptase (pol gene); 3) the envelope (env) gene, often mutated or
absent in endogenous retroviruses, which facilitates infection of a neighboring cell; as well as
additional regions including, a primer binding site, (used by the virus to begin reverse
transcription), leader sequence, (non-translated region downstream of the transcription start site,
present at the 5' end of all virus mRNAs), polypurine tract, a short run of (~10) A/G residues for
initiating (+) strand synthesis during reverse transcription. The internal coding region is flanked
by 5' and 3' LTRs: a U3 region, which contain promoters (including transcription factor binding
sites) and enhancers (including hormone response elements) to further their expression; a
terminally redundant Repeat (R) region; and a U5 region, a unique, non-coding region, first part of
the genome to be reverse transcribed, forming the 3' end of the provirus genome. Three
different classes of LTR retrotransposons have been described in mice. LTR Class I family
members (e.g. the murine leukemia virus, Mlv1) contain all three gag, pol and env genes flanked
by LTRs. Many members of the Mlv1 family are defective due to deletions with pol and/or env
genes. Without sequencing of individual insertions, it is difficult to determine whether these LTR
Class I retroviruses are defective or not. LTR Class II retrotransposons, such as the intracisternal
A particle (Iap) contain gag and pol genes between their 5' and 3' LTR sequences, whereas early
transposon element 1 (Etn1) genes lack functional enzymatic genes but contain normal LTR
sequences. LTR Class III retrotransposons contain normal LTRs and may or may not have pol
genes; the mammalian apparent non-autonomous LTR retrotransposon (MaLR) family members,
specifically MTs or mouse transcripts, are examples of Class III elements. Most transposable
elements are able to propagate within the DNA of cells under the appropriate conditions, such as
when a cell’s means to suppress viruses/double stranded RNA/heterochromatin has been
compromised.
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Dysfunctional molecules involved in RNA interference might affect unsilencing of
transposable elements. RNA interference, RNAi, suppresses target sequences
(retrotransposons, repetitive sequences, viruses, and other elements) through formation of
double-stranded RNA (dsRNA), which ultimately triggers silencing. Initially, when endogenous
retrotransposons are transcribed, it is in both sense and antisense directions, which then results
in formation of dsRNA141. In mammals, dsRNA is processed to 21-26-nucleotide-long sense and
antisense fragments by an endoribonuclease III, DICER1, to produce small interfering RNAs
(siRNAs). Next, together with a member of the Argonaute family of translation initiation factors,
an RNA-dependent RNA polymerase (RdRP), a helicase, and the rest of RISC, RNA-induced
silencing complex, the siRNAs target complementary mRNAs for degradation. RNAi is functional
in plants, worms, flies, mice, and humans, although the enzymes involved may differ among
organisms.
RNAi machinery operates similarly for microRNAs (miRNAs), functioning as a posttranscriptional mechanism to regulate gene expression. One notable difference is that miRNAs
predominantly bind to the 3' untranslated region of mRNAs. Whereas siRNAs are gene-specific,
miRNAs are cis-acting regulatory sequences that bind to numerous transcripts to regulate entire
groups of genes. Like expression of gene transcripts, expression of miRNAs may be cell-type
specific and their up-regulation or down-regulation effects the protein levels of their targets.
Several key genes aid in miRNA production: RNASEN (formerly DROSHA) and the
microprocessor complex with DGCR8 cleave pri-miRNAs to form pre-miRNAs that are exported
out to the nucleus by XPO5, exportin 5. Once in the cytoplasm, cleavage by DICER1 results in
the functional, mature miRNA, which can bind with the RISC complex (a similar mechanism to
siRNAs) to repress translation and/or cleave target mRNA molecules (for review, see142). Upand down-regulation of different miRNAs is associated with human diseases, including cancer
and metastases (see143-147 for reviews of miRNAs in various diseases). Moreover, transcription or
repression of miRNAs may be regulated by DNA methylation and/or modifications to histone tails
(for review see148). Thus, it may be a combination of mechanisms by which retrotransposons are
transcriptionally activated and associated with open chromatin, genes are deregulated, mutations
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occur without repair, cells escape apoptosis, chromosomes exhibit genomic instability, and
ultimately uninhibited growth favors progression of tumorigenesis to invasion.
A causal relationship between carcinogenesis and integration of endogenous retroviruses is
well established. De novo insertions of LTR class I, murine leukemia virus 1 (Mlv1), has been
shown to activate the myelocytomatosis oncogene (Myc or c-Myc), proviral integration site 1
(Pim1), or lymphocyte protein tyrosine kinase (Lck) genes leading to development of lymphomas
in mice149. Insertional mutagenesis by Mouse Mammary Tumor Virus (MMTV) and subsequent
activation of the following: fibroblast growth factor 3 (Fgf3, formerly Int2); Notch gene homolog 4
(Notch4/Int3); eukaryotic translation initiation factor 3, subunit E (Eif3e, formerly Int6); or
wingless-related MMTV integration site 1 (Wnt1), leads to mammary carcinoma149-151. Insertional
gene activation by a LTR class II elements, intracisternal a particle (Iap), results in mammary
carcinoma, lymphoma and myeloid leukemia in mice152,153. To date, no relationship between LTR
class III retrotransposons and carcinogenesis has been described, although these elements drive
alternative transcripts and expression of many genes in oocytes and cleavage stage embryos154.
Insertional mutations due to LINE1 elements result in human breast cancer, hemophilia A, and
Duchenne muscular dystrophy155-157. Similarly, a novel insertion of the SINE element Alu results
in aberrant splicing of the E74-like factor 3, Elf3, gene in human breast cancer and cell lines158;
this gene has been shown to be over expressed in human DCIS and breast cancer159. Recently,
increased numbers of SINEs in close proximity of a gene was shown to be proportional to the
deregulation of that gene’s expression in tumors160. Based on these findings and other data,
several laboratories are utilizing retroviral insertional mutagenesis strategies as a cancer gene
discovery tools and to generate new mouse models161-165, or for review166,167.
LTR class II elements, Human Endogenous RetroVirus (HERV)-H, HERV-K, and their splice
variants, are up-regulated in breast, ovarian, colon and testicular cancers; leukemia; germ cell
tumors; and tumor cells lines when compared with normal tissues168-171. In ovarian cancer,
HERV-W expression increased four-fold, and LINE1 element increased fifty-fold when compared
with non-malignant ovarian controls172. In prostate cancer, HERV-E was found to be highly
expressed and similarly, HERV-F was overly active in a variety of cancer cell lines173,174. In five
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human DCIS samples from breast biopsy, HERV-K env expression was up-regulated six- to
twenty-fold compared with normal controls168. Thus, it is possible that over expression of HERV
env could be used as an early indicator of malignant transformation in early ductal carcinoma in
situ. A thorough evaluation of transposable elements across many mouse models as well as
human breast cancer and carcinoma in situ will clarify whether elevated expression of
retrotransposons may serve as a useful marker for detection of early alterations in tumorigenesis.
1.8. Statistical Microarray Analysis
The most important aspect of microarray analysis is proper experimental design to permit
accurate, reliable, and consistent data collection that form the basis of scientific interpretation.
Sufficient sample size, multiple levels of replication, and randomization techniques throughout will
simplify analysis of the data by ensuring enough degrees of freedom (see definition below) to
perform statistical tests, providing a specified level of confidence in the results, avoiding and/or
reducing biases which can lead to skewed interpretation of the data. Another important concept
is that statistical tests are performed only on samples from the true population. Therefore, all of
the estimates are approximations for the population, based on the samples.
There are many sources of error that need to be adequately addressed in the experimental
and technical design of microarray experiments. There is biological variation (i.e. mouse to
mouse differences), technical variation due to RNA extraction, cDNA synthesis, labeling,
hybridization, as well as scanning and gridding of the array spots with two-color arrays, and array
variation (array to array and within array variation, such as non-uniformity, spatial heterogeneity,
dust, scratches, print-tip problems, etc.) In addition, with two-color microarray experiments, there
can be dye variation (Cy3 versus Cy5), which can be decreased by using a dye-swap or loop
experimental design or eliminated with single-color arrays. Thus, the first task is to decrease
and/or stabilize the variance in the microarray experiment as much as possible by utilizing the
following criteria: 1) several samples per sample ‘group’ or ‘treatment’ (biological replicates); 2)
multiple arrays per sample and/or numerous spots for each gene per array; 3) quality control tests
and appropriate data transformation. Reducing the variation increases the power (i.e. the
probability of detecting true differential gene expression) in a microarray experiment. In addition
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to design considerations, the appropriate statistical test needs to be applied to the dataset to yield
useful results.
One statistical test common in microarray experiments is the analysis of variance
(ANOVA). ANOVA is a method of conducting statistical tests to determine differences among
samples within and across treatments. It offers a level of confidence in the results that cannot be
achieved by direct comparison alone. ANOVA utilizes the inherent variation in the each individual
value across samples as well as the variance among samples within each treatment. The
ANOVA model separates the total variance into multiple components, each of which can be
treated as either fixed or random effects. In a fixed ANOVA model, only one source of variation is
used to calculate the test statistics. However, if there is more than one source of random
variation in the model, then the mixed ANOVA model offers a method to treat additional
components as random effects, (i.e. if the population was sampled again, these components
would show similar, but not identical effects)175.
For microarray data, R/MAANOVA (MicroArray ANalysis Of VAriance, in R) provides relative
differential gene expression levels, which are both statistically and biologically significant175.
R/MAANOVA is a software package used to analyze a wide variety of microarray data. It
provides a list of statistically significant genes with an associated level of confidence, rather than
merely a fold-change in the expression of a particular gene between two samples. Initially, two
models are developed, a null model: no differential gene expression (i.e. the variation in the
mean expression (log transformed) of a gene across samples is zero) and an alternative model:
there is differential gene expression (i.e. that variation does not equal zero). As an example, a
reference dye-swap design can be used to demonstrate the ANOVA model for a two-color
microarray experiment. A reference dye-swap involves each mouse tumor sample and a
standard reference be put on two arrays. On the first array, one sample is labeled with Cy3, while
the reference is labeled with Cy5 and then dyes are swapped for the second array, using another
aliquot of the same sample and reference. As mentioned above, this design reduces the
variation due to dye effects and adds another level of technical replication. The ANOVA model
for two-color array experiment, in which each gene is fit to the following model, is
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yij = μ + Ai + Dj + Rh + Mk + Tl + εij

Equation 1

where, yij = log2 of the signal intensity for any given gene, μ= mean expression level for that gene,
Ai = array effect, Dj = dye effect, Rh = for the reference, Mk = mouse effect, i.e. the variation from
mouse to mouse, Tl = treatment effect for that gene, and εij = the residual175-177. In a mixed
ANOVA model, μ, Dj, Rh, Tl and Gm are treated as fixed effects and Ai, Mk, and εij are random
effects175,176. Random effects are estimated using restricted maximum likelihood (REML, a
means to approximate components in a mixed ANOVA linear model)178 and used to compare
treatments.
For single-color Affymetrix array experiments, where one mammary tumor sample, for
example is placed onto a single array, the following model is fit for every gene:
yij = μ + αi + βj + Tk + εij

Equation 2

where, yij = log2 of the signal intensity for any given gene, μ = mean expression intensity, αI =
effect of the probe (for which there are several probes per gene), βj = effect of the array, Tk =
treatment effect for that gene and εij = the residual error176,179. Since only one sample per mouse
was put onto an array, the array and mouse effect are completely confounded, and no mouse
term is included in the model. The fixed ANOVA model is most frequently used for Affymetrix
datasets, since, aside from the residual, the only additional random effect would be array (βj) and
that has only a minute influence on the test statistic, so array becomes part of the residual error
component175,176.
As shown in the equations above, R/MAANOVA utilizes the variation of each gene across
samples (but also within and across treatments) to determine statistically significant expression
differences. R/MAANOVA calculates the expression level of each gene in a sample relative to its
weighted average across all samples. Since microarray data error variances may not be normally
distributed, or their distribution may be unknown, for hypothesis testing or to determine
significance thresholds and confidence intervals, randomization techniques are employed.
Unless the sample size is very large, the method used is shuffling of the residuals (the difference
between the observed value and the fitted value according to the null model); R/MAANOVA then
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computes p-values (the probability of getting such an extreme result if the null hypothesis is true)
as well as confidence intervals (estimates of the true values for the population, that show the
variance and/or precision of those estimates). By conducting permutations – ‘shuffling the data’ across genes, the magnitude and distribution of gene expression differences can be simulated.
For comparison of two sample groups a t-test (test statistic) or pairwise comparison is
often used because it compares the mean expression levels between two treatments, utilizing the
variance within each treatment (within group variation) separately (unless otherwise stated). In
R/MAANOVA, inference methods for the test statistic are based on the t-distribution (assuming a
normal distribution of the population from which the samples came) with modified degrees of
freedom due to non-equal variances180. The degrees of freedom in an experiment depend upon
how many ‘things’ can fluctuate freely in the model175; in the simplest situation, if you are only
estimating one factor, it is one less than the number of samples. Determining the degrees of
freedom becomes more complicated when estimating error across many treatments. Using the
log-ratios of the expression levels, for each gene (one at a time), the t-test utilizes the inherent
within group variation, i.e. between mice within one sample group, for both treatments, to
estimate the variation within the experiment and calculate significant expression levels.
Therefore, if the within group variation is high within one treatment, R/MAANOVA may
underestimate the number of statistically significant genes between treatments. Since only two
treatments are being compared in a t-test, the variation across treatments cannot be utilized, like
ANOVA accomplishes, therefore for large datasets, contrasts are preferred over t-tests.
A contrast is a method used for comparisons ranging from a simple pair-wise comparison to
a comparison between two averages of treatment means or a comparison of one treatment mean
against the average of all treatment means for the experiment. Furthermore, in some instances
weighed averages may also be incorporated181. Like ANOVA, contrasts utilize the within as well
as across treatment variation, to determine statistically significant genes. For simple pairwise
comparisons, a contrast integrates information across all treatments and samples, while only
calculating the expression values and the error associated with the two treatments of interest.
For example, for 6 treatments, many different contrasts could be designed to compare them.
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However, suppose that treatments 1&2 are similar (but not quite the same), while treatments 4&5
are also similar, but differ from treatments 1&2, and that comparing treatments 3&6 are not
relevant. Using planned contrasts, treatments 1&2 can be compared to treatments 4&5, without
calculating each pair-wise comparison individually, but while utilizing all the variation. For this
contrast, the null hypothesis would be that the average of each of the two groupings (1&2 vs.
4&5) will be same (i.e. the difference between them will be zero), whereas the alternative
hypothesis is that the mean averages will be different (i.e. the difference does not equal zero).
Contrasts offer more power than a standard t-test comparison.
The R/MAANOVA software offers orthogonal contrasts as part of the function ‘matest’ in
which the user may specify a matrix for comparison of the treatment term. For the above
example, zero represents a treatment that is NOT in the contrast, 1 is used for the first half of the
comparison and -1 for the second half of the comparison. Therefore, the contrast would be
1,1,0,-1,-1,0 in which treatments 1&2 are given a value of 1 and treatments 4&5 are given a value
of -1. In R/MAANOVA contrasts greatly reduce the amount of preparation time needed to set up
all pairwise comparisons among treatments. Instead, a contrast matrix can be called to retrieve
as many as 14 contrast results with one ANOVA test.
The F-test, a generalization of the t-test statistic, is used for analysis of more than two
groups of samples. It detects differences among sample means (and treatments) by evaluating
the sample variation within and among different treatments. Inference procedures for F-tests are
gene-specific, rely on the models, and are calculated using the residual sum of squares (i.e. the
sum of the square of the residuals, see above) and associated degrees of freedom. Significance
levels are derived from the F-distribution (or permutation techniques). There are two primary Fstatistics for either the fixed or mixed ANOVA model with the common F-test essentially the same
as the F1 test below, which follows an F-distribution. The other F-test has an unknown
distribution and therefore permutation tests are performed. Using an approximation of the
variance within an experiment, the confidence intervals are calculated: F1, which estimates
gene-specific error variance; Fs, which uses a James-Stein shrinkage estimator to compute the
gene-specific variances and does not make any assumptions about constant error variances176.
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Unlike F1, which uses only gene-specific variances, the Fs test utilizes the data across genes as
well, in order to attain more powerful estimates176.
The recent R/MAANOVA algorithms used to compute the Fs statistic have several
advantages: the most consistent results, despite permutation test stochasticity, better variance
histograms than F1 tests, and very manageable gene lists (due to the shrinkage estimator).
Therefore, the Fs statistic is the most suitable test-statistic for microarray analysis176 and was
used for all analyses in which raw data was available.
When thousands of genes are tested, resulting in thousands of hypothesis tests, the
problem of multiple testing becomes evident: there will be a large number of false-positives
among the true statistically significant results due to random chance. This yields a situation
called a Type I error or ‘false-positive error’, which indicates a gene is considered differentially
expressed and rejects the null hypothesis although it is not truly significant. The other error,
Type II error, occurs when a gene that is truly differentially expressed is not detected as
significant, which is also known as a false-negative error. Hypothesis testing in a microarray
experiment typically attempts to control for type I error, achieving a certain power (see above;
also defined as one minus the probability of a type II error), depending on the sample size and
experimental design. There are two primary ways to address the problem of multiple testing,
Family-Wise Error Rate (FWER) and False-Discovery Rate (FDR) adjustments to the test
statistics, both of which increase the level of confidence in detecting true differential gene
expression.
Hypothesis testing with a family-wise error rate (FWER) adjustment gives the probability of
producing one or more false-positive (type I) errors based on all of the statistical tests
performed175. There are multiple FWER adjustments: 1) the Bonferroni correction, simply divides
the significance value by the number of hypothesis tests performed; 2) the Westfall and Young
one-step adjustment method takes into consideration that test statistics may not be
independent182. FWER adjustment sets a level of significance for all tests in the experiment,
regardless of the comparison(s) made; it is very strict and therefore offers a high level of
confidence that the list of differentially expressed genes does not contain false-positives.
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However, this adjustment may be associated with a loss of statistical power and may be too
stringent to detect smaller changes, which may be biologically important. Therefore, FDR is the
more sensible way to handle ‘multiplicity of testing’ when analyzing microarray data.
The false discovery rate (FDR) modification to the test statistic supplies a post-data level of
confidence in the results. FDR adjustment establishes the proportion of type I (false-positive)
errors according to the total number of null hypotheses rejected (i.e. differentially expressed
genes). Therefore, with FDR control, the number of false-positives expected is based on the
estimated number of differentially expressed genes, not on the number of tests performed (like
FWER). FDR type of control allows a certain number of ‘errors of inference’ in order to gain
better sensitivity and more power than the rigid FWER adjustment183. Thus, FDR improves the
power, utilizes the number of differentially expressed genes (post ANOVA), and allows detection
of smaller changes between treatments, even when the sample size is small184. In R/MAANOVA,
the FDR-adjustment of the Fs statistic is performed using pooled permutation p-values to produce
the q-values184,185.
1.9. Summary
Putative early markers of DCIS which were predictive of invasion, currently lacking in human
carcinogenesis, were identified through this thesis research. Using whole gland and
microdissected samples taken throughout the lifespan of the Waptag1 mouse model of human
breast cancer, microarray analyses were used to uncover early transcriptional changes
associated with tumor progression. Comparison of Waptag1 gene expression profiles with those
of human DCIS reveals the following early alterations: genes involved in cell cycle, cell division,
and DNA replication are up-regulated predominantly within tumor cells; chromatin modification
transcriptional changes coincide with retrotransposon over expression; the most efficient form of
energy derivation, electron carrier activity, is dysfunctional. Genes in these categories may
provide potential markers of human DCIS, predictive of invasion, to perhaps reduce invasion and
metastatic spread in patients with breast cancer.
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Chapter 2
MATERIALS AND METHODS
2.1. Mice and Samples
2.1.1. Mice
Multiparous females of C57BL/6J-Tg(WapTAg)1Knw (Waptag1; JAX® Mice stock# 003188,
The Jackson Laboratory, Bar Harbor, ME) or age- and parity-matched C57BL/6J controls (B6;
JAX® Mice stock# 000664) were housed in cages with pine shavings and free access to water
and food (6% fat NIH PMI Mills) on a photoperiod of 12:12 (lights on 06:00) with a male until 6-11
months of age. Females were continuously mated in pairs or trios at 6 weeks of age and first
litters were weaned approximately 6 weeks later. Virgins, single and dual pregnancy females
failed to develop consistent, predictable mammary tumors. Therefore, only females that
sustained a minimum of three pregnancy and lactation cycles were retired at monthly intervals (611 months) and group housed until their mammary glands were collected (no sooner than 3
weeks post-wean to insure adequate time for mammary gland involution). Non-lactating glands
were collected from Waptag1 females which had not sustained three pregnancies at 4 and 5
months of age; these were Waptag1 ‘normal’ controls. Mice were euthanized by cervical
dislocation before their tumors reached ~10mm in size, according to approved Institutional Animal
Care and Use Committee protocols. Briefly, each tumor-bearing mouse was monitored three
times weekly by checking for changes in tumor size or appearance and the mouse’s behavior and
mobility. If changes appeared that would result in discomfort to the mouse, it was euthanized.
The Jackson Laboratory’s Animal Care and Use Committee (ACUC) summary for Dr. Barbara
Knowles (#01011, ACUC summary name: Cell Cycle Control), was amended and approved for
this research.
2.1.2. Whole mammary tumors and glands
Immediately following euthanization, ~90% of each gland or tumor was removed under
aseptic conditions and dissected into 8mm3 pieces in RNAlater (Ambion, Inc., cat. no. 7021),
while the remainder was fixed in Telly’s (Fekete’s acid-alcohol-formalin) or Bouin’s for histology.
All samples for RNA were left at room temperature for 3-6 hours to allow the RNAlater to
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penetrate the tissue, kept overnight at 4oC, and stored at -20oC until RNA extraction and
purification (TRIzol reagents) according to the manufacturer’s protocols (Invitrogen Life
Technologies, cat. no. 15596018). RNA concentration and purity was determined
spectrophotometrically and RNA was stored at -70oC until cDNA/cRNA preparation (First-Stand
cDNA Synthesis, Superscript III, Invitrogen). Following reverse transcription with Superscript III
(Invitrogen) and an oligo(dT)-T7 primer, in vitro transcription with a T7 RNA Polymerase (Ambion)
and biotinylated nucleotides (Enzo Diagnostics) created the labeled cRNA that was hybridized to
the Affymetrix chips (see below).
2.1.3. Cryopreserved tumors and mammary glands
Immediately following euthanization, samples were collected following aseptic technique and
cryopreserved in Optimal Cutting Temperature (OCT) compound using 2-methyl butane, chilled
by liquid nitrogen. Ten slides of eight micron cryosections were cut from each mammary gland or
tumor using a cryostat (kept at–40o to –20oC). Serial cryosections were mounted on ten
nuclease-free, plus glass slides. For histological classification, slides one and six were stained
with hematoxylin and eosin, while the remaining eight slides were stored at -80oC until laser
capture microdissection was performed.
2.1.4. Laser Capture Microdissected Samples
For each mammary cryoblock, serial cryosections were cut (at eight to twelve microns thick)
and mounted onto ten nuclease-free, plus glass slides. For histological classification, slides one
and six were stained with Hematoxylin and Eosin (H&E), while the remaining eight slides were
stored below -80oC until time of laser capture. H&E was only used for histological identification of
stages of tumor progression, as this was not optimal for staining tissues when downstream
applications required good quality RNA. Although it did not allow identification of cells of atypia
(see Figure 3.1), a toluididine blue-based nuclear stain was chosen to facilitate identification of
epithelial cells from stromal, muscle, or fat cells within the cryosections. The resolution of the
microscope was not optimal (at 40x) to distinguish subtle differences, such as atypical versus
normal epithelial cells; however, training and practice allowed recognition of the appropriate cells
of normal B6, ductal carcinoma in situ (DCIS) and tumors (as shown in Figure 2.1). Variations in
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thickness of the cryosections, high fat cell content of the whole mammary glands, and faulty LCM
caps further complicated cryosectioning, staining, and/or isolation of specific epithelial cells.
Even with these obstacles, sufficient amplified RNA, from laser-captured cells across three
biological replicates per stage of tumor progression was obtained. For each sample histologically
defined as advanced DCIS (AdvDCIS), cells were captured across multiple slides, but only from
one area of AdvDCIS per sample, i.e. if one region of DCIS was used from slide 2, then that
same AdvDCIS would be used from slides 3 and 4, to obtain the ~100 cells desired. Since
regions of early DCIS (EDCIS) were substantially smaller and dispersed more thinly than in
AdvDCIS glands, multiple regions of EDCIS were collected per slide in order to achieve sufficient
numbers of cells, within the time constraint. Figure 2.1 shows representative sections from each
of the stages of Waptag1 tumor progression: areas of EDCIS (Figure 2.1.A-E), AdvDCIS nodules
(Figure 2.1.F-I), papillary adenocarcinomas (Figure 2.1.J-L), and solid, invasive tumors (Figure
2.1.M, N), as they appeared before, during and/or after LCM. Because LCM only picks up the top
layer of cells, thicker sections showed cells remaining after initial laser capture (Figure 2.1.D). In
these instances, the slide was moved slightly and the region with cells remaining was pulsed with
the laser a second time to remove all the cells of DCIS.
Figure 2.1. Laser Capture Microdissection (LCM) Images. A) Early DCIS lesion (Female 3991, R4
mammary gland) before LCM; B) same Early DCIS after initial collection of cells and cap was removed;
C) LCM cap containing about 15 cells of Early DCIS; D) H&E stained section of Advanced DCIS lesion,
Female 6460, L2 mammary gland; E) same Advanced DCIS before LCM; F) same Advanced DCIS after
cap was removed; G) LCM cap containing about 30 cells of Advanced DCIS; H) H&E stained section of
Papillary adenocarcinoma, Female 4549, L2 mammary tumor; I) same Papillary tumor, before LCM; J)
LCM cap containing about 25 Papillary tumor cells; K) Solid, invasive tumor, Female 4545, R1 mammary
tumor; L) same Solid tumor, after LCM, with cells removed; M) Isolation of single tumor cells, under
textbook conditions: ideal thickness of the tissue section for model staining and capture; an optimal LCM
cap, which rested perfectly on the surface of the glass slide; laser with the precise focus and voltage
pulsed directly on the cells of interest; 9 cells are shown. [Magnification: 40x(A-C, G,I,J, M); ±40x(DF,K,L); 4x(H). HistogeneTM, toluididine blue stain (Arcturus Bioscience, Inc.), unless otherwise stated.
Abbreviations: H&E, hematoxylin and eosin; DCIS, ductal carcinoma in situ.]
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Figure 2.1. Continued.

Single slides were removed from the freezer, one at a time, fixed in 75% ethanol, stained,
dehydrated and dried for 15 minutes (HistogeneTM LCM Frozen Section Staining Kit, Arcturus)
immediately preceding LCM. A longer drying time was used to completely evaporate the xylene.
For isolation of RNA, no sample was extended more than a 90-minute window of time at room
temperature, from removal from the freezer through to extraction of the cells for RNA.
Approximately 100 epithelial cells were isolated per sample using the PixCellR IIe LCM System at
the following settings: laser spot size, 7.5µm; pulse power, 80-100mW; pulse width, 0.80ms; and
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threshold voltage, 180-220mV, depending upon thickness of the section. Following LCM, the film
was peeled from the cap and cells were lysed in 50 microliters extraction buffer (XB) for 20
minutes at 42oC (PicoPureTM RNA Extraction Kit, Arcturus). After incubation, the film was swirled
around in the tube using forceps, flicked to remove any remaining buffer, and then discarded;
extracted cells were stored in extraction buffer at -70oC. RNA was extracted, purified, and
linearly amplified according to protocols (PicoPureTM RNA Extraction Kit and RiboAmpTM RNA
amplification Kit, Arcturus). Following amplification, RNA quality was assessed using a 2100
Bioanalyzer instrument and RNA 6000 Nano LabChip assay (Agilent Technologies); good quality
amplified RNA was hybridized to microarray chips.
2.2. Microarrays
Two color microarrays were initially used, primarily for detection of retrotransposons, within
unknown and/or unannotated clones. However, single-color Affymetrix (Affy) arrays offer many
advantages over traditional two-color glass slide arrays. Affy arrays are uniquely synthesized in
silico using photolithographic masks. Each target sequence (gene) on the array is represented
by a ‘probe set’, consisting of more than 3 different 25-mer oligonucleotides per gene (perfect
matches) and 1 mismatch per perfect match. The advantage of this technology is that a single
gene is being interrogated by a ‘probe set’, thereby reducing sequence-dependent factors, nonspecific background effects, error and variance.
2.2.1. Mouse
Two-color microarrays (Toronto, Ontario, Canada) were hybridized with cDNA from Waptag1
whole tumors or whole gland samples, or control C57BL/6J glands. These NIA microarrays
feature 60mer oligonucleotide probes which encompass most of the NIA 15K clone set, allowing
for discovery of unknown elements (http://lgsun.grc.nia.nih.gov/cDNA/15k.html)186. The
experimental design was a reference dye-swap177; each cDNA sample was hybridized against the
Stratagene Universal Mouse Reference using Cy5 (sample) and Cy3 (reference), then a second
aliquot of the same sample & reference were labeled with dyes swapped. The cDNA
hybridization, scanning, & gridding, were performed as described187. Briefly, samples were
hybridized in pairs at 42oC for about 18 hours, then washed and dried before scanning with
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GenePix 4000B (Axon Instruments) scanner. Although raw mean-intensity data was adjusted
with and without background subtraction, the background- subtracted median-intensity values
were used for subsequent data analysis.
Single-color Affymetrix GeneChipR Mouse Genome 430 v2.0 (Affy) microarrays were used for
the majority of the experiments. The Affy 430 v2.0 arrays include alternative transcripts and
unknown sequences as part of their repertoire for a total of 16K to 39K transcripts, depending on
pre-processing (see below). Biotinylated cRNA from one sample was hybridized per Affy chip
according to manufacturer’s protocols (Affymetrix, Inc.) A streptavidin-phycoerythrin biotinylated
anti-streptavidin antibody tagged the sample and slides were washed, stained and dried prior to
scanning at high resolution (GeneChipR Scanner 3000, Affymetrix) for detection of a single
fluorophore. The raw image data (.CEL files) were obtained for statistical analysis.
2.2.2. Human
Human Dataset1 breast cancer data from samples enriched in DCIS (27 samples) or Invasive
Breast Cancer (IBC; 24 samples) was received from Drs. D. Craig Allred and Sangjun Lee
(Washington University, St. Louis, MO) as .CEL files; samples were run on the Affymetrix (Affy)
U95Av2 human gene chips. Normal human breast data, Human Dataset2 was downloaded from
the Gene Expression Omnibus [GEO; http://www.ncbi.nlm.nih.gov/geo/; Acc# GDS2250] as .CEL
files; seven samples were run on Affy U133plus2.0 gene chips188. Human Datasets3-5, were
downloaded from GEO for independent analysis of the prognostic value of genes mutual to early
stages of tumor progression in Waptag1 and human37,189,190.
2.3. Statistical Experimental Design and Analysis
Numerous distinct experiments, three mouse and eight human datasets were analyzed
during this thesis research and will be described briefly below. At least three biological replicates
were used for every stage of Waptag1 tumorigenesis, each mouse mammary tumor model, or
controls, to capture, utilize, and potentially reduce the inherent biological mouse variation. For
the NIA 15K and the Compugen two-color microarrays, a reference dye-swap design was utilized.
Since Affy arrays are single color, no dye-swap design was available, without using two arrays for
every sample; therefore, technical variation was integrated into the overall error in the model.
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2.3.1. NIA 15K two-color microarrays (Waptag1 only)
To reduce error in the model as much as possible, four data quality checks were performed in
R statistical program, which, depending on the quality of the raw data, led to removal of ‘bad’
spots. A natural log transformation of the data insured that the sources of variation (error) would
be additive. Using either a fixed model, which embraces the variation between biological
replicates, or a mixed model, which treats that variation as a random effect, we fit the data to the
model and completed the statistical analysis. Using the pooled permutation p-values from the Fs
statistic of the fixed model (unless otherwise stated), we determined which genes were
statistically significant at p≤0.05. The Fs test adds a shrinkage estimation to the variance that
takes into account both gene-specific error and common error across all genes176. The result is a
list of statistically significant genes. Although a multiple test correction was used for ANOVA
analysis across all stages of tumorigenesis (q≤0.01), due to the small differences between
adjacent stages of Waptag1 tumor progression (as well as no genes significant at the less
stringent q≤0.1 threshold), we chose no FDR-adjustment (p≤0.05), with the understanding that
false positives were not taken into account in the pair-wise comparisons, however, subtle gene
expression changes could be uncovered.
2.3.2. Affy one-color microarrays (Waptag1 or human)
For each of the three different Affy arrays (430 v2.0 mouse, U95Av2 human, and
U133plus2.0 human) the raw image data (.CEL files) were imported into R/MAANOVA for
separate preprocessing. Pre-processing and normalization (including mean-centering) of the
data was performed using RMA, Robust Multivariate Analysis191, and the appropriate cdf file (see
details below). With many sequences interrogating each gene, we collapsed the probe set data
using the University of Michigan Brain Array method (UMBA cdf)192 resulting in just over 16,000
unique genes. For evaluation of retrotransposons and other repetitive elements only, the Affy
annotation {http://www.affymetrix.com/support/technical/byproduct.affx?cat=arrays} method (Affy
cdf) was used for pre-processing. Using both the Affy and UMBA cdf files to collapse the probe
set data resulted in two gene lists for every analysis. Data was next filtered and control spots
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(except GAPDH) were removed prior to analysis. For the two different human microarrays, only
the subset of common genes was used for further analysis.
Using R/MAANOVA177 we fit the data to the fixed model and completed the statistical
analysis, using the pooled permutation p-values from the modified Fs test-statistic184. The
resulting lists included statistically significant genes, with false discovery rate multiple test
adjustment (q≤0.1) as well as without it (p≤0.05). In addition to the statistical cutoffs mentioned
above, any transcript with a fold change of >2x in any pairwise contrast was also included in the
gene list, regardless of statistical significance193.
For mouse Affy cdf analyses, pair-wise comparisons were made, similar to the standard ttest; however, with UMBA cdf analyses, pair-wise contrasts were run instead to utilize the across
tumor type variation, rather than just the variation between the two groups. In retrospect, contrast
matrices should have been used for both analyses, because with a contrast, information from
other samples throughout all stages of tumor progression (i.e. samples not used in the contrast)
can be intergraded, whereas the t-test can only use the information within and between the two
tumor types. However, since only the retrotransposons were evaluated using the Affy cdf
method, the previously run pair-wise comparison results were used.
2.3.3. Survival Analysis
All survival analyses were performed using R/SURVIVAL. Kaplan-Meier log-rank test was
used to assess statistical significance between our 63-gene signature, extracted from the
commonalities between Waptag1 and human DCIS for prediction of poor prognosis (see Table
4.3), and 3 independent human breast cancer datasets37,189,190. The clinical endpoints for
evaluation of reduced survival were either time to metastasis37,189 or time to death190 with followup limited to 10 years. Cox-hazard regression analysis was used to identify individual genes
whose expression levels showed significant association with tumor free survival (p≤0.01) in three
human breast cancer cohorts37,189,190.
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2.4. Retrotransposons
2.4.1. Datasets
2.4.1.1. Mouse Microarrays
Mouse Dataset1 consisted of forty-six single transgenic lactating and non-lactating mammary
tumors (representing four transgenics: Myc, Neu, Wnt1, and Notch4) as well as FVB/NJ control
mammary glands, with at a minimum of three-fold biological and two-fold technical replication,
run on ninety-two oligonucleotide arrays. Arrays were spotted from the 22K Mouse Release 2.0
Oligo Library (Compugen, San Jose, CA) and labeled cDNA from each sample was hybridized in
pairs, with the Universal Mouse Reference (Stratagene, La Jolla, CA), using a reference dyeswap design to reduce the bias due to the dye. Using the pooled permutation p-values from the
Fs statistic of the mixed model, we determined which genes were statistically significant, using a
multiple test correction for ANOVA analysis (q≤0.01). Only the ANOVA results across all
transgenic tumors (compared with normal controls) will be discussed here. Mouse Dataset2
consisted of Waptag1 data across all stages of tumor progression from NIA arrays (see above).
Mouse Dataset3 was comprised of the Affymetrix array results throughout all stages of Waptag1
tumor progression (see above).
2.4.1.2. Human Two Color Microarray Data
Human Dataset6 was obtained from publicly available data at GEO, the Gene Expression
Omnibus [http://www.ncbi.nlm.nih.gov/geo/]. It featured 50 human breast tumors (32 luminal, 10
basal, and 9 ERBB2-positive) and four normal breast tissue samples. Luminal tumors are
estrogen receptor positive (ER+) and androgen receptor positive (AR+); basal tumors are ER
negative (ER-) and AR negative (AR-). Samples were run on cDNA microarrays harboring over
8,000 human genes including expressed sequence tags (GEO accession GDS84)4,5. Mediancentered data was used; statistical significance was determined for each tumor type (luminal,
basal, or ERBB2+) compared against normal breast using a two-tailed t-test (p≤0.05) analysis in
GEO as the complete raw data was unavailable.
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2.4.1.3. Human Affymetrix Data
Independent data from four human datasets was analyzed for comparison with Waptag1.
Raw data was retrieved from GEO, unless otherwise stated. Human Dataset7 featured 49 breast
tumors (27 luminal, 16 basal, and 6 apocrine). Apocrine tumors are ER- and AR+; as mentioned
above, luminal tumors are ER+ and AR+; basal tumors are ER- and AR- (GEO accession
GDS1329)6. Samples were hybridized to Affymetrix GeneChipR Human Genome U133 Array Set
(Affy HG-U133A) chips and .CEL files were normalized with RMA6. Statistical significance was
determined for each tumor type (luminal, basal, or apocrine) compared against each other using
a two-tailed t-test (p≤0.01) analysis in GEO as the complete raw data was unavailable. Human
Dataset8 featured four fresh Atypical Ductal Hyperplasia (ADH) samples from women with a
history of cancer compared against four samples from women with NO history of cancer (GEO
accession GDS1250)3. Affy HG-U133A arrays were used; significance was determined for using
a two-tailed t-test (p≤0.05) analysis in GEO as the complete raw data was unavailable. As
mentioned above, Human Dataset1 was received as rawdata (.CEL files) from collaborators, Dr.
D. Craig Allred and Dr. Sanjun Lee, Washington University School of Medicine (St. Louis, MO).
This dataset featured 27 samples enriched in DCIS and 24 Invasive Breast Cancer (IBC) samples
run on Affy HG-U95Av2 arrays. Human Dataset2 was downloaded as rawdata (.CEL files) from
GEO; among other samples, it featured 7 normal breast samples run on Affy HG-U133plus2
arrays. Human Dataset1 and Dataset2 were combined after RMA pre-processing (using Affy cdf
for pre-processing), as previously described (see above) and ANOVA results of statistically
significant genes from the permuted Fs statistic, based on FDR multiple test adjustment
(q≤0.01), were searched for retrotransposons.
2.4.2. Classification
All target sequences for the entire Affymetrix chip (either human or Waptag1) were run
through RepeatMasker (http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker); for the two
color arrays (either human or mouse), only unknown or un-annotated sequences were queried
against RepeatMasker database to obtain proper annotation of repeat sequences.
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The main drawback of using microarray data to look for retrotransposons is that the target
sequences must be queried; the actual array probes may or may not contain the repeat.
However, our hypothesis was that retrotransposons are over-expressed early in the tumorigenic
process, specifically within the tumor cells; the identification of exactly which elements was not
our primary objective, but rather the similarity of mechanism of retrotransposon expression within
early tumorigenesis.
2.5. Cross-Species Comparisons
Official mouse gene symbols and human / mouse gene orthology was determined using
Mouse Genome Informatics (MGI) database (http://www.informatics.jax.org/), which features
curated data with evidence codes and/or references for each orthologous match between mouse
and human. Among the 16,026 unique mouse genes on the Affy 430 v2.0 arrays, 1689 had no
human ortholog and 7392 were not found on the human arrays, whereas of 8065 unique human
genes (common between the two human arrays), 513 had no human ortholog and 711 were not
on the Affy 430 v2.0 arrays using the UMBA cdf. In total, 6945 genes were orthologous and
represented on all microarrays, regardless of species. ANOVA pair-wise contrast results of
human or Waptag1 DCIS or tumors (versus the appropriate species-specific normal controls)
were compared between species. Similarities and differences among joined results were
determined three ways: 1) genes that were common to both human and mouse; 2) genes that
were only expressed in Waptag1 stages of tumor progression; 3) genes which were only
expressed in human DCIS or IBC.
2.6. Gene Ontology and Pathway Analysis
2.6.1. VisuaL Annotation Display (http://proto.informatics.jax.org/prototypes/vlad-1.02/)
VisuaL Annotation Display (VLAD) was used to classify genes according to their Gene
Ontology (GO) terminology194 and (Richardson J and Bult C, unpublished). To determine the
statistical significance of a gene list, VLAD uses a hyper-geometric statistical analysis, comparing
one gene list to a universal set. Several universal sets were used for all analysis, but the MGI
default universe will be described. For mouse datasets, the default is all genes annotated in MGI;
for human genes, the default is all genes annotated in GOA_Human. VLAD was the source of all
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GO classification results; the threshold set was p<0.001, unless otherwise stated; reduced
threshold was p<0.01.
2.6.2. GenMAPP Energy Pathway Analysis (http://www.genmapp.org)
Using Entrez gene identifiers, statistically significant genes (from R/MAANOVA) were
mapped using GenMAPP to specific metabolic pathways, in particular, those suggested by VLAD
results as being significantly over-represented. Unlike VLAD, gene lists in GenMAPP were NOT
compared against a universal set, as genes were merely mapped to pathways according to
expression levels, because they were already determined to be significantly up or down-regulated
compared with normal controls. Besides its flexibility and short learning curve, a user can choose
and alter any color scheme according to their preferences in GenMAPP software. In addition,
GenMAPP borrows curated pathway information from KEGG, providing a level of confidence to
the user195,196.
2.6.3. MouseCyc Pathway Representation (www.informatics.jax.org/pathways)
The Pathway Tools software development kit software (version 10.0) was downloaded from
SRI and installed on a Sun Fire X4100 server running SUSE Linux, the dedicated host for the
MouseCyc database (http://mousecyc.jax.org, ver. 1.36, June 2008; 19). Briefly, a catalog of
mouse genes and their annotations were downloaded from MGI (November 6, 2007). Gene
annotations included gene name and symbol, EC numbers, Gene Ontology annotations, genome
coordinates and accession identifiers for Entrez Gene, UniProt, and MGI. RNA genes and
pseudogenes were excluded. A total of 47 input files were created as input to the PathoLogic
algorithm. Annotation files were created for 19 mouse autosomes, 2 sex chromosomes, the
mitochondrial genome, and for genes with unknown chromosome location. Following the
automated build of MouseCyc, the data-editing tools built into the PathwayTools software system
are used for on-going manual refinement and annotation of biochemical pathways and reactions.
Using MGI gene identifiers, statistically significant genes were mapped to classical and cellular
metabolic pathways. MouseCyc features biochemical pathways curated from the wealth of data
available in the Mouse Genome Informatics databases.
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Chapter 3
CHARACTERIZATION OF WAPTAG1, A MOUSE MODEL OF DUCTAL CARCINOMA IN SITU
WITH PROGRESSION TO INVASIVE CANCER
3.1. Waptag1 Tumorigenesis, a Multi-Stage Progressive Disease with Delayed-Onset
C57BL/6J-Tg(WapTAg)1Knw (Waptag1) mice contain a transgene comprised of the entire
SV40 Tumor antigen early region (SV40 Tag; coding for all three proteins: Large Tag, small tag,
and 17K tag) which is driven by the hormone-responsive whey acidic protein (WAP) promoter50.
Waptag1-induced tumors develop mid-life in multiparous females, remarkably resembling the
latent human condition50. Whereas virgins, single and dual pregnancy females failed to develop
consistent, predictable mammary tumors, in females that sustained a minimum of three
pregnancy and lactation cycles, tumors arose by 12-14 months of age. To visualize the earliest
stages of tumorigenesis, several females were sacrificed at monthly intervals, starting at 4
months up until the development of tumors. Histological evaluation of samples revealed no
abnormalities until 6-8 months of age when atypical cells were observed (Figure 3.1.A) in females
that sustained a minimum of three pregnancy/lactation/involution cycles. Multiple stages of
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Figure 3.1. Tumor Progression in Waptag1 Mammary Carcinogenesis. In the initial stage of atypia
(A), the epithelium lining the mammary ducts contains a few scattered light atypical cells (white arrows) with
large hyperchromatic nuclei. In more complex lesions (B,C), ductal carcinoma in situ is depicted by
intraductal neoplastic proliferation in which malignant cells stack multifocally in a disorderly fashion and
occasionally form minute papillae; mild fibrosis and lymphocytic inflammation are observed. Papillary
adenocarcinoma (D), the primary tumor in Waptag 1 mice, is characterized by formation of papillary
projections lined by cuboidal to columnar malignant epithelial cells, supported by a moderate amount of
fibrovascular stroma. Solid / invasive carcinoma (E) is comprised of large solid areas with inconspicuous
lumen and very little stroma. These tumors also exhibit invasion into the surrounding tissues. The
myoepitheliomas (F) is comprised of solid areas of spindloid to polygonal cells supported by a scant amount
of fibrovascular stroma. (Hematoxylin and Eosin stain. Magnification: A,100x; B,C,40x; D,E,F,10x.)
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ductal carcinoma in situ (DCIS) were evident in females of 8-10 months of age (Figure 3.1.B,
3.1.C). Mammary tumors of one or more histological subtypes developed at 9-14 months:
papillary adenocarcinomas (Figure 3.1.D), solid/invasive carcinomas (Figure 3.1.E), and rarely,
myoepitheliomas (Figure 3.1.F).
Figure 3.2. Hierarchical
Clustering across
Stages of Waptag1
Mammary Tumor
Progression.
A) Whole and LCM
samples. Right side:
genes with similar
expression across all
samples; bottom: how the
samples cluster across
genes, based on ANOVA
expression values of the
top 844 significant genes
(q≤0.00001). Red, high
expression; blue, low or
negative expression.
[Abbreviations: w, whole
gland or tumor sample, if
no “w” is listed, the sample
is linearly amplified cells
isolated using Laser
Capture Microdissection
(LCM); PapT, Papillary
tumor; DCIS, ductal
carcinoma in situ; S, solid
tumor cells; EDCIS, early
DCIS; B6, C57BL/6J
controls.]

To fully characterize the potential of the Waptag1 mouse model, whole glands or tumors and
laser-capture microdissected cells were collected throughout the lifespan of multiparous Waptag1
females. Age- and parity-matched C57BL/6J (B6) mammary glands or epithelial cells were
collected as controls. Using these samples and an appropriate experimental design (see
methods), we performed microarray analysis to investigate global gene expression changes in
Waptag1 tumorigenesis. Figure 3.2 displays the unsupervised clustering of all samples, based
on the ANOVA microarray results.
3.2. Waptag1 Whole Glands and Tumors Exhibit Stage-Specific Expression Profiles
Waptag1 whole mammary glands showed much variation within certain tumorigenic stages.
Since histological classification of each stage was based on less than 1% of the mammary gland
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(or tumor), multiple stages of tumor progression, not visible in the histological sample, may have
been present in the sample collected for RNA. To better document the extent of within-stage
variation, scatter plots were used to depict the mean expression values of one biological replicate
plotted against another across all genes on the microarray. For comparison purposes, C57BL/6J
samples (Figure 3.3.A) demonstrate how expression data scatter rather tightly around the y=x
line, with very few values outside of the threshold (log2 of the fold changes between the two
arrays, at greater than 1.5 times the standard deviation, across all arrays). Waptag1 Normal
samples show some variation (Figure 3.3.B), but appear adequate as biological replicates.
Conversely, as Figure 3.3.D and E show, the variation among the same tumorigenic stage can be
large; the greatest deviation appears in Array2 of Waptag1 advanced DCIS (Figure 3.3.D).
However, a sharp 45 degree (y=x) line is found with early DCIS replicates (Figure 3.3.C).
Papillary tumor replicates display a moderate amount of variation, which is commonly observed
when scattering expression data of one tumor against another within the same transgenic model
(Fancher K, personal observation). With a large amount of within-stage variation, it may be
difficult to unmask the across-stage genetic differences, even with a relaxed significance
threshold. Indeed, this emphasizes the importance of scrutinizing specific cell types within each
stage of tumor progression, thereby obtaining results based on only the specific DCIS or papillary
tumor cells of interest.
3.2.1. Transcriptional Changes in Whole Glands (Early DCIS vs. C57BL/6J)
In the pair-wise contrast between whole early DCIS (EDCIS) and Waptag1 normal glands,
only 73 genes were expressed at a significantly different level (p≤0.05). However, when EDCIS
glands were compared with control C57BL/6J (B6) glands, 461 genes were significantly
differentially expressed (p≤0.05). Anti-apoptosis and negative regulation of apoptosis genes
were over expressed compared to B6 controls (Table 3.1). Thus, inhibition of apoptosis is one of
the earliest changes occurring in Waptag1 tumorigenesis, probably due to dysfunctional TRP53
and PP2A, the consequence of the SV40 Tag transgene. Regulation of immune system process
and regulation of immune response genes were down-regulated in whole glands containing
EDCIS (Table 3.1). C57BL/6J inbred mice are normally ‘high-responders’ to SV40 Tag. Thus,
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these findings probably reflect the fact that, like other SV40 Tag transgenic mice, Waptag1 mice
are tolerant to SV40 Tag197-200 and (Knowles BB, unpublished). Genes involved in organ
development, specifically organ morphogenesis were up-regulated in whole EDCIS glands,
compared with whole B6 glands, coinciding with the accepted paradigm that genes involved in
development are often over expressed in cancer and/or function as oncogenes201-210.
3.2.2. Transcriptional Changes in Whole Glands (Advanced DCIS vs. Early DCIS)
To determine gene alterations during progression to the next tumorigenic stage, each
remaining stage was compared with the stage immediately preceding it, which could mask
dominant gene alterations observed throughout tumor progression. In the pair-wise contrast
between whole glands containing advanced DCIS (AdvDCIS) and EDCIS, 1323 genes were
differentially expressed (p≤0.05). Genes involved in cell cycle, specifically mitotic cell cycle, cell
division and DNA replication, chromosome segregation and response to DNA damage stimulus
(in particular DNA repair) were up-regulated in AdvDCIS glands (Tables 3.1 and data not shown).
Additionally, when analyzed by Affy cdf, retrotransposons were found in target sequences for
‘genes’ with the highest fold changes (see Chapter 5). Monocarboxylic acid, oxidation reduction,
and fatty acid metabolic processes, oxidoreductase activity, as well as the cellular components
mitochondrion and peroxisome were down-regulated in glands containing AdvDCIS vs. those with
EDCIS (Tables 3.1 and Fancher K et.al., future publication). Although defects in mitochondrial
energy metabolism have been associated with disease and cancer, (for review211) these
mutations usually result in generation of reactive oxygen species (ROS), though there are
exceptions. Oxidative damage to lipids, proteins, and even DNA occurs under conditions of
oxidative stress, hypoxia, and/or production and accumulation of ROS, and cells respond by
attempting to neutralize ROS. Were this a response to stress, one would expect up-regulated,
rather than down-regulated, expression of genes in these categories. Other genes with downregulated expression in glands of AdvDCIS compared against EDCIS, fell into the following GO
categories: vasculature development, blood vessel development, blood vessel morphogenesis,
and angiogenesis. Genes in these categories do not overlap with other GO terms, however, so
this finding was a bit perplexing, since one ‘Hallmark of Cancer’ is maintaining angiogenesis11.
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Figure 3.3. Scatter Plots across Biological Replicates of Control or Waptag1 Mammary Gland and
Tumor Samples. A) Control C57BL/6J glands; B) Waptag1 ‘Normal’ mammary gland samples; C)
Waptag1 early DCIS samples; D) Waptag1 advanced DCIS samples; E) Waptag1 papillary tumors.
Each set of scatter plots depicts the variation between any two arrays, based on RMA-preprocessed
expression data. X- and Y-axes are normalized mean expression values for the 16,642 genes (no qvalue limitation). Upper and lower boundaries (blue dashed lines) depict values 1.5 times the standard
deviation, based on all arrays, with outliers (green spots) showing log 2 fold changes (between the two
arrays) greater than this threshold.
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3.2.3. Transcriptional Changes in Papillary Tumors vs. Whole Glands Containing
Advanced DCIS
In the pair-wise contrast of whole papillary tumors versus glands containing AdvDCIS, 2160
genes were differentially expressed. Among 1114 up-regulated genes, cell cycle/cell division,
DNA replication, chromosome segregation, and DNA repair genes were further over expressed
(Table 3.1), while genes involved in ATP binding, and DNA binding were also over represented,
at a reduced threshold (data not shown). Genes down-regulated in papillary tumors when
compared with glands containing AdvDCIS were those in GO categories carboxylic acid
metabolic process, monocarboxylic acid metabolic process, lipid metabolic process, fatty acid
metabolic process and oxidoreductase activity (five GO terms); many of which were further downregulated from the previous pairwise comparison (Table 3.1 and Fancher K et.al., future
publication). In addition, overabundance of down-regulated electron carrier activity genes in
papillary tumors (Table 3.1) suggests that the most efficient method of ATP production is
dysfunctional. However, ATP is still being consumed for cell cycle, cell division, and DNA
replication processes.
In summary, analyses of entire mammary glands containing early stages of tumor
progression are not ideal to understand the genetic changes occurring throughout tumorigenesis
in Waptag1. High within-stage variation and low between-stage genetic changes made the
discovery of the true, important stage-specific signatures complicated. However, several distinct
and consistent transcriptional alterations seem to define each stage of tumor progression.
Initially, in EDCIS mammary glands, anti-apoptotic genes first appear transcriptionally and
regulation of immune response genes are down-regulated, compared with control glands.
Mammary glands containing these sparsely-dispersed early nodules display one highly
characteristic change associated with cancer (i.e. diminished apoptosis) and they appear to be
negatively regulating immune responsiveness. Glands containing densely-packed regions of
AdvDCIS appear to be in the commitment stage for tumorigenesis, exhibiting up-regulated
expression of genes involved in cell cycle/division and DNA replication (Table 3.1), as well as
chromatin modification genes, retrotransposons, and histone variants (see Chapter 5). In
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addition, transcripts of genes regulating oxidoreductase activity were down-regulated. In papillary
tumors, further up-regulation of genes involved in cell cycle/division, DNA replication, and DNA
repair was apparent and immune response genes were over expressed. Interestingly,
oxidoreductase activity, carboxylic acid metabolism, and lipid metabolic process genes were
further down-regulated compared to glands containing AdvDCIS, and genes involved in electron
carrier activity were also significantly down-regulated.

Table 3.1. Genes Representative of Stage-Specific Transcriptional Changes within the Most
Significant Gene Ontology Classifications in Waptag1 Mammary Glands and Tumors. Each
stage of progression exhibits a unique profile. Early DCIS results represent gene changes in glands
containing Early DCIS (based on histological classification) compared to C57BL/6J control glands;
Advanced DCIS, glands containing Advanced DCIS vs. those of Early DCIS; Papillary tumor,
papillary tumor samples vs. glands containing Advanced DCIS. Fold changes determined by
pairwise contrasts listed above and results were statistically significant (p≤0.05, ANOVA; p≤1.0 x
10-08, VisuaL Annotation Display). [Abbreviations: UP, Gene Ontology term for which gene
expressed was up-regulated in the stage listed; DOWN, down-regulated.]

Stage of Tumorigenesis
GO_Category / Gene symbol

Significance:
fold change/p-value

Gene Name

Early DCIS
Anti-apoptosis UP
Akt1
Cebpb
Dapk1
Hspa1b
Mapk8ip1
Spp1
Stat5a
Trp63
Regulation of immune system
process DOWN
Btla
Cd19, Cd28, Cd4, Cd5, Cd55,
Cd79b
Fcer2a
H2-Oa
Icosl
Il27ra, Il2rg
Lck
Prkcq
Ptpn6, Ptprc
Tnfrsf13c

2.64 x 10-7
thymoma viral proto-oncogene 1
CCAAT/enhancer binding protein (C/EBP), beta
death associated protein kinase 1
heat shock protein 1B
mitogen-activated protein kinase 8 interacting protein 1
secreted phosphoprotein 1
signal transducer and activator of transcription 5A
transformation related protein 63

1.78x
1.84x
1.35x
1.66x
1.39x
1.63x
1.55x
1.35x

B and T lymphocyte associated

-5.06x

CD# antigens
Fc receptor, IgE, low affinity II, alpha polypeptide
histocompatibility 2, O region alpha locus
icos ligand
interleukin receptors
lymphocyte protein tyrosine kinase
protein kinase C, theta
protein tyrosine phosphatases
tumor necrosis factor receptor superfamily, member 13c

-1.33x to -6.32x
-2.05x
-2.69x
-1.56x
-2.01x, -1.94x
-2.09x
-1.74x
-2.26x, -1.93x
-2.38x

1.71 x 10-18

42

Stage of Tumorigenesis
GO_Category / Gene symbol

Gene Name

Significance:
fold change / p-value

aurora kinases
baculoviral IAP repeat-containing 5
budding uninhibited by benzimidazoles 1 homologs (S. cerevisiae)
cyclins

4.18 x 10
3.94x, 3.56x
8.79x
3.85x, 3.60x
4.3x, 7.1x, 6.2x, 2.2x

cell division cycle homologs
F-box protein 5
helicase, lymphoid specific
MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast)
Mdm2, transformed 3T3 cell double minute p53 binding protein
non-SMC condensin complex, subunits
NDC80 kinetochore complex component homologs (S. cerevisiae)
NIMA (never in mitosis gene a)-related expressed kinase 2
nucleolar and spindle associated protein 1
polo-like kinase 1 (Drosophila)
regulators of chromosome condensation
structural maintenance of chromosomes
ubiquitin-conjugating enzyme E2C

1.69x to 6.02x
2.52x
4.83x
3.08x
1.92x
3.47x, 2.88x, 3.18x
2.35x to 4.95x
3.89x
5.02x
3.39x
1.75x, 2.48x
1.98x, 2.64x
5.19x

Advanced DCIS
Mitotic cell cycle UP
Aurka, Aurkb
Birc5
Bub1, Bub1b
Ccna2, Ccnb1, Ccnb2, Ccnf
Cdc20, Cdc25b, Cdc25c, Cdc2a,
Cdc6, Cdca2, Cdca3, Cdca5, Cdca8
Fbxo5
Hells
Mad2l1
Mtbp
Ncapd2, Ncapg2, Ncaph
Ndc80, Nuf2, Spc24, Spc25
Nek2
Nusap1
Plk1
Rcc1, Rcc2
Smc2, Smc4
Ube2c
DNA Replication UP
Blm
Cdc45l, Cdc6
Cdt1
Chaf1b
Gins1
Mcm2-7, Mcm10
Pola1,d1,e,e2
Prim1, Prim2
Rad51, Rad51c, Rad54l
Rfc2, Rfc3, Rfc4
Rpa1, Rpa2, Rpa3
Rrm1, Rrm2
Tk1
Oxidation Reduction &
Oxidoreductase Activity DOWN
Acadl, Acads, Acox1
Adh1, Adhfe1, Aldh1a1, Aldh1a7,
Aldh1l1, Aldh2, Aldh6a1, Aldh9a1
Aoc3, Aox1, Maob
Cdo1
Cyp27a1, Cyp2e1, Cyp4b1, Cyp4v3
Decr1
Dpyd, Ehhadh, Gpd1, Hsd11b1,
Hsd3b7, Hsdl2, Idh1, Pdha1, Xdh
Fasn, Nos3
Fmo1, Fmo5
Heph
Loxl1
Mod1
Por
Sc5d, Scd1
Sod3
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-26

2.23 x 10
Bloom syndrome homolog (human)
cell division cycle homologs (S. cerevisiae)
chromatin licensing and DNA replication factor 1
chromatin assembly factor 1, subunit B (p60)
GINS complex subunit 1 (Psf1 homolog)
minichromosome maintenance deficient genes
polymerases (DNA directed)
DNA primase, p49 & p58 subunits
RAD51, 54 homologs (S. cerevisiae)
replication factor C (activator 1) genes
replication protein A genes
ribonucleotide reductase M genes
thymidine kinase 1

2.92x
2.52x, 2.95x
3.5x
3.68x
2.58x
1.99x to 4.51x
2.54x, 1.77x, 3.2x, 3.1x
3.38x, 2.19x
2.41x, 1.63x, 3.13x
1.67x, 2.49x, 3.08x
1.8x, 2.04x, 1.78x
2.5x, 7.02x
4.04x
9.13 x 10

12

&
-10

acyl-Coenzyme A dehydrogenases & oxidase1, palmitoyl

2.32x10
-1.58x, -1.51x, -2.14x

alcohol & aldehyde dehydrogenases
amine, aldehyde & monoamine oxidases
cysteine dioxygenase 1, cytosolic
cytochrome P450, family members
2,4-dienoyl CoA reductase 1, mitochondrial

-1.68x to -8.3x
-6.88x, -3.64x, -4.7x
-4.85x
-1.88x to -5.38x
-2.55x

dehydrogenases (miscellaneous)
fatty acid & nitric oxide synthases
flavin containing monooxygenase
hephaestin
lysyl oxidase-like 1
malic enzyme, supernatant
P450 (cytochrome) oxidoreductase
sterol-C5 & stearoyl-CoA desaturases
superoxide dismutase 3, extracellular

-1.6x to -3.95x
-2.58x, -1.82x
-2.59x -2.69x
-4.37x
-2.06x
-2.49x
-2.97x
-2.25x, -3.92x
-3.51x

Table 3.1. Continued.

43

Stage of Tumorigenesis GO_Category
/ Gene symbol
Gene Name

Significance:
fold change / p-value

PAPILLARY TUMOR
Immune Response UP
B2m
Bcl3
C1qb, C1qg
Ccl2,3,4,5, Ccl7,8, Ccl12, Cxcl2,
Cxcl10, Cxcl16
Fcer1g, Fcgr1
H2-Aa, H2-Ab1, H2-D1
Il1b, Il1rn, Il4ra
Irf7
Ly86, Ly96
Mx1, Mx2
Pglyrp1
Tlr2, Tlr3, Tlr13

-10

1.67 x 10
beta-2 microglobulin
B-cell leukemia/lymphoma 3
complement component 1, q subcomponents

1.51x
1.65x
2.03x, 2.04x

chemokine (C-C and C-X-C motif) ligands
Fc receptor, IgE or IgG, high affinity I
histocompatibility 2, class II antigen A or D region locus 1
interleukin genes
interferon regulatory factor 7
lymphocyte antigen 86 and 96
myxovirus (influenza virus) resistance genes
peptidoglycan recognition protein 1
toll-like receptors

1.53x to 5.98x
2.09x, 2.65x
2.24x, 2.53x, 1.64x
1.81x, 2.5x, 1.66x
4.57x
3.23x, 1.73x
3.62x, 1.63x
7.5x
1.85x, 2x, 1.9x

Cell Division UP
Ccne2, Cdk2, Cdkn2a
Cdc14a, Cdc45l, Cdca4
Cep55
Dsn1, Nsl1
Kif11
Kntc1, Zwilch
Lig1
Mis12
Plk1, Prc1
Racgap1
Sept5, Sept9
Sgol1, 2
Spc24, 25
Syce2
Timeless
Top2a

genes listed above not shown, even if further up-regulated

1.1 x 10
4.59x, 1.72x, 2.59x
1.83x, 2.63x, 1.58x
2.77x
2.45x, 2.26x
2.66x
2.16x, 3.85x
2.49x
1.88x
2.83x, 4.37x
4.3x
2.88x, 1.53x
3.2x, 3.41x
3.66x, 2.9x
2.57x
2.1x
4.27x

Electron Carrier Activity DOWN
Acad11, Acadsb, Acox1
Aifm2
Cox6a2, Cox7a1, Cox7a2l
Cyp1a1, Cyp1b1
Dhdh, Ivd, Sdha
Etfb
Glrx5
Ndufs1, Ndufs8, Ndufv2
Uqcrfs1

genes listed above not shown, even if further down-regulated

cyclin E2, cyclin-dependent kinase 2 & inhibitor
cell division cycle homologs
centrosomal protein 55
MIND kinetochore complex components, homologs
kinesin family member 11
kinetochore associated genes
ligase I, DNA, ATP-dependent
MIS12 homolog (yeast)
polo-like kinase 1 (Drosophila) & protein regulator of cytokinesis 1
Rac GTPase-activating protein 1
septins 5, 9
shugoshin-like 1, 2 (S. pombe)
spindle pole component 24, 25 homologs (S. cerevisiae)
synaptonemal complex central element protein 2
timeless homolog (Drosophila)
topoisomerase (DNA) II alpha
acyl-Coenzyme A dehydrogenase & oxidase genes
apoptosis-inducing factor, mitochondrion-associated 2
cytochrome c oxidase, subunits
cytochrome P450, family 1, subfamilies a,b polypeptide 1
dehydrogenases (dihydrodiol, isovaleryl Co-A, succinate)
electron transferring flavoprotein, beta polypeptide
glutaredoxin 5 homolog (S. cerevisiae)
NADH dehydrogenase (ubiquinone) genes
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1

-30

-08

1.25 x 10
-2.31x, -2.15x, -1.98x
-2.72x
-3.18x, -2.06x, -1.5x
-2.16x, -3.12x
-2.55x, -2.5x, -1.68x
-1.6x
-1.6x
-1.7x, -1.52x, -1.51x
-1.79x

Table 3.1. Continued.

3.3. Laser Capture Microdissected Tumor Cell Transcriptomes are Nearly Identical,
Irrespective of Waptag1 Tumorigenic Stage
In whole gland samples (described above), it is possible that multiple stages of tumor
progression, not seen in the histological sample, may have been present in the sample taken for
RNA and processed on the microarray since these samples were classified based on less than
1% of the mammary gland (or tumor) that was collected. Variation among biological replicates
may have affected the results of our analysis. Therefore, to circumvent this potential problem, we
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used laser capture microdissection to isolate specific cell types from each stage of Waptag1
tumor progression. To obtain sufficient quantities of RNA from the laser captured cells, however,
linear amplification was performed using the RNA from ~100 cells. Linear amplification was not
performed on the whole gland samples; therefore this is a substantial difference in the procedures
between whole glands and laser-captured cells prior to their analysis on microarrays.
3.3.1. Laser Capture Microdissection(LCM) of Mammary Samples
Results from one of three biological replicates for each stage of Waptag1 tumor progression
are shown in Figure 2.1. Variation was minimal across biological replicates. Unlike the whole
mammary glands, laser-captured cells exhibit very little within-stage variation, with scatter plots
appearing similar to whole papillary tumor replicates (Figure 3.2. and data not shown). The
majority of this variation was due to the cells comprising the DCIS lesion appearing more tumorlike or more B6-like than could be determined from histological classification for the stage of
progression. This is illustrated in the hierarchical clustering across all LCM samples (Figure 3.4.),
in which DCIS sample #3539 clustered with the LCM cells from papillary and solid tumors,
whereas DCIS sample #5714 grouped with the B6 cells.
3.3.2. A Tumor Profile Within LCM Cells of DCIS
Among the very early changes in Waptag1 cells, i.e. comparing LCM cells of EDCIS with
LCM control B6 epithelial cells, genes with up-regulated expression were involved in the following
processes: cell cycle, specifically mitotic cell cycle and cell cycle checkpoint; cell division, DNA
replication, DNA repair, and chromosome organization and biogenesis. These findings, though
familiar gene categories, were not observed at this early stage in whole glands. The genetic
profile of these specific cells within EDCIS is comparable to those obtained from Waptag1 whole
tumors. Many of these alterations are due to the functions of SV40 Tag proteins, thus confirming
isolation of the appropriate cells during LCM. In addition, retrotransposons and twenty-eight
genes categorized under the classification of chromosome organization and biogenesis (2.02 x
10-5; 28 of 223 genes) including histone variants H2afx, H2afz, and Hist1h4i, the histone
deacetylase, Hdac10, and the chromatin remodeling factors Ezh2, Sirt7 and Smarcd2 were over
expressed in LCM EDCIS cells. Thus, deregulation of chromatin maintenance machinery and
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transcriptional activation of retrotransposons occur early and within the specific pre-tumor cells of
Waptag1 mammary glands.
Genes with down-regulated expression in LCM EDCIS cells were categorized as energyrelated. Generation of precursor metabolites and energy, specifically, aerobic respiration,
tricarboxylic acid cycle, and electron transport as well as coenzyme catabolic process,
oxidoreductase activity, electron carrier activity, and the related cellular component
mitochondrion, mitochondrial envelope, and mitochondrial inner membrane genes were downregulated, compared with LCM B6 cells. These results suggest that the cancer cell switch from
normal mitochondrial respiration, ATP production via electron transport chain (which produces 36
ATP/glucose molecule) to less efficient glycolysis/fermentation (the breakdown of glucose into
Figure 3.4. Hierarchical
Clustering across LaserCaptured Stages of Waptag1
Mammary Tumor Progression.
Clustering based on normalized
median expression values after
RMA (no q-value limitation).
[Abbreviations: laser capture
microdissection (LCM); P,
papillary tumor; D, ductal
carcinoma in situ; S, solid tumor
cells; E, early DCIS; B6,
C57BL/6J controls.]

LCM Sample

lactic acid, which produces only 2 ATP/glucose) even in the presence of oxygen, as hypothesized
by Warburg and described by others12,211-214 occurs early in the tumorigenic process. Indeed,
phosphofructokinase Pfkm, which controls glycolysis, is up-regulated in LCM EDCIS cells,
thereby supporting glycolysis as a means by which these cells obtain ATP when electron
transport genes are down-regulated.
Based on the laser-capture early DCIS cell results, once fat, normal epithelium and stromal
cells (including lymphocytes and other immune cells) are excluded, LCM EDCIS cells and
papillary tumors are quite similar. In fact, transcriptional differences (genes up- or down-
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regulated) in LCM EDCIS cells versus B6 control cells were further deregulated in LCM Papillary
tumor cells versus LCM EDCIS cells.
In the pair-wise contrast of LCM AdvDCIS with LCM EDCIS cells, only a couple of hundred
genes were differentially up- or down-regulated and no GO categories were significantly
represented at the specified threshold for VLAD (p<0.001). In light of this, the data from LCM
AdvDCIS cells was compared against LCM B6 control cells and the GO categories were
screened for categories not found in the EDCIS versus B6 comparison described above. In
AdvDCIS cells, no additional GO categories were observed among genes up-regulated. Genes
down-regulated in LCM AdvDCIS cells, but not in EDCIS cells, were categorized as involved in
lipid and fatty acid metabolic processes, fatty acid oxidation, and FAD binding. Fatty acid
metabolism and oxidoreductase activity (mentioned above) gene changes are indicative of a
cellular stress response. However, the organelles which harbor enzymes to oxidize molecules,
catalyze the generation of energy, and neutralize reactive oxygen species, are under-expressed
in cells of AdvDCIS: the mitochondrion (also introduced above) and the peroxisome. Thus, in
Waptag1 tumorigenesis, either reactive oxygen species are not being generated or if present,
they are not being neutralized.
3.3.3. LCM Papillary Tumor Genetic Changes
In the pairwise contrast of LCM Papillary tumor with LCM AdvDCIS cells, the same GO
categories revealed further up- and down-regulation, as both the numbers expressed and the
magnitude of expression of genes in these categories were increased. Besides changes
observed in EDCIS and AdvDCIS, when LCM papillary tumor cells were compared with B6
control epithelial cells, significant changes were in the GO categories mRNA metabolic process,
in particular mRNA processing, as well as RNA splicing, RNA transport, specifically mRNA
transport, and related cellular component, spliceosome. This suggests that aberrant mRNA
metabolism / processing may be a factor contributing to tumor progression. Additionally, upregulation of DNA-dependent ATPase activity, DNA binding, helicase activity, and DNA
packaging genes, supports the massive up-regulation of DNA replication previously observed in
whole papillary tumors. Considering SV40 Tag proteins contain both ATPase and helicase
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activities, however, some of these results may be effects of SV40 Tag expression. Regardless,
they undoubtedly play a role during tumorigenesis in Waptag1.
Alongside the aforementioned gene classifications, in LCM papillary tumor cells, organ
morphogenesis and vasculature development, specifically blood vessel development and in
particular, blood vessel morphogenesis genes were down-regulated, similar to a previous finding
in whole glands containing AdvDCIS (see above). As stated previously, this is a perplexing
finding since increased vasculature is anticipated to promote invasion during carcinogenesis.
3.3.4. LCM Solid, Invasive Tumor Cell-Specific Alterations
Regrettably, whole solid, invasive tumors were not included as part of the original whole
glands/tumors put on Affymetrix arrays. However, these solid tumor cells were captured to
complete the profile of gene expression throughout all stages of Waptag1 tumor progression.
LCM solid, invasive tumor cells were markedly similar to LCM papillary tumor cells: only a few
hundred genes, and consequently no GO categories, showed up-regulation in the pair-wise
contrast between these two. The only new GO term, in addition to those discussed above, with
genes significantly up-regulated in LCM solid tumor cells versus B6 control cells was RNA
localization, which, when combined with the mRNA processing, RNA splicing, and RNA transport
cited above, suggests extensive RNA alterations are prevalent within these late-stage tumor cells,
such as processing of the mRNA and then export out of the nucleus, for example.
The LCM solid, invasive tumor cells, when compared with B6 cells, exhibited down-regulation
of genes in the GO categories glutathione transferase activity, lyase activity, vitamin metabolism,
in particular, water-soluble vitamin metabolism, which happen to fall under the oxidative stress
response. Interestingly, vitamins are required for normal metabolism within cells; in addition,
antioxidants, such as vitamins A, C & E, can reduce the potential damage to a cell. Therefore, it
seems complimentary to find down-regulation of vitamin metabolism alongside energy metabolic
process and oxidative stress response genes. Sulfur metabolic process genes were decreased
as well. Thus, even within the late stage cells of Waptag1 tumorigenesis inhibition is maintained.
These analyses 1) confirmed changes previously uncovered in whole glands, although many
transcriptional alterations were realized in advance in LCM EDCIS cells; 2) identified up-
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regulation of transposable elements and chromatin modification genes within specific pre-tumor
cells of Waptag1 mammary glands; 3) demonstrated the unexpected similarity of pre-tumor and
tumor cells when surrounding stroma, fat, etc. are removed, leaving only an oncogene-induced
tumor-like profile.
3.4. Stroma-Related Transcriptional Changes
Stromal cells were captured at the time of LCM tumor cell collection. Unfortunately,
insufficient numbers of cells, inadequate biological replicates, and technical obstacles prohibited
satisfactory analysis of stromal cells across all stages of Waptag1 tumor progression. Therefore,
to dissect potential stromal changes, which contribute to the ‘cancer phenotype’ in Waptag1, from
whole gland results, we used a subtraction approach. Significant genes from two pairwise
contrasts, whole AdvDCIS versus whole B6 glands and LCM AdvDCIS versus LCM B6 cells ,
were filtered for common genes with the same directionality. The remaining 2179 genes were
analyzed for enrichment of specific GO terms; these represent stroma-contributed gene
expression changes. Table 3.2 lists the significantly over represented GO categories (p<0.0001)
among the expression changes of the 2179 ‘stromal’ genes; genes over expressed in whole
glands of AdvDCIS as well as under expressed are classified. Cell adhesion genes were the
most significantly up-regulated in Waptag1 glands containing DCIS compared to B6 glands, but
this was not the case in LCM DCIS cells (Table 3.2 and 3.2.1). Additionally, ‘stromal’ genes
showed enrichment in actin cytoskeleton components, extracellular matrix structural constituents,
collagen family members, cytoskeleton organization and biogenesis, and were part of the apical
junction complex (Table 3.2). Although these findings might be anticipated, they confirmed the
appropriate techniques and methods used for laser-captured cells. Cell to matrix or extracellular
matrix genes, specifically those increased in whole glands containing AdvDCIS, are listed in
Table 3.2.1. The level of significance of (mono)carboxylic acid metabolism genes among downregulated ‘stromal’ genes (Table 3.2) suggests that some of the energy-related metabolic
changes may reside within cells of the stroma, rather than exclusively within pre-tumor and tumor
cells. Genes in blood vessel and vasculature developmental categories were also predominantly
down-regulated in AdvDCIS whole gland samples (Table 3.2), compared with whole C57BL/6J
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glands, a consistent recurring finding. Finally, immune system genes were a significant part of
the ‘stroma-related’ changes (Table 3.2 and 3.2.2) as might be expected when comparing whole
glands with laser-captured cells.
Table 3.2. Early Stroma-Related Gene Ontology Classifications. GO categorization of 2179 genes
up- or down-regulated in whole glands containing AdvDCIS versus whole C67BL/6J glands (p≤0.0001,
VLAD). Genes were directionally different or absent in LCM AdvDCIS versus LCM B6 cells.
[Abbreviations: GO, Gene Ontology; BP, Biological Process, MF, Molecular Function, CC, Cellular
Component; VLAD, VisuaL Annotation Display software. A full list of genes and expression values will
appear in Fancher K et.al. future publication.]
GO
Ontology
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

p-value # genes # in MGI
7.33E-15
123
575
7.33E-15
123
575
3.77E-08
517
4028
1.01E-07
752
6204
1.28E-07
469
3635
7.91E-07
298
2194
1.15E-06
680
5616
1.60E-06
428
3344
2.98E-06
670
5557
3.88E-06
247
1799
4.08E-06
113
708
6.04E-06
45
216
1.45E-05
132
878
1.48E-05
72
415
1.61E-05
72
416
1.88E-05
141
955
3.09E-05
39
189
3.65E-05
220
1625
4.47E-05
39
192
7.10E-05
135
932
7.48E-05
73
443

BP
BP
BP

GO Classification
cell adhesion
biological adhesion
biological regulation
metabolic process
regulation of biological process
cellular component organization and biogenesis
cellular metabolic process
regulation of cellular process
primary metabolic process
anatomical structure development
regulation of developmental process
monocarboxylic acid metabolic process
negative regulation of cellular process
carboxylic acid metabolic process
organic acid metabolic process
negative regulation of biological process
blood vessel development
system development
vasculature development
positive regulation of biological process
cytoskeleton organization and biogenesis
transmembrane receptor protein tyrosine kinase
GO:0007169 signaling pathway
GO:0002376 immune system process
GO:0048646 anatomical structure formation

7.95E-05
8.59E-05
8.66E-05

32
105
37

150
694
184

MF
MF
MF
MF
MF
MF
MF
MF

GO:0005488
GO:0005515
GO:0001871
GO:0030247
GO:0005539
GO:0008201
GO:0005201
GO:0003824

8.42E-19
1.03E-18
1.03E-06
1.13E-06
2.79E-06
3.32E-06
5.97E-06
1.31E-05

1258
685
26
25
23
20
19
609

10373
4943
89
84
77
62
59
5016

1.80E-05
6.05E-05
7.36E-05

12
120
50

29
804
272

MF
MF
MF

GO ID
GO:0007155
GO:0022610
GO:0065007
GO:0008152
GO:0050789
GO:0016043
GO:0044237
GO:0050794
GO:0044238
GO:0048856
GO:0050793
GO:0032787
GO:0048523
GO:0019752
GO:0006082
GO:0048519
GO:0001568
GO:0048731
GO:0001944
GO:0048518
GO:0007010

binding
protein binding
pattern binding
polysaccharide binding
glycosaminoglycan binding
heparin binding
extracellular matrix structural constituent
catalytic activity
extracellular matrix structural constituent
GO:0030020 conferring tensile strength
GO:0005509 calcium ion binding
GO:0030246 carbohydrate binding
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GO
Ontology
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC

GO ID
GO:0044424
GO:0015629
GO:0005622
GO:0005737
GO:0005581
GO:0030017
GO:0044449
GO:0030016
GO:0032432
GO:0043292
GO:0043226
GO:0043229
GO:0044420
GO:0043296
GO:0001725
GO:0005578

GO Classification
intracellular part
actin cytoskeleton
intracellular
cytoplasm
collagen
sarcomere
contractile fiber part
myofibril
actin filament bundle
contractile fiber
organelle
intracellular organelle
extracellular matrix part
apical junction complex
stress fiber
proteinaceous extracellular matrix

p-value
7.49E-08
1.78E-07
1.82E-07
2.57E-06
3.09E-06
6.01E-06
1.24E-05
1.40E-05
1.51E-05
2.15E-05
2.33E-05
2.63E-05
5.03E-05
7.05E-05
7.05E-05
8.11E-05

# genes
1041
46
1072
691
15
22
22
23
10
23
862
861
24
23
9
52

# in MGI
8607
192
8926
5547
37
73
76
82
20
84
7174
7170
94
90
19
280

Table 3.2. Continued.

3.4.1. Cell Adhesion Genes
Up-regulation of genes involved in cell adhesion, with 123 genes differentially expressed in
whole Waptag1 DCIS tissue compared with whole B6 glands (and absent in LCM cells), was the
most significant finding (Table 3.2.1). GO terms related to cell adhesion, such as genes that
belong to the cellular components extracellular matrix part and collagen were also significantly
expressed (Table 3.2). These findings, though anticipated, confirm and verify the use of the
8430419L09Rik

Cd97

Col5a1

Dst

Lgals1

Pcdhga4

Pecam1

Stab2

Adam23

Cdh1

Col5a3

Emilin2

Lgals7

Pcdhga5
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Col6a1

Epdr1

Lypd3

Pcdhga6
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Cd209d
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Ctgf
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Table 3.2.1. Cell Adhesion Genes, Stroma-Related. Of the 2179 gene changes found in whole
AdvDCIS lesions, which were not present in LCM AdvDCIS cells, 123 genes were classified as cell
adhesion genes (p=7.33 x 10-15, VLAD), the majority of which were up-regulated. Official mouse
gene symbols were obtained from the Mouse Genome Informatics (www.informatics.jax.org).
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laser-capture microdissection techniques and methods to isolate and analyze control epithelial
and tumor cells. Cell to matrix or extracellular matrix genes specifically increased in whole
glands containing AdvDCIS were as follows: cadherins, Chd1, Cdh16, and the related cadherin
EGF LAG seven-pass G-type receptor 1, Celsr1; catenin (cadherin associated protein), alpha 1,
Ctnna1; protocadherins, Pcdh1, Pcdh21; CEA-related cell adhesion molecules, Ceacam1,
Ceacam20; claudins Cldn1, Cldn3, Cldn23; integrins Itga6, Itgb8; collagens, in particular type IV
family members, Col4a5, Col4a6; fibrillin, Fbn2; matrix metallopeptidases, Mmp12, Mmp13,
Mmp14; tenascin C, Tnc; tight junction proteins, Tjp2, Tjp3. Additional over expressed genes that
appear to be stroma-related include: stromal cell-derived factor 2-like 1, Sdf2l1; engulfment and
cell motility 3, ced-12 homolog, Elmo3; endothelial cell-specific molecule 1, Esm1.
3.4.2. Immune System Genes
Immune system genes were significantly over-represented in whole Waptag1 AdvDCIS
glands compared with whole B6 samples (Table 3.2). In total, about 100 immune system process
transcripts were differentially expressed in whole glands that were not present in LCM cells.
Several related GO terms were just below the cutoff threshold shown in Table 3.2 including
antigen processing and presentation, specifically MHC Class II, and leukocyte migration.
Selected immune genes up-regulated greater than 1.5x in whole glands include the following: Bcell leukemia/lymphoma gene, Bcl11a; chemokine (C-C motif) ligand 12, Ccl12; CD24a antigen,
2210010L05Rik
Abcc9
Ada
Akt1
Alas2
Bank1
Bcl10
Bcl11a
Bmp4
Btla
C1r
C1s
C2
Casp3
Cbfb

Cblb
Cblc
Ccl12
Ccl24
Ccl6
Ccl5-6
Ccl9
Ccr7
Cd14
Cd24a
Cd27
Cd300lg
Cd34
Cd55
Cd74

Cd79b
Cfb
Cfp
Clec4d
Coro1a
Cr2
Cx3cl1
Cxcl12
Cxcl13
Cxcl15
Cxcl9
Cxcr4
Dyrk3
Egr1
Epas1

Ercc1
Faim3
Fcgrt
G6pdx
H2-Aa
H2-Ab1
H2-DMb1
H2-DMb2
H2-Eb1
H2-Oa
H2-Ob
Hells
Id2
Igbp1
Ighg

Igl-C1
Igl-C2
Igl-V1
Il15
Il16
Il18
Il18r1
Itga6
Jag2
Jmjd1a
Kit
Ltb
Lyst
Ms4a1
Msh2

Msh6
Myd88
Ndrg1
Nup85
Pglyrp1
Plscr1
Prkcd
Ptprc
S100a9
Satb1
Scye1
Sh2b2
Sigirr
Sp1
Tal1

Tap2
Tbx1
Tgfb2
Tlr2
Tnfrsf13c
Tnfsf12
Tnfsf13
Tnfsf9
Trp53
Trpm4
Tshr
Xrcc6
Zbtb16

Table 3.2.2. Immune System Genes, Stroma-Related. Of the 2179 gene changes found in whole
AdvDCIS lesions, which were not present in LCM AdvDCIS cells, 103 genes were classified as
involved in the immune system process (p=8.59 x 10-05, VLAD). Official mouse gene symbols were
obtained from the Mouse Genome Informatics (www.informatics.jax.org).
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Cd24a; chemokine (C-X3-C motif) ligand or receptor, Cx3cl1, Cxcr4; early growth response 1,
Egr1; integrin alpha 6, helicase, lymphoid specific, Hells; Itga6; Immunoglobulin heavy chain
(gamma polypeptide), Ighg; immunoglobulin-like domain containing receptor 1, Ildr1; mutS
homologs, Msh2, Msh6; nucleoporin, Nup85; S100 calcium binding protein A9 (calgranulin B),
S100a9; transforming growth factor, beta 2, Tgfb2; toll-like receptor 2, Tlr2. Unconventional
genes, showing substantially increased expression in AdvDCIS whole glands, which did not
appear in Table 3.2.2 were E26 avian leukemia oncogene 2, 3' domain, Ets2; the T-cell
differentiation protein 2, Mal2; leukocyte cell derived chemotaxin 1, Lect1; lymphocyte antigen 6related genes, Ly6e, Lypd3; T-cell, immune regulator, Tcirg1; T-cell immunoglobulin and mucin
domain containing 2, Timd2.
3.5. Summary
Microarray analysis was used as a data-driven, discovery approach to uncover transcriptional
changes associated with the early stages of tumorigenesis in a mouse model of human breast
cancer, Waptag1. For each stage of tumor progression in Waptag1 whole glands and tumors, a
unique transcriptional signature was apparent. In whole glands containing EDCIS, anti-apoptosis
genes first appeared transcriptionally, while genes regulating immune response were downregulated compared with normal glands. In AdvDCIS glands, genes involved in cell cycle/division
and DNA replication, as well as retrotransposons and histone variants were over expressed,
whereas oxidoreductase activity genes were decreased, when compared with EDCIS. In whole
papillary tumors, cell cycle/division, and DNA replication genes were further up-regulated, when
compared with AdvDCIS glands, as well as immune response and DNA repair genes;
alternatively, oxidoreductase activity genes were further down-regulated than in AdvDCIS glands
and carboxylic acid and lipid metabolic process genes were also down-regulated. Contrary to
stage-specific gene expression profiles found in whole glands and tumors, only minute step-wise
expression changes could be found in laser capture microdissected (LCM) cells. Once fat,
normal epithelium and stromal cells (including immune cells) were removed, leaving only
transcriptional changes from LCM pre-neoplastic EDCIS or AdvDCIS epithelial cells lining the
ducts, cells strikingly resembled whole papillary tumor results. Amplified LCM cells exhibited a
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global tumor transcriptional profile, i.e. abundant transcription of genes involved in cell cycle, cell
division, DNA replication, and DNA repair as well as transcription of chromatin modification genes
and retrotransposons. Gene categories that showed significant down-regulated genes expressed
included aerobic respiration, electron transport, and oxidoreductase activity genes, even as
prematurely as EDCIS. These findings suggest that at the cellular level, a pre-tumor cell is
predominantly a tumor cell; therefore, in the case of SV40 Tag-induced tumors, the surrounding
tumor cell microenvironment presents the stage-specific transcriptional alterations. Comparison
of whole glands with microdissected samples at the same stage of tumor progression confirmed
these theories, exhibiting changes in cell adhesion, immune response, and vasculature genes.
Future comparison of early changes in Waptag1 DCIS and tumors with those of human will
elucidate the significance of these findings in mouse, for potential earlier detection of the human
disease.
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Chapter 4
EARLY TRANSCRIPTIONAL CHANGES IN WAPTAG1 PARALLEL
HUMAN BREAST CARCINOGENESIS
To determine, at the molecular level, the full potential of the Waptag1 mouse model in
detecting early changes relevant to breast cancer, 58 human breast samples were analyzed,
using the same statistical procedures as for the mouse, across three histological classifications:
normal breast tissue, DCIS, or invasive breast cancer (IBC). Unsupervised hierarchical clustering
suggested multiple stages of DCIS and IBC in the human samples as well as two DCIS outliers.
Therefore the DCIS and IBC samples were reclustered (Figure 4.1.A) and the samples were
regrouped accordingly: DCIS1, 9 samples; DCIS2, 16 samples; IBC1, 8 samples; IBC2, 16
samples, and 7 normal human samples (not shown in Figure 4.1.A). When clustered alone, the
two distinct DCIS groups were recapitulated (Figure 4.1.B). Allred and colleagues independently
showed the same clustering for DCIS samples but further defined each cluster as a specific
subtype27. The ERBB2+ or basal samples have been grouped together here as ‘DCIS1’ and the
luminal/mixed samples are designated ‘DCIS2’. The pairwise contrast of human DCIS1 versus
normal breast samples resulted in 6771 differences (q≤0.05), of which 396 had no mouse
ortholog and 588 were not represented on the mouse microarray chip, although mouse orthologs
were known.
Waptag1 samples were regrouped according to clustering (Figure 3.4) for consistency and to
determine the greatest commonalities between species. Unsupervised hierarchical clustering of
the 15 Waptag1 LCM samples revealed two DCIS samples clustered tightly with the C57BL/6J
control cells (D_5714 and E_3991, Figure 3.4). After their removal, the remaining four DCIS
samples were grouped together. The pairwise contrast between Waptag1 LCM DCIS cells and
whole C57BL/6J samples returned 10,393 differences (q≤0.05), of which 922 had no human
ortholog and 4794 were not represented on the human microarrays.
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Figure 4.1. Hierarchical
Clustering across
Human Samples.
A) Unsupervised
clustering of human
samples enriched in IBC
or DCIS; B) DCIS
samples cluster into two
main subgroups, DCIS1
and DCIS2, respectively.
[Normalized median
expression values after
RMA (no q-value
limitation, see methods).
Abbreviations: DCIS,
ductal carcinoma in situ;
IBC, Invasive Breast
Cancer.]

A

B
‘DCIS1’

‘DCIS2’

4.1. Similarities between Human and Waptag1 Ductal Carcinoma In Situ (DCIS)
Waptag1 mammary tumorigenesis remarkably resembles human breast carcinogenesis, at
both the histological, as well as the molecular, levels. Comparison of microarray results from
human DCIS1 with those from Waptag1 DCIS revealed 2097 genes commonly differentially
expressed, of 6945 genes orthologous and represented on all microarrays (Figure 4.2).

10,393

6771

Figure 4.2. Venn Diagram of Common Transcriptional Changes in
Waptag1 LCM DCIS and Human DCIS1. Cross-species comparison revealed
2097 genes commonly up- or down-regulated of 6945 orthologous genes.
Within the 10,393 LCM Waptag1 DCIS (n=4) versus whole B6 samples (n=4)
gene changes (q≤0.05; Fancher K et.al., future publication), 922 had no
human ortholog and 4794 were not represented on the human microarrays.
Among 6771 human DCIS1 (n=9) versus normal samples (n=7) transcriptional
differences (q≤0.05; Fancher K et.al., future publication), 396 had no mouse
ortholog and 588 were not represented on the mouse chip (see methods for
additional details).

Regulation of apoptosis is aberrant in both human and Waptag1 DCIS. Although apoptosisrelated Gene Ontology terms were not significant (p≤0.0001), genes categorized as involved in
regulation of apoptosis and regulation of programmed cell death were among the 2097 genes
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commonly differentially expressed between these two species, albeit at a reduced threshold.
However, species-specific differences revealed apoptosis, regulation of apoptosis, and
specifically positive regulation of apoptosis genes down-regulated in Waptag1 DCIS (see above).
Similarly, in human DCIS1, genes categorized under negative regulation of apoptosis and antiapoptosis exhibited up-regulated expression, whereas apoptosis, particularly positive regulation
of apoptosis genes were down-regulated (see below).
Genes in the GO categories developmental process, system development, specifically
nervous system development and cellular developmental process, cell-cell signaling and
neurotransmitter transport genes were up-regulated in Waptag1 and human DCIS (Table 4.1).
4.1.1. Cells of Waptag1 DCIS and Human DCIS1 are Dividing and Mitotically Active
Waptag1 DCIS cells show abundant mitotic figures (Figure 3.1.B,C) and the 969 genes
commonly up-regulated and orthologous in human and Waptag1 DCIS were enriched in the GO
terms DNA replication, cell cycle, specifically M phase of the mitotic cell cycle, as well as the
cellular component nucleus (Table 4.1). Figure 4.3 depicts predominantly genes over expressed
in the cell cycle, from among all 2097 common differentially expressed genes in Waptag1 mouse
and human DCIS. Of interest, Trp53/TP53 is down-regulated among the plethora of genes upregulated (Figure 4.3). Additional key genes commonly over expressed in Waptag1 and human
DCIS, including Aurka/AURKA, Birc5/BIRC5, Ccnb1/CCNB1, Erbb2/ERBB2, Grb7/GRB7,
Mki67/MKI67, Mmp11/MMP11 (Table 4.3 and Fancher K et.al., future publication), are used as
clinical prognostic indicators for human breast cancer in the commercial OncoTypeDXTM platform.
Increased expression of these genes is associated with high risk of recurrence in human breast
cancer.
These findings address two previous uncertainties: first, the appropriate use of microarrays
for cross-species comparison of global gene expression changes; second, Waptag1 is an
approximate mouse model for the study of human DCIS early changes, predictive of invasive
breast cancer.
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Figure 4.3. Cell Cycle Gene Changes Mutual to Waptag1 LCM DCIS and Human DCIS1. Among the
2097 significant common transcriptional changes, cell cycle genes were predominantly up-regulated (red)
in both species [blue, down-regulated compared with species-specific controls; mouse GenMAPPv2
pathway and software.]

Figure 4.4. Electron Transport Chain Transcriptional Alterations Common to Waptag1 LCM
DCIS and Human DCIS1. A classical aerobic energy-derivation pathway is predominantly downregulated (blue shading) in both species based on the 2097 common genes. [red, up-regulated in
DCIS compared with species-specific controls; mouse GenMAPPv2 pathway and software.]
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Table 4.1. Significant Gene Ontology Classifications Among the 2097 Genes Commonly
Differentially Expressed in Waptag1 DCIS and Human DCIS1. The most over-represented Gene
Ontology terms in A) the 969 genes up-regulated, B) the 1128 genes down-regulated (p≤0.0001,
VLAD, mouse). [Abbreviations: GO, Gene Ontology; BP, Biological Process; MF, Molecular Function;
CC, Cellular Component. A full list of genes and expression values will appear in Fancher K et.al.,
future publication.]
A GO
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

GO_ID
GO:0032502
GO:0030154
GO:0048869
GO:0006259
GO:0007049
GO:0006260
GO:0048856
GO:0043283
GO:0009653
GO:0044237
GO:0044238
GO:0048731
GO:0007275
GO:0051301
GO:0022403
GO:0009987
GO:0065007
GO:0022402
GO:0007399
GO:0000278
GO:0000279
GO:0006468
GO:0007267
GO:0009719
GO:0021983
GO:0008152
GO:0050789
GO:0007268
GO:0043170
GO:0007067
GO:0000087
GO:0007417
GO:0048699
GO:0021536
GO:0006974
GO:0006836
GO:0022008
GO:0016310
GO:0030182
GO:0006139
GO:0050794
GO:0045944
GO:0051179
GO:0048513
GO:0007420
GO:0048666
GO:0000902
GO:0032989
GO:0019226
GO:0001505

GO_Classifications of Up-regulated Genes
developmental process
cell differentiation
cellular developmental process
DNA metabolic process
cell cycle
DNA replication
anatomical structure development
biopolymer metabolic process
anatomical structure morphogenesis
cellular metabolic process
primary metabolic process
system development
multicellular organismal development
cell division
cell cycle phase
cellular process
biological regulation
cell cycle process
nervous system development
mitotic cell cycle
M phase
protein amino acid phosphorylation
cell-cell signaling
response to endogenous stimulus
pituitary gland development
metabolic process
regulation of biological process
synaptic transmission
macromolecule metabolic process
mitosis
M phase of mitotic cell cycle
central nervous system development
generation of neurons
diencephalon development
response to DNA damage stimulus
neurotransmitter transport
neurogenesis
phosphorylation
neuron differentiation
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
regulation of cellular process
positive regulation of transcription from RNA polymerase II promoter
localization
organ development
brain development
neuron development
cell morphogenesis
cellular structure morphogenesis
transmission of nerve impulse
regulation of neurotransmitter levels
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p-value
6.47E-11
1.38E-10
1.38E-10
4.90E-10
8.24E-10
1.80E-09
1.09E-08
1.64E-08
1.93E-08
3.23E-08
5.62E-08
9.30E-08
1.13E-07
1.55E-07
1.65E-07
1.67E-07
1.77E-07
2.66E-07
3.88E-07
5.05E-07
6.85E-07
1.57E-06
1.86E-06
2.08E-06
2.59E-06
2.60E-06
3.78E-06
3.88E-06
4.08E-06
4.09E-06
4.57E-06
4.87E-06
6.53E-06
6.74E-06
1.04E-05
1.26E-05
1.38E-05
1.91E-05
1.98E-05
2.02E-05
2.07E-05
2.42E-05
2.59E-05
2.72E-05
2.83E-05
3.11E-05
3.25E-05
3.25E-05
3.47E-05
4.35E-05

GO
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

GO_ID
GO:0030030
GO:0048858
GO:0032990
GO:0045941
GO:0006793
GO:0006796
GO:0006281
GO:0032508
GO:0032392
GO:0006268
GO:0000904

Up-regulated Genes
cell projection organization and biogenesis
cell projection morphogenesis
cell part morphogenesis
positive regulation of transcription
phosphorus metabolic process
phosphate metabolic process
DNA repair
DNA duplex unwinding
DNA geometric change
DNA unwinding during replication
cellular morphogenesis during differentiation

MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF

GO:0005524
GO:0032559
GO:0005488
GO:0030554
GO:0032555
GO:0032553
GO:0017076
GO:0005515
GO:0000166
GO:0004674
GO:0004672
GO:0030594
GO:0042165
GO:0016773
GO:0016772
GO:0015370
GO:0008504
GO:0022857
GO:0022836
GO:0003824
GO:0016301
GO:0022891

ATP binding
adenyl ribonucleotide binding
binding
adenyl nucleotide binding
purine ribonucleotide binding
ribonucleotide binding
purine nucleotide binding
protein binding
nucleotide binding
protein serine/threonine kinase activity
protein kinase activity
neurotransmitter receptor activity
neurotransmitter binding
phosphotransferase activity, alcohol group as acceptor
transferase activity, transferring phosphorus-containing groups
solute; sodium symporter activity
monoamine transmembrane transporter activity
transmembrane transporter activity
gated channel activity
catalytic activity
kinase activity
substrate-specific transmembrane transporter activity

5.92E-12
1.41E-11
1.62E-10
1.64E-10
1.78E-09
1.78E-09
1.21E-08
5.56E-08
7.27E-08
2.60E-07
5.25E-07
8.63E-07
8.63E-07
3.05E-06
4.18E-06
7.59E-06
8.45E-06
3.53E-05
4.26E-05
4.71E-05
7.04E-05
8.67E-05

CC
CC
CC
CC
CC
CC
CC
CC
CC

GO:0044421
GO:0005615
GO:0045202
GO:0005622
GO:0044424
GO:0005634
GO:0000793
GO:0044456
GO:0005576

extracellular region part
extracellular space
synapse
intracellular
intracellular part
nucleus
condensed chromosome
synapse part
extracellular region

5.00E-07
1.63E-06
2.08E-06
7.55E-06
9.60E-06
1.55E-05
3.09E-05
3.57E-05
9.12E-05

Table 4.1. Continued.
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GO_Classification

p-value
5.12E-05
5.12E-05
5.12E-05
5.30E-05
5.46E-05
5.46E-05
5.55E-05
5.85E-05
5.85E-05
5.85E-05
9.32E-05

B
GO
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP
BP

GO_ID
GO:0008152
GO:0044237
GO:0044238
GO:0048518
GO:0019538
GO:0044267
GO:0001568
GO:0001944
GO:0048514
GO:0043170
GO:0048522
GO:0044260
GO:0009987
GO:0006629
GO:0006631
GO:0032787
GO:0006091
GO:0015980
GO:0006464
GO:0044255
GO:0006793
GO:0006796
GO:0019221
GO:0043412
GO:0042127
GO:0048856
GO:0007243
GO:0016310
GO:0032103
GO:0048513
GO:0043283
GO:0002260
GO:0006084
GO:0048869
GO:0019752
GO:0006082
GO:0045859
GO:0048731
GO:0009887

Down-regulated Genes
metabolic process
cellular metabolic process
primary metabolic process
positive regulation of biological process
protein metabolic process
cellular protein metabolic process
blood vessel development
vasculature development
blood vessel morphogenesis
macromolecule metabolic process
positive regulation of cellular process
cellular macromolecule metabolic process
cellular process
lipid metabolic process
fatty acid metabolic process
monocarboxylic acid metabolic process
generation of precursor metabolites and energy
energy derivation by oxidation of organic compounds
protein modification process
cellular lipid metabolic process
phosphorus metabolic process
phosphate metabolic process
cytokine and chemokine mediated signaling pathway
biopolymer modification
regulation of cell proliferation
anatomical structure development
protein kinase cascade
phosphorylation
positive regulation of response to external stimulus
organ development
biopolymer metabolic process
lymphocyte homeostasis
acetyl-CoA metabolic process
cellular developmental process
carboxylic acid metabolic process
organic acid metabolic process
regulation of protein kinase activity
system development
organ morphogenesis

MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF
MF

GO:0005515
GO:0005488
GO:0003824
GO:0004713
GO:0016301
GO:0050662
GO:0017076
GO:0030554
GO:0016563
GO:0016740
GO:0016773
GO:0000166
GO:0016627
GO:0050660
GO:0048037
GO:0016772
GO:0004672

protein binding
binding
catalytic activity
protein tyrosine kinase activity
kinase activity
coenzyme binding
purine nucleotide binding
adenyl nucleotide binding
transcription activator activity
transferase activity
phosphotransferase activity, alcohol group as acceptor
nucleotide binding
oxidoreductase activity, acting on the CH-CH group of donors
FAD binding
cofactor binding
transferase activity, transferring phosphorus-containing groups
protein kinase activity

Table 4.1. Continued.
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GO_Classification

p-value
4.71E-16
5.06E-14
3.17E-11
7.82E-09
9.96E-09
1.07E-08
1.51E-08
2.29E-08
8.41E-08
1.56E-07
1.61E-07
1.90E-07
4.76E-07
5.88E-07
7.20E-07
2.10E-06
2.28E-06
2.35E-06
3.99E-06
1.08E-05
1.15E-05
1.15E-05
1.17E-05
1.45E-05
1.47E-05
1.62E-05
1.66E-05
1.77E-05
1.86E-05
2.05E-05
2.47E-05
3.77E-05
3.77E-05
4.15E-05
4.81E-05
5.12E-05
7.58E-05
9.01E-05
9.43E-05
7.97E-21
3.64E-20
1.14E-12
2.46E-06
3.21E-06
5.81E-06
7.57E-06
8.53E-06
8.85E-06
1.05E-05
1.75E-05
1.90E-05
2.42E-05
4.98E-05
5.52E-05
6.14E-05
9.81E-05

GO
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC

GO_ID
GO:0005737
GO:0005622
GO:0044424
GO:0043227
GO:0044444
GO:0043231
GO:0043226
GO:0043229
GO:0031090
GO:0005739
GO:0005783
GO:0019866
GO:0031967
GO:0031975
GO:0012505
GO:0005740
GO:0044429
GO:0044422
GO:0005743
GO:0043234
GO:0031966
GO:0044446
GO:0044432
GO:0005578
GO:0031300
GO:0031012
GO:0044421
GO:0005623
GO:0044464
GO:0031227
GO:0005789
GO:0042175
GO:0000267
GO:0005746

Down-regulated Genes
cytoplasm
intracellular
intracellular part
membrane-bounded organelle
cytoplasmic part
intracellular membrane-bounded organelle
organelle
intracellular organelle
organelle membrane
mitochondrion
endoplasmic reticulum
organelle inner membrane
organelle envelope
envelope
endomembrane system
mitochondrial envelope
mitochondrial part
organelle part
mitochondrial inner membrane
protein complex
mitochondrial membrane
intracellular organelle part
endoplasmic reticulum part
proteinaceous extracellular matrix
intrinsic to organelle membrane
extracellular matrix
extracellular region part
cell
cell part
intrinsic to endoplasmic reticulum membrane
endoplasmic reticulum membrane
nuclear envelope-endoplasmic reticulum network
cell fraction
mitochondrial respiratory chain

GO_Classification

p-value
1.61E-38
1.02E-31
1.48E-31
9.67E-23
1.50E-22
2.75E-22
1.21E-19
5.81E-19
1.61E-13
9.76E-11
2.44E-07
2.48E-07
3.38E-07
3.66E-07
7.57E-07
7.85E-07
9.30E-07
9.67E-07
1.05E-06
1.45E-06
1.50E-06
1.85E-06
2.63E-06
4.27E-06
4.98E-06
6.06E-06
7.50E-06
7.98E-06
7.98E-06
1.23E-05
3.42E-05
5.65E-05
8.08E-05
8.81E-05

Table 4.1. Continued.

4.1.2. Inhibition of Normal Energy Derivation
The 1128 orthologous genes whose expression was commonly down-regulated in Waptag1
DCIS and human DCIS1 were categorized under the following GO terms: generation of
precursor metabolites and energy, specifically energy derivation by oxidation of organic
compounds, lipid metabolic process, and the cellular components mitochondrion, specifically
mitochondrial membrane and mitochondrial respiratory chain (Table 4.1.B). At a reduced
threshold, genes down-regulated in both species were involved in oxidoreductase activity, aerobic
respiration, particularly tricarboxylic acid cycle, electron carrier activity, cofactor binding,
specifically coenzyme binding, and lastly, ATP binding. Figure 4.4 depicts the electron carrier
activity genes as visualized on the electron transport chain pathway diagram. Genes in each
complex of the respiratory pathway are commonly down-regulated. Figure 4.5 shows genes
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under expressed within the aerobic respiration pathway. Ubiquinol-cytochrome c reductase
genes, Uqcrh, and Uqcrfs1 show the most substantial down-regulation in mouse. Additional
genes in these GO categories were down-regulated in either human or Waptag1 as well (though
not both), suggesting that some genes may have evolved different functions over time in each
species.

Figure 4.5. Aerobic Respiration, Electron Donor II Pathway Commonly Down-Regulated in Waptag1
LCM DCIS and Human DCIS1. Another classical aerobic energy-derivation pathway is predominantly
down-regulated (yellow to green to blue spectrum) in DCIS in both species compared with species-specific
controls. [Expression data from mouse is shown. Color Codes: yellow, down-regulated more than 4x
(log2); green, beyond 1.8x (log2); blue, more than 0.6-fold (log2) down; MouseCyc software.]
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One important finding, presented here in an in vivo model, is the down-regulation of the most
efficient form of energy production, early in the tumorigenic process, in both mice and humans.
When oxidative phosphorylation and generation of energy via the electron transport chain are
predominantly inhibited, glycolysis is likely the means of ATP production. In support of this,
numerous genes in the glycolysis pathway (for example, aldolase B, fructose-bisphosphate,
Aldob/ALDOB, enolase 2, Eno2/ENO2, and hexokinase 3 Hk3/HK3) were commonly over
expressed in DCIS (although the GO term itself was not significant at the cutoff threshold).
Additionally, lactate dehydrogenases, Ldhb and Ldhc, in Waptag1, and ENO1, ENO3,
glyceraldehyde-3-phosphate dehydrogenase, GAPDH, phosphoglycerate mutase 2 (PGAM2) and
phosphofructokinases PFKP and PFKL in human DCIS were up-regulated compared with
controls. (Of note, Gapdh and Eno1 were not represented in the annotation for the mouse array.)
Finally, the transcriptional coactivators and enhancers of oxidative phosphorylation, peroxisome
proliferative activated receptors Ppargc1a and Ppargc1b, are both down-regulated in lasercaptured cells of Waptag1 DCIS compared with B6 controls. (However, these genes were not
present on the U95Av2 human array.)
4.1.3. Chromatin Remodeling, an Early Pre-tumor Modification
In Waptag1 DCIS, chromatin remodeling was among the early transcriptional changes,
accompanied by over expression of retrotransposons, histones, and histone variants. Similarly,
among genes commonly up-regulated in Waptag1 and Human DCIS, the following GO categories
were significantly over-represented: positive regulation of transcription, specifically, positive
regulation of transcription from RNA polymerase II promoter (Table 4.1.A). At a reduced
threshold, chromatin binding, histone modification, and the cellular components, chromosome, in
particular condensed chromosome categories were enriched in both human and Waptag1 DCIS.
In Waptag1 and human DCIS, epigenetic modifications and transcriptional deregulation of the
genome appear to be an early event in tumorigenesis. Alongside the up-regulated common
histone variants (H2afx and H2afy) and chromatin assembly, organization, modifying/remodeling
factors: Actl6a/ACTL6A, Bmi1/BMI1, Cenpa/CENPA, Chaf1b/CHAF1B, Ezh2/EZH2,
Mcm2/MCM2, Rad54l/RAD54L, and Smarcd2/SMARCD2 (Table 4.2), chromatin binding was a
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significant GO category in the list of 2097 genes (at a reduced threshold). Table 4.2 depicts
genes categorized predominantly under the GO terms chromatin modification and/or chromatin
organization & biogenesis, however known and/or predicted chromatin-associated factors,
including those that activate, repress, or may regulate chromatin have been included as well
(Table 4.2). Of note, chromobox genes Cbx4/CBX4 and Cbx7/CBX7, suppressor of zest,
Suz12/SUZ12, and methyl CpG binding protein, Mecp2/MECP2, genes were down-regulated in
DCIS in both species (Table 4.2). Since the MECP2 protein binds methylated cytosines to
maintain silenced DNA, it further supports the alteration of epigenetic suppression of chromatin.
AURKB/Aurkb expression was up-regulated in human and Waptag1 DCIS (Tables 4.2 and
4.3). Phosphorylation of histone H3 by mitotic AURKB, which occurs during M phase of the cell
cycle, results in the liberation of Hp1, or another chromobox (CBX) protein, from
heterochromatin124,125. Thus, up-regulation of AURKB/Aurkb may be a potential key early player
because unsilencing of heterochromatin is associated with chromatin modifications. Perhaps
Aurkb is a harbinger of changes that are to come.

Table 4.2. Chromosome Modification or Organization Factors in Waptag1 DCIS and Human
DCIS1. Genes involved in chromatin modification/organization were selected to detail the expression
levels of chromatin-related gene changes. Fold changes shown are statistically significant according
to Fs statistic (ANOVA, q≤0.01). [Abbreviations: MGI, Mouse Genome Informatics; Wapt1,
Waptag1; LCM, laser-capture microdissection; DCIS, ductal carcinoma in situ; whB6, whole glands
from C57BL/6J; N/A, no mouse or human ortholog; NOA, not on array; NS, not significant, though the
gene was present on the array.]

MGI_symbol
Acd
Actl6a
Actl6b
Aebp2
Akap8
Aof2
Ard1
Arid1a
Arid4b
Asf1a
Asf1b
Ash1l
Aurkb

Gene_Name
adrenocortical dysplasia
actin-like 6A
actin-like 6B
AE binding protein 2
A kinase (PRKA) anchor protein 8
amine oxidase (flavin containing) domain 2
N-acetyltransferase ARD1 homolog (S. cerevisiae)
AT rich interactive domain 1A (Swi1 like)
AT rich interactive domain 4B (Rbp1 like)
ASF1 anti-silencing function 1 homolog A (S. cerevisiae)
ASF1 anti-silencing function 1 homolog B (S. cerevisiae)
ash1 (absent, small, or homeotic)-like (Drosophila)
aurora kinase B
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Fold Change
Waptag1 LCM
DCIS vs. whB6

Human
Symbol

FoldChange
Human DCIS1
vs. Norm

NS
2.92
1.19
NOA
NS
3.13
-3.42
-2.08
-1.27
2.39
4.77
NS
14.53

ACD
ACTL6A
ACTL6B
AEBP2
AKAP8
AOF2
ARD1A
ARID1A
ARID4B
ASF1A
ASF1B
ASH1L
AURKB

2.37
5.19
4.18
NOA
-1.20
-1.45
-1.23
-5.45
NOA
-6.28
NOA
NOA
14.02

MGI_symbol
Banp
Baz1a
Baz1b
Bcor
Bcorl1
Blm
Bmi1
Bptf
Brca2
Brd8
Brdt
Bub3
Carm1
Cbx1
Cbx2
Cbx3
Cbx4
Cbx5
Cbx6
Cbx7
Cbx8
Ccnb1ip1
Cdyl
Cebpg
Cenpa
Cenph
Chaf1b
Chd1
Chd3
Chd4
Chd6
Chd7
Chd9
Cit
Cpeb1
Crebbp
Dapk3
Dclre1c
Dmap1
Dnmt1
Dnmt3a
Dnmt3b
Eed
Ehmt2
Ep400
Epc1
Epc2
Ercc1
Ezh2
Fancd2
Fbxl10
Fbxl11
Gpx4
Gsg2
H1f0
H2afv
H2afx
H2afy
H2afy2
H2afz
H3f3a
H3f3b
Hdac1
Hdac10
Hdac11
Hdac2
Hdac3
Hdac4
Hdac5
Hdac6
Hdac7
Hdac8
Hdac9
Hells
Hils1
Hira

Fold Change
Waptag1 LCM
DCIS vs. whB6

Gene_Name

Btg3 associated nuclear protein
bromodomain adjacent to zinc finger domain 1A
bromodomain adjacent to zinc finger domain, 1B
Bcl6 interacting corepressor
BCL6 co-repressor-like 1
Bloom syndrome homolog (human)
Bmi1 polycomb ring finger oncogene
bromodomain PHD finger transcription factor
breast cancer 2
bromodomain containing 8
bromodomain, testis-specific
budding uninhibited by benzimidazoles 3 homolog
coactivator-associated arginine methyltransferase 1
chromobox homolog 1 (Drosophila HP1 beta)
chromobox homolog 2 (Drosophila Pc class)
chromobox homolog 3 (Drosophila HP1 gamma)
chromobox homolog 4 (Drosophila Pc class)
chromobox homolog 5 (Drosophila HP1a)
chromobox homolog 6
chromobox homolog 7
chromobox homolog 8 (Drosophila Pc class)
cyclin B1 interacting protein 1
chromodomain protein, Y chromosome-like
CCAAT/enhancer binding protein (C/EBP), gamma
centromere protein A
centromere protein H
chromatin assembly factor 1, subunit B (p60)
chromodomain helicase DNA binding protein 1
chromodomain helicase DNA binding protein 3
chromodomain helicase DNA binding protein 4
chromodomain helicase DNA binding protein 6
chromodomain helicase DNA binding protein 7
chromodomain helicase DNA binding protein 9
citron
cytoplasmic polyadenylation element binding protein 1
CREB binding protein
death-associated protein kinase 3
DNA cross-link repair 1C, PSO2 homolog (S. cerevisiae)
DNA methyltransferase 1-associated protein 1
DNA methyltransferase (cytosine-5) 1
DNA methyltransferase 3A
DNA methyltransferase 3B
embryonic ectoderm development
euchromatic histone lysine N-methyltransferase 2
E1A binding protein p400
enhancer of polycomb homolog 1 (Drosophila)
enhancer of polycomb homolog 2 (Drosophila)
excision repair cross-complementing rodent repair deficiency, co
enhancer of zeste homolog 2 (Drosophila)
Fanconi anemia, complementation group D2
F-box and leucine-rich repeat protein 10
F-box and leucine-rich repeat protein 11
glutathione peroxidase 4
germ cell-specific gene 2
H1 histone family, member 0
H2A histone family, member V
H2A histone family, member X
H2A histone family, member Y
H2A histone family, member Y2
H2A histone family, member Z
H3 histone, family 3A
H3 histone, family 3B
histone deacetylase 1
histone deacetylase 10
histone deacetylase 11
histone deacetylase 2
histone deacetylase 3
histone deacetylase 4
histone deacetylase 5
histone deacetylase 6
histone deacetylase 7
histone deacetylase 8
histone deacetylase 9
helicase, lymphoid specific
histone H1-like protein in spermatids 1
histone cell cycle regulation defective homolog A

Table 4.2. Continued.
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1.68
NS
-1.76
NS
1.30
6.76
2.18
1.43
1.46
1.32
1.22
NS
-1.31
1.67
NS
NOA
-1.80
NS
NS
-1.53
NS
NS
-1.29
1.30
11.55
2.91
4.47
-2.76
1.23
-2.10
2.35
NS
NS
NOA
-1.85
-1.94
-4.15
1.37
1.97
1.36
1.90
1.61
1.24
-2.28
NS
1.89
3.19
NS
4.71
1.64
NOA
NOA
NOA
4.55
NS
NS
2.81
1.46
-1.42
2.32
NOA
1.53
NOA
1.58
1.98
-1.61
1.32
NS
1.53
-1.21
-1.57
NS
-1.35
3.62
1.53
NS

Human
Symbol

FoldChange
Human DCIS1
vs. Norm

BANP
BAZ1A
BAZ1B
BCOR
BCORL1
BLM
BMI1
BPTF
BRCA2
BRD8
BRDT
BUB3
CARM1
CBX1
CBX2
CBX3
CBX4
CBX5
CBX6
CBX7
CBX8
CCNB1IP1
CDYL
CEBPG
CENPA
CENPH
CHAF1B
CHD1
CHD3
CHD4
CHD6
CHCHD7
CHD9
CIT
CPEB1
CREBBP
DAPK3
DCLRE1C
DMAP1
DNMT1
DNMT3A
DNMT3AB
EED
EHMT2
EP400
EPC1
EPC2
ERCC1
EZH2
FANCD2
FBXL10
FBXL11
GPX4
GSG2
H1F0
H2AFV
H2AFX
H2AFY
H2AFY2
H2AFZ
H3F3A
H3F3B
HDAC1
HDAC10
HDAC11
HDAC2
HDAC3
HDAC4
HDAC5
HDAC6
HDAC7
HDAC8
HDAC9
HELLS
HILS1
HIRA

NOA
1.28
-2.88
NOA
NOA
1.97
1.93
NOA
NS
1.46
-1.39
-1.40
3.43
-1.35
1.76
NS
-2.06
NOA
NOA
-1.71
NOA
NOA
1.88
-1.85
3.04
NOA
1.56
1.28
2.10
4.12
NOA
NOA
NOA
-2.08
NOA
-1.63
6.11
NOA
NOA
NS
NOA
NOA
1.87
NOA
-1.63
NOA
NOA
1.62
5.86
NOA
NOA
1.45
1.40
NOA
-13.79
NS
1.45
1.89
NOA
-2.61
NOA
-6.40
-1.78
NOA
NOA
NS
-4.06
1.64
1.80
NS
NOA
NOA
1.53
NOA
NOA
2.63

MGI_symbol
Hist1h1b
Hist1h1c
Hist1h1d
Hist1h1e
Hist1h1t
Hist1h2ad
Hist1h2ae
Hist1h2ai
Hist1h2ak
Hist1h2be
Hist1h2bf
Hist1h2bk
Hist1h2bl
Hist1h2bm
Hist1h3f
Hist1h4b
Hist1h4c
Hist1h4h
Hist1h4i
Hist2h2be
Hist2h3c1
Hist2h3c2
Hist3h2a
Hist3h2ba
Hltf
Hmg20a
Hmg20b
Hmgn1
Hnf1a
Hopx
Hp1bp3
Hspa1a
Hspa1b
Ing2
Ing3
Jarid1a
Jarid1b
Jarid1c
Jarid1d
Jmjd1a
Jmjd1b
Jmjd1c
Jmjd2a
Jmjd2b
Jmjd2c
Jmjd2d
Jmjd3
Kat2b
Kat5
Klf1
L3mbtl2
Lig4
Mad2l1
Map3k12
Mbd1
Mbd2
Mbd3
Mcm2
Mecp2
Men1
Mettl8
Mlh3
Mll1
Mll3
Mll5
Morf4l1
Morf4l2
Mphosph8
Msh4
Msh5
Msl31
Msx3
Mta2
Myst1
Myst2
Myst3
Myst4

Gene_Name
histone cluster 1, H1b
histone cluster 1, H1c
histone cluster 1, H1d
histone cluster 1, H1e
histone cluster 1, H1t
histone cluster 1, H2ad
histone cluster 1, H2ae
histone cluster 1, H2ai
histone cluster 1, H2ak
histone cluster 1, H2be
histone cluster 1, H2bf
histone cluster 1, H2bk
histone cluster 1, H2bl
histone cluster 1, H2bm
histone cluster 1, H3f
histone cluster 1, H4b
histone cluster 1, H4c
histone cluster 1, H4h
histone cluster 1, H4i
histone cluster 2, H2be
histone cluster 2, H3c1
histone cluster 2, H3c2
histone cluster 3, H2a
histone cluster 3, H2ba
helicase-like transcription factor
high mobility group 20A
high mobility group 20 B
high mobility group nucleosomal binding domain 1
HNF1 homeobox A
HOP homeobox
heterochromatin protein 1, binding protein 3
heat shock protein 1A
heat shock protein 1B
inhibitor of growth family, member 2
inhibitor of growth family, member 3
jumonji, AT rich interactive domain 1A (Rbp2 like)
jumonji, AT rich interactive domain 1B (Rbp2 like)
jumonji, AT rich interactive domain 1C (Rbp2 like)
jumonji, AT rich interactive domain 1D (Rbp2 like)
jumonji domain containing 1A
jumonji domain containing 1B
jumonji domain containing 1C
jumonji domain containing 2A
jumonji domain containing 2B
jumonji domain containing 2C
jumonji domain containing 2D
jumonji domain containing 3
K(lysine) acetyltransferase 2B
K(lysine) acetyltransferase 5
Kruppel-like factor 1 (erythroid)
l(3)mbt-like 2 (Drosophila)
ligase IV, DNA, ATP-dependent
MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast)
mitogen-activated protein kinase kinase kinase 12
methyl-CpG binding domain protein 1
methyl-CpG binding domain protein 2
methyl-CpG binding domain protein 3
minichromosome maintenance deficient 2 mitotin
methyl CpG binding protein 2
multiple endocrine neoplasia 1
methyltransferase like 8
mutL homolog 3 (E coli)
myeloid/lymphoid or mixed-lineage leukemia 1
myeloid/lymphoid or mixed-lineage leukemia 3
myeloid/lymphoid or mixed-lineage leukemia 5
mortality factor 4 like 1
mortality factor 4 like 2
M-phase phosphoprotein 8
mutS homolog 4 (E. coli)
mutS homolog 5 (E. coli)
male-specific lethal-3 homolog 1 (Drosophila)
homeobox, msh-like 3
metastasis-associated gene family, member 2
MYST histone acetyltransferase 1
MYST histone acetyltransferase 2
MYST histone acetyltransferase (monocytic leukemia) 3
MYST histone acetyltransferase monocytic leukemia 4
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Fold Change
Waptag1 LCM
DCIS vs. whB6
NOA
1.55
NOA
NS
1.51
NOA
NOA
NOA
NOA
NOA
NOA
NOA
NOA
NOA
2.31
NOA
NOA
-7.34
3.86
5.47
-1.50
3.56
1.89
1.93
1.74
NS
-2.92
3.92
NS
-1.95
1.28
2.51
2.04
1.93
NS
NS
NS
-1.42
NS
2.06
1.25
NS
NOA
-1.26
-1.58
1.43
1.77
-1.59
-2.83
NS
NS
1.68
7.14
1.90
1.92
-1.73
-1.98
4.37
1.44
-1.50
3.99
2.84
NS
NS
NOA
NOA
NOA
1.37
NS
1.71
2.06
1.18
-3.02
-1.34
-1.21
NS
1.78

FoldChange
Human Symbol Human DCIS1 vs.
Norm
3.30
HIST1H1B
-2.08
HIST1H1C
3.57
HIST1H1D
1.72
HIST1H1E
NS
HIST1H1T
17.67
HIST1H2AD
2.19
HIST1H2AE
-2.33
HIST1H2AI
-1.20
HIST1H2AK
2.24
HIST1H2BE
-1.49
HIST1H2BF
-1.83
HIST1H2BK
2.32
HIST1H2BL
6.60
HIST1H2BM
NOA
HIST1H3F
1.28
HIST1H4B
-2.04
HIST1H4C
NOA
HIST1H4H
NOA
HIST1H4I
-1.67
HIST2H2BE
NOA
HIST2H3C
N/A
NOA
HIST3H2A
NOA
HIST3H2BA
-6.54
HLTF
NOA
HMG20A
NS
HMG20B
NOA
HMGN1
NS
HNF1A
-1.48
HOP
NOA
HP1BP3
NOA
HSPA1A
NOA
HSPA1B
-1.98
ING2
-2.45
ING3
-1.46
JARID1A
NS
JARID1B
1.46
JARID1C
2.25
JARID1D
-2.59
JMJD1A
-10.18
JMJD1B
-8.36
JMJD1C
2.70
JMJD2A
1.78
JMJD2B
NOA
JMJD2C
NOA
JMJD2D
2.51
JMJD3
-3.10
PCAF
-3.09
HTATIP
1.40
KLF1
NOA
L3MBTL2
-2.35
LIG4
NS
MAD2L1
2.25
MAP3K12
-4.80
MBD1
5.66
MBD2
1.71
MBD3
3.95
MCM2
1.57
MECP2
NS
MEN1
NOA
METTL8
NS
MLH3
2.43
MLL
NOA
MLL3
NOA
MLL5
NOA
MORF4L1
-2.09
MORF4L2
-3.02
HSMPP8
-1.74
MSH4
NOA
MSH5
-3.40
MSL3L1
N/A
NOA
MTA2
2.29
MYST1
-4.39
MYST2
2.12
MYST3
NOA
MYST4

MGI_symbol
Nap1l1
Nap1l2
Nap1l3
Nap1l4
Ncapd2
Ncapd3
Ncapg2
Ncaph
Ncaph2
Ncor1
Nek2
Noc2l
Npm2
Nr3c1
Nsd1
Nusap1
Padi4
Parp1
Parp12
Parp14
Parp16
Parp2
Parp9
Pax5
Pcgf2
Phf21a
Pot1a
Prdm9
Prkdc
Prm1
Prm2
Prm3
Prmt5
Pttg1
Rad54l
Rb1
Rbbp4
Rbbp7
Rbl1
Rbl2
Rcbtb1
Rcor1
Recql4
Rere
Ring1
Rnf2
Rnf20
Rnf40
Rtel1
Ruvbl1
Ruvbl2
Sap18
Satb1
Set
Setd1b
Setd7
Setd8
Setdb1
Setdb2
Sgol2
Shprh
Sirt1
Sirt2
Sirt3
Sirt4
Sirt5
Sirt6
Sirt7

Gene_Name
nucleosome assembly protein 1-like 1
nucleosome assembly protein 1-like 2
nucleosome assembly protein 1-like 3
nucleosome assembly protein 1-like 4
non-SMC condensin I complex, subunit D2
non-SMC condensin II complex, subunit D3
non-SMC condensin II complex, subunit G2
non-SMC condensin I complex, subunit H
non-SMC condensin II complex, subunit H2
nuclear receptor co-repressor 1
NIMA (never in mitosis gene a)-related expressed kinase 2
nucleolar complex associated 2 homolog (S. cerevisiae)
nucleophosmin/nucleoplasmin 2
nuclear receptor subfamily 3, group C, member 1
nuclear receptor-binding SET-domain protein 1
nucleolar and spindle associated protein 1
peptidyl arginine deiminase, type IV
poly (ADP-ribose) polymerase family, member 1
poly (ADP-ribose) polymerase family, member 12
poly (ADP-ribose) polymerase family, member 14
poly (ADP-ribose) polymerase family, member 16
poly (ADP-ribose) polymerase family, member 2
poly (ADP-ribose) polymerase family, member 9
paired box gene 5
polycomb group ring finger 2
PHD finger protein 21A
protection of telomeres 1A
PR domain containing 9
protein kinase, DNA activated, catalytic polypeptide
protamine 1
protamine 2
protamine 3
protein arginine N-methyltransferase 5
pituitary tumor-transforming 1
RAD54 like (S. cerevisiae)
retinoblastoma 1
retinoblastoma binding protein 4
retinoblastoma binding protein 7
retinoblastoma-like 1 (p107)
retinoblastoma-like 2
regulator of chromosome condensation (RCC1) and BTB (POZ)
domain containing protein 1
REST corepressor 1
RecQ protein-like 4
arginine glutamic acid dipeptide (RE) repeats
ring finger protein 1
ring finger protein 2
ring finger protein 20
ring finger protein 40
regulator of telomere elongation helicase 1
RuvB-like protein 1
RuvB-like protein 2
Sin3-associated polypeptide 18
special AT-rich sequence binding protein 1
SET translocation
SET domain containing 1B
SET domain containing (lysine methyltransferase) 7
SET domain containing (lysine methyltransferase) 8
SET domain, bifurcated 1
SET domain, bifurcated 2
shugoshin-like 2 (S. pombe)
SNF2 histone linker PHD RING helicase
sirtuin 1 (silent mating type information regulation 2, homolog) 1
(S. cerevisiae)
sirtuin 2
sirtuin 3
sirtuin 4
sirtuin 5
sirtuin 6
sirtuin 7

Table 4.2. Continued.
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Fold Change
Waptag1 LCM
DCIS vs. whB6

Human
Symbol

FoldChange
Human DCIS1
vs. Norm

NS
1.21
-1.21
-1.18
NOA
NS
3.24
9.01
2.83
-1.42
7.82
NOA
NS
NS
NS
16.50
1.67
NS
NS
2.65
2.38
1.59
NS
-1.25
-1.61
1.39
1.23
NS
2.07
NS
-1.23
1.66
-1.58
-1.70
6.81
3.38
-3.80
2.87
2.17
-5.87

NAP1L1
NAP1L2
NAP1L3
NAP1L4
NCAPD2
NCAPD3
NCAPG2
NCAPH
NCAPH2
NCOR1
NEK2
NOC2L
NPM2
NR3C1
NSD1
NUSAP1
PADI4
PARP1
PARP12
PARP14
PARP16
PARP2
PARP9
PAX5
PCGF2
PHF21A
POT1
PRDM9
PRKDC
PRM1
PRM2
PRM3
PRMT5
PTTG1
RAD54L
RB1
RBBP4
RBBP7
RBL1
RBL2

-3.48
NOA
-2.00
3.41
4.11
-1.25
NOA
NS
NOA
NOA
-1.49
NS
NOA
-3.18
NOA
NOA
NOA
1.52
NOA
NOA
NOA
-1.95
NOA
3.33
4.93
3.01
NOA
NOA
-1.39
1.60
2.00
NOA
NOA
2.26
6.10
-5.19
-1.86
NOA
3.62
-3.68

-1.78
NS
3.31
NS
-1.93
-2.26
NS
-1.40
2.08
NOA
-1.44
1.32
-6.55
NOA
NS
NS
-1.36
NS
1.93
5.81
NS

RCBTB1
RCOR1
RECQL4
RERE
RING1
RNF2
RNF20
RNF40
RTEL1
RUVBL1
RUVBL2
SAP18
SATB1
SET
SETD1B
SETD7
SETD8
SETDB1
SETDB2
SGOL2
SHPRH

NOA
NOA
2.02
6.59
NOA
3.76
NOA
NS
3.60
1.28
1.42
NS
-2.19
2.27
-3.10
NOA
NOA
1.35
NOA
NOA
NOA

-2.05
-1.51
1.26
-1.51
-1.24
1.23
1.45

SIRT1
SIRT2
SIRT3
SIRT4
SIRT5
SIRT6
SIRT7

NOA
NOA
NOA
NOA
NOA
NOA
NOA

MGI_symbol

Smarca1
Smarca2
Smarca4
Smarca5
Smarcal1
Smarcb1
Smarcc1
Smarcc2
Smarcd1
Smarcd2
Smarcd3
Smarce1
Smc1a
Smc1b
Smc2
Smc3
Smc4
Smchd1
Smyd1
Smyd3
Sox1
Sox3
Stag3
Stra8
Suds3
Supt4h1
Supt4h2
Suv39h1
Suv39h2
Suv420h1
Suv420h2
Suz12
Syce2
Tbl1xr1
Terf1
Terf2
Tinf2
Tlk1
Tlk2
Tnp2
Top2a
Trrap
Tspyl1
Tspyl2
Tspyl4
Tspyl5
Ttf1
Utp3
Utx
Uty
Vps72
Wbp7
Whsc1
Wrn
Xrn1
Yeats4
1600027N09Rik
1700054O13Rik
2210018M11Rik
2410016O06Rik
2610028A01Rik

Gene_Name
SWI/SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily a, member 1
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
SWI/SNF related, matrix associated, regulator of chromatin
structural maintenance of chromosomes 1A
structural maintenance of chromosomes 1B
structural maintenance of chromosomes 2
structural maintenace of chromosomes 3
structural maintenance of chromosomes 4
SMC hinge domain containing 1
SET and MYND domain containing 1
SET and MYND domain containing 3
SRY-box containing gene 1
SRY-box containing gene 3
stromal antigen 3
stimulated by retinoic acid gene 8
suppressor of defective silencing 3 homolog (S. cerevisiae)
suppressor of Ty 4 homolog 1 (S. cerevisiae)
suppressor of Ty 4 homolog 2 (S. cerevisiae)
suppressor of variegation 3-9 homolog 1 (Drosophila)
suppressor of variegation 3-9 homolog 2 (Drosophila)
suppressor of variegation 4-20 homolog 1 (Drosophila)
suppressor of variegation 4-20 homolog 2 (Drosophila)
suppressor of zeste 12 homolog (Drosophila)
synaptonemal complex central element protein 2
transducin (beta)-like 1X-linked receptor 1
telomeric repeat binding factor 1
telomeric repeat binding factor 2
Terf1 (TRF1)-interacting nuclear factor 2
tousled-like kinase 1
tousled-like kinase 2 (Arabidopsis)
transition protein 2
topoisomerase (DNA) II alpha
transformation/transcription domain-associated protein
testis-specific protein, Y-encoded-like 1
TSPY-like 2
TSPY-like 4
testis-specific protein, Y-encoded-like 5
transcription termination factor 1
UTP3, small subunit processome component, homolog
ubiquitously transcribed tetratricopeptide repeat gene, X
chromosome
ubiquitously transcribed tetratricopeptide repeat gene, Y
chromosome
vacuolar protein sorting 72 (yeast)
WW domain binding protein 7
Wolf-Hirschhorn syndrome candidate 1 (human)
Werner syndrome homolog (human)
5'-3' exoribonuclease 1
YEATS domain containing 4
RIKEN cDNA 1600027N09 gene
RIKEN cDNA 1700054O13 gene
RIKEN cDNA 2210018M11 gene
RIKEN cDNA 2410016O06 gene
RIKEN cDNA 2610028A01 gene

FoldChange
Human DCIS1
vs. Norm

Fold Change
Waptag1 LCM
DCIS vs. whB6

Human
Symbol

NS
NS
NS
-3.21
-1.34
NS
NS
-1.45
-1.80
4.53
NS
-1.66
NS
NS
1.69
-1.98
1.92
NOA
-1.18
NS
1.52
NS
NS
1.58
NS
NOA
NOA
1.39
1.61
NOA
-1.19
-2.49
6.41
NOA
NS
NS
1.95
NS
NS
1.28
7.05
-1.54
-1.91
NS
1.68
NS
NOA
NS

SMARCA1
SMARCA2
SMARCA4
N/A
SMARCAL1
SMARCB1
SMARCC1
SMARCC2
SMARCD1
SMARCD2
SMARCD3
SMARCE1
SMC1A
SMC1B
SMC2
SMC3
SMC4
SMCHD1
SMYD1
SMYD3
SOX1
SOX3
STAG3
STRA8
SUDS3
SUPT4H1
N/A
SUV39H1
SUV39H2
SUV420H1
SUV420H2
SUZ12
SYCE2
TBL1XR1
TERF1
TERF2
TINF2
TLK1
TLK2
TNP2
TOP2A
TRRAP
TSPYL1
TSPYL2
TSPYL4
TSPYL5
TTF1
SAS10

NOA
1.64
2.29
-2.10
-1.38
1.90
NS
1.55
2.18
NOA
NS
-1.32
-4.50
-5.33
NOA
NOA
3.79
5.02
NOA
NOA
NOA
-1.84
NOA
NOA
NOA
NOA
NOA
-4.74
NOA
NOA
-2.18
-4.69
NOA
8.47
1.52
-2.06
6.34
NS
-13.58
-2.11
-1.53
-2.05
-3.13
-1.55

-1.84

UTX

-5.54

NS
-3.82
1.34
1.37
1.39
1.38
1.25
-1.33
NS
1.53
1.92
4.58

UTY
VPS72
MLL4
WHSC1
WRN
XRN1
YEATS4
C20orf20
CXorf27
C11orf30
C14orf169
PINX1

NS
2.07
3.28
3.47
-1.35
NOA
NOA
NOA
-1.38
NOA
NOA
NOA

NS
NS
1.79

Table 4.2. Continued.

4.1.4. Transcriptional Activation and Expression of Retrotransposons
Retrotransposons, often found in heterochromatic regions, are abundantly expressed in both
Waptag1 and human DCIS. Although there is little sequence similarity among human and mouse
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retrotransposons, the similarity of mechanisms underlying activation of these elements early in
tumorigenesis in both human and mouse is very likely, given that these repetitive elements are
generally not expressed in normal cells. To query for retrotransposon expression, specifically in
the datasets described here, the target sequences for each of the Affymetrix probes on the
mouse or human arrays were processed through RepeatMasker215. (These data are the only
ones for which the UMBA cdf was not used for pre-processing.) Numerous retrotransposons
were among the top transcripts with the highest changes in expression, irrespective of the
species (Table 5.4, Chapter 5). Long terminal repeat (LTR) Class I, II, and III retrotransposons,
as well as LINEs and SINEs, were over-expressed in Waptag1 and human DCIS. The LTR
retrotransposons that may be genetic predictors of committed transformation to tumorigenesis are
discussed in Chapter 5.
Since transcriptional activation of retrotransposons is associated with epigenetic changes and
aberrant gene expression, these molecules may prove useful indicators of early stages of
mammary tumorigenesis. Data presented in the next chapter test the hypothesis: there may be
a common mechanism by which repetitive elements are activated early in the tumorigenic
process in both mouse and human mammary cancer.
4.1.5. Early Transcripts in Waptag1 DCIS and Human DCIS1 Predictive of Reduced
Survival in Human Breast Cancer
To find the earliest gene changes in LCM Waptag1 DCIS that could be putative predictive
markers of an invasive phenotype in human and indicative of progression from DCIS1 to invasive
breast cancer and metastasis, the data were reanalyzed. LCM Waptag1 DCIS samples were
regrouped , to remove D_3539, the LCM DCIS sample that clustered closest to the tumor
samples (Figure 3.4), leaving five DCIS samples that were the most similar to B6. The pairwise
contrast with whole B6 resulted in 8238 significantly expressed genes (q≤0.05). Comparison of
the mouse genes from the LCM DCIS samples to the 6771 human DCIS1-Norm (see above)
genes, revealed an overlap of 1488 differentially expressed genes, with the same directionality.
Since DCIS2 was predicted to be less likely to be invasive27, these 1488 genes were then
compared with the human DCIS1-DCIS2 contrast (data not shown). These subtractions resulted
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in 63 up-regulated genes, which predicted progression to invasion in three independent human
breast cancer datasets (Kaplan-Meier log-rank test; p≤0.017; Figure 4.6; Table 4.3). Although a
subset of the 65 down-regulated genes was not prognostic (data not shown), among the 128 total
commonly up- and down-regulated genes, 14 of the 63 up-regulated showed significant
enrichment for genes indicative of poor breast cancer survival in human, a much greater
proportion than would be expected by chance alone (p=1.1 x 10-19; Figure 4.6.B; Table 4.3).
Within the 2097 transcriptional changes most common between species (detailed throughout this
chapter), expression levels of all 63 up-regulated genes were significant, showing substantial fold
changes in human DCIS1 and Waptag1 DCIS, when compared with normal controls (Table 4.3
and Fancher K et.al., future publication).

A

B

Figure 4.6. Prognostic Value of the Waptag1 Early
DCIS 63 Gene Subset. A) Within three independent
37,189,190
, the 63 gene
human breast cancer datasets
signature predicted progression to invasion and decreased
survival in humans (Kaplan-Meier survival; lower lines); B)
14 genes of the 63 up-regulated were highly significant
-19
(p=1.1 x 10 ; Cox-hazard regression analysis).
[Abbreviations: cohorts1-3, human datasets 6-8; p, pvalue; overall, combined data, 63 up- and 65 downregulated genes.]
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MGI Mouse
Symbol

FoldChange
Wapt1 LCM
DCIS-whB6

Human
Symbol

Fold Change
Human DCIS1Norm

Aurkb
Faim2
Cdc45l
Mcm6
Abp1
Tpx2
Dmbt1
2810417H13Rik*
Aurka *
Ccna2
Lad1
Kif11 *
Top2a *
Krt6a
Hmmr *
Cdc20 *
Nudt1
Mcm2
Pik3cb
Tk1
Krt86
Gpr161
Trip13
Slc7a6
St14
Abtb2
Rrm2 *
Cenpa *
Cdc6
Fanca
Ube2c *
B830045N13Rik
Ccnb1
Nfrkb
Ada
Fgb
Marveld3
Bub1b *
Amd1
Stmn1
Fadd
Cdkn3 *
Arhgef4
Srpk3
Stk10
Col13a1
Mall
Nptx2
Cdc2a *
Smarcd2
BC039210
Srd5a1
Cdk8
Tram2
Gpx2
Spag5 *
Traf3ip2
Myo1e
Orc5l
Camsap1
Tagln2
Ccnb2 *
Prpf19

14.53
1.85
5.02
10.96
1.98
11.44
1.44
5.87
3.23
7.37
6.93
6.38
7.05
1.62
2.63
13.48
2.53
4.37
2.92
5.64
1.40
1.20
2.12
1.24
5.12
3.80
19.12
11.55
8.23
2.45
4.05
1.37
35.29
1.58
2.45
1.95
4.00
11.97
1.46
8.17
1.20
3.27
1.83
1.77
1.31
1.38
1.59
1.59
3.87
4.53
1.86
1.82
2.38
1.54
8.08
2.73
2.06
2.23
1.77
1.45
2.37
8.43
1.91

AURKB
FAIM2
CDC45L
MCM6
ABP1
TPX2
DMBT1
KIAA0101 *
AURKA *
CCNA2
LAD1
KIF11 *
TOP2A *
KRT6A
HMMR *
CDC20 *
NUDT1
MCM2
PIK3CB
TK1
KRT86
GPR161
TRIP13
SLC7A6
ST14
ABTB2
RRM2 *
CENPA *
CDC6
FANCA
UBE2C *
FAM5C
CCNB1
NFRKB
ADA
FGB
MARVELD3
BUB1B *
AMD1
STMN1
FADD
CDKN3 *
ARHGEF4
SRPK3
STK10
COL13A1
MALL
NPTX2
CDC2 *
SMARCD2
FAM38A
SRD5A1
CDK8
TRAM2
GPX2
SPAG5 *
TRAF3IP2
MYO1E
ORC5L
CAMSAP1
TAGLN2
CCNB2 *
PRPF19

14.02
9.13
8.45
11.05
7.84
7.78
6.39
7.58
6.68
5.96
5.78
5.02
6.34
4.44
3.75
4.55
3.47
3.95
3.05
3.60
3.20
2.87
3.55
2.97
2.95
3.26
3.21
3.04
4.69
2.51
3.12
2.52
2.88
2.38
2.39
3.58
3.53
2.74
2.82
2.17
2.00
2.30
2.05
1.87
2.04
1.83
2.15
2.37
1.75
1.90
2.03
2.19
1.63
1.73
1.54
1.95
1.77
1.66
1.52
1.45
1.78
1.91
1.96

MGI Name
aurora kinase B
Fas apoptotic inhibitory molecule 2
cell division cycle 45 homolog (S. cerevisiae)-like
minichromosome maintenance deficient 6(S. cerevisiae)
amiloride binding protein 1 (amine oxidase, copper-containing)
TPX2, microtubule-associated protein homolog
deleted in malignant brain tumors 1
RIKEN cDNA 2810417H13 gene
aurora kinase A
cyclin A2
ladinin
kinesin family member 11
topoisomerase (DNA) II alpha
keratin 6A
hyaluronan mediated motility receptor (RHAMM)
cell division cycle 20 homolog (S. cerevisiae)
nudix (nucleoside diphosphate linked moiety X)-type motif 1
minichromosome maintenance deficient 2 mitotin
phosphatidylinositol 3-kinase, catalytic, beta polypeptide
thymidine kinase 1
keratin 86
G protein-coupled receptor 161
thyroid hormone receptor interactor 13
solute carrier family 7 (cationic amino acid transporter), 6
suppression of tumorigenicity 14 (colon carcinoma)
ankyrin repeat and BTB (POZ) domain containing 2
ribonucleotide reductase M2
centromere protein A
cell division cycle 6 homolog (S. cerevisiae)
Fanconi anemia, complementation group A
ubiquitin-conjugating enzyme E2C
RIKEN cDNA B830045N13 gene
cyclin B1
nuclear factor related to kappa B binding protein
adenosine deaminase
fibrinogen, B beta polypeptide
MARVEL (membrane-associating) domain containing 3
budding uninhibited by benzimidazoles 1 homolog, beta
S-adenosylmethionine decarboxylase 1
stathmin 1
Fas (TNFRSF6)-associated via death domain
cyclin-dependent kinase inhibitor 3
Rho guanine nucleotide exchange factor (GEF) 4
serine/arginine-rich protein specific kinase 3
serine/threonine kinase 10
collagen, type XIII, alpha 1
mal, T-cell differentiation protein-like
neuronal pentraxin 2
cell division cycle 2 homolog A (S. pombe)
SWI/SNF related, matrix associated, regulator of chromatin, subfa
cDNA sequence BC039210
steroid 5 alpha-reductase 1
cyclin-dependent kinase 8
translocating chain-associating membrane protein 2
glutathione peroxidase 2
sperm associated antigen 5
Traf3 interacting protein 2
myosin IE
origin recognition complex, subunit 5-like (S. cerevisiae)
calmodulin regulated spectrin-associated protein 1
transgelin 2
cyclin B2
PRP19/PSO4 pre-mRNA processing factor 19 homolog

Table 4.3. Waptag1 Early DCIS Genes Predictive of Poor Prognosis in Human. These sixty-three
genes were over expressed in Waptag1 early DCIS and Human DCIS1, but not in human DCIS2
lesions and may be predictors of progression, invasion, metastases and/or reduced survival in human
breast cancer. Genes were statistically significant in each species-specific contrast (q≤0.05).
[Abbreviations: MGI, Mouse Genome Informatics; Wapt1, Waptag1; LCM, laser-capture
microdissection; DCIS, ductal carcinoma in situ; whB6, whole glands from C57BL/6J; *, indicates the 14
most significant prognostic genes represented in Figure 4.6.B]
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4.2. Cross-Species Differences Found in Waptag1 Tumorigenesis
It is critical to consider divergence when investigating cross-species comparisons. Speciesspecific gene alterations may fall into the same or similar ontologies, thereby further supporting
the commonalities among mouse and human expression changes during tumorigenesis. Indeed,
deregulation of apoptosis is one example where changes in different genes, but with similar GO
categories are found. Aside from gene expression changes common between species, Waptag1
DCIS and tumors revealed up-regulation of supplemental cell cycle, cell division, and DNA
replication genes, as well as the associated nucleic acid binding and cellular components nucleus
and chromosome, pericentric region. Based on the effects of the SV40 Tag transgene, these
findings seem appropriate for this model. Complementary to the chromatin remodeling changes
and rampant expression of retrotransposons mentioned above, aberrant gene expression
abounds in Waptag1 DCIS. The GO categories gene expression, regulation of gene expression,
transcription, regulation of transcription were enriched among genes up-regulated in Waptag1
DCIS. Waptag1 exhibits even further down-regulation of genes involved in energy derivation than
was common with human DCIS [i.e. generation of precursor metabolites and energy (40
additional genes) oxidoreductase activity (148 more genes), fatty acid metabolism / lipid
metabolism (50 and 129 genes, respectively), and cofactor binding (50 extra genes), specifically
coenzyme binding (32 other genes) as well as the cellular components mitochondrial part (103
more genes), specifically mitochondrial inner membrane (73 extra genes)]. However, these
findings could be due to orthological differences, as suggested by the further down-regulation of
energy-related genes in the human results, not common to Waptag1 (see below). Mice exhibit a
faster basal metabolic rate than humans and may account for some additional down-regulation of
genes involved in metabolism; alternatively, this could be a consequence of the SV40 Tag
oncogene. Vitamin binding (33 genes) was another GO category of genes down-regulated in
Waptag1 DCIS versus B6 controls that was not discovered among human results, perhaps due to
lack of a human ortholog for several of these genes. Vitamin binding is required to regulate
normal metabolism within cells especially antioxidants, such as vitamins A, C & E, can reduce the
potential direct oxidative stress damage to a cell. Interestingly, five of the genes exhibiting
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significant down-regulation normally bind vitamin C (ascorbic acid). Therefore, it seems
complimentary to find down-regulated expression of genes involved in vitamin binding alongside
genes down-regulated in various metabolic processes as well as those involved in oxidative
stress response.
4.2.1. DNA Repair Mechanisms in Waptag1 cells of DCIS
One striking difference among the global gene expression changes in DCIS between species
was the up-regulated expression of genes in the GO biological process DNA repair, specifically
double-strand break repair in LCM Waptag1 DCIS. Since transgene-induced SV40 Tag proteins
bind to and inhibit NBS1, Nijmegen breakage syndrome protein 1, a protein involved in doublestrand break repair, and the mitotic checkpoint protein BUB1(budding uninhibited by
benzimidazoles 1 homolog), genomic instability results, without the need for down-regulation of
DNA repair. Conversely, genes in the GO categories regulation of DNA repair, in particular
positive regulation of DNA repair genes were down-regulated at the cutoff threshold in human
DCIS1. The only two common DNA repair genes with alternate directionality (up-regulated in
Waptag1 and down-regulated in human) are the familial breast cancer prognostic, Brca1/BRCA1
and the ubiquitin molecule, Ube2n/UBE2N. Although the particular genes may vary between
mouse and human DCIS, both species deregulate DNA repair mechanisms to promote tumor
progression. However, this brings up a technical flaw in these comparisons: of 80 DNA repair
genes significantly over expressed in Waptag1 DCIS, 44 were not represented on the human
microarray chips.
4.3. Cross-Species Divergence Discovered in Human Carcinogenesis
The most significant GO term represented amid all up-regulated genes in human DCIS was
developmental process. Related GO categories include anatomical structure development,
multicellular organismal development, system development, organ development, nervous system
development. Given that developmental genes were previously found over represented among
the 969 genes up-regulated in the 2097 list, this suggests that genes in these categories show
further up-regulation (of gene numbers and expression levels) than is common between species.
Up-regulated expression of ‘developmental’ genes is frequently associated with cancer. For
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example, Pthrp, parathyroid hormone-related protein, is normally expressed during (and is
essential for) development of the mammary gland201. Over-expression of Pthrp has been
detected in human breast cancer and is usually associated with invasive properties, bone
metastases, and a poor prognosis202-207. Additionally, the Notch, Wnt, and Fgf families of genes
are also included in these GO categories and these genes are not only important for
development, but play significant roles in signal transduction in cancer. When Notch1, Notch4,
Wnt1 or Fgf3 are aberrantly over expressed in mice, either by integration of the mouse mammary
tumor virus or by using an MMTV promoter/enhancer, mammary cancer results (for review208-210).
Cell-cell signaling and signal transduction genes are over-represented in human DCIS1 as well,
though some of these genes could represent differences between laser-captured Waptag1 DCIS
cells and the DCIS-enriched human samples.
Human DCIS1 samples showed further down-regulated expression of genes involved in
energy metabolism. Genes in the following categories showed additional down-regulation:
generation of precursor metabolites and energy (32 extra genes), lipid metabolism (71 more)
genes, specifically (59) cellular lipid metabolic process genes, oxidoreductase activity (18 genes),
in human DCIS1 samples compared with normal breast controls. Undoubtedly, there will be
tissue-, environment-, species-specific, and even individual differences within these altered
energy pathways. Nonetheless, in both Waptag1 and human DCIS, normal aerobic respiration
and energy production via the electron transport chain is inhibited early in the tumorigenic
process; some of the genes are orthologous and similarly down-regulated, whereas other genes
are uniquely down-regulated in each species, but both show further down-regulation with
increasing severity of the disease.
4.3.1. Defense Response Genes Over Represented in Human DCIS1
One striking distinction between the human DCIS1 and the laser-captured DCIS mouse
results is the up-regulated expression of genes involved in response to stimulus. In total, 64
defense response genes, specifically 35 genes involved in response to biotic stimulus, and
fourteen cellular defense response genes were found. At least 11 of these genes either did not
have mouse orthologs or were represented in the mouse annotation. Interestingly, response to
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stress genes were both up- and down-regulated among human DCIS results. Genes categorized
in the T cell activation, response to virus, and lymphocyte / leukocyte activation GO categories
were significantly over-represented among genes up-regulated in human DCIS1, but not in lasercapture microdissected Waptag1 DCIS cells. Of course it is intriguing to find immune system
genes up-regulated early in human carcinogenesis as was found previously in Waptag1 whole
tumors (though not in the laser-capture results). A few stromal-related gene changes were found
in the human DCIS1 samples, but these were obviously not in the laser-captured Waptag1 DCIS
samples used for these cross-species comparisons. Previous preliminary analyses suggested
that human samples ‘enriched’ in DCIS and linearly amplified showed greatest similarity with
linearly-amplified laser-captured Waptag1 DCIS cells (data not shown). However, the findings
mentioned above as well as the enrichment of genes involved in locomotor behavior, localization
of cell, and cell motility (also found among unique human DCIS results) suggest that there may
be deregulation of analogous stromal genes between human and mouse DCIS.
4.4. Summary
By comparing human DCIS transcriptional changes with genes differentially expressed in
Waptag1 DCIS, over two thousand genes were found to be commonly up- or down-regulated
across species. Genes involved in regulating the cell cycle, cell division, DNA replication, and
chromatin remodeling were up-regulated (compared with appropriate normal controls), and in
addition, retrotransposons were over expressed. A sixty-three gene signature (common to
mouse and human DCIS) exhibited significant prognostic ability and was associated with
decreased survival in three independent human breast cancer datasets. Genes commonly downregulated in DCIS across species were classified under the GO categories generation of
precursor metabolites and energy, specifically fatty acid metabolism, electron transport, and
oxidoreductase activity, suggesting that ATP is generated via an alternative energy pathway,
such as glycolysis, early in tumor progression.
As one of the ‘Hallmarks of Cancer’ the finding that escape from cell cycle regulation in order
to attain uncontrolled growth occurs early in the tumorigenic process, though intriguing, is not
novel11. However, this result coupled with over expression of chromatin remodeling genes and
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retrotransposons and a metabolic switch in the bioenergetics of the DCIS lesions presents a
unique cross-species portrait of the early stages of mammary tumor progression in vivo. To
complete this evaluation of transcriptional changes in DCIS, however, the full contribution of the
stroma in the human DCIS microenvironment is essential, to identify potential stroma-related
early markers of progression to invasion. Likewise, isolation of paired tumor cells and stromal
components within lesions of Waptag1 DCIS and tumors could expose the real contribution of the
stroma to mammary tumor progression.

77

Chapter 5
UP-REGULATION OF RETROTRANSPOSONS IN MOUSE AND HUMAN CARCINOGENESIS
Abundant expression of retrotransposons was a common finding among ten microarray
datasets, containing either mouse or human mammary cancer data. This finding was shared
among all mouse mammary tumors tested, regardless of genetic background, and in seven
subtypes of human breast cancer. To date, six different classes of retrotransposable elements
have been described: Long Terminal Repeat (LTR) Class I, II, & III family members and Long
and Short Interspersed Nuclear Elements (LINEs and SINEs). As mentioned previously, although
specific retrotransposons may differ among tumor models or human breast cancer subtypes, the
commonality of the causes and mechanisms underlying transcriptional activation of these
normally silenced elements is the focus of interest.
5.1. Retrotransposons are Over Expressed in Five Independent Transgenic Mouse
Mammary Cancer Models
Retrotransposons were initially discovered to be over expressed in Waptag1 DCIS and
tumors by uncovering the origin of the most significantly up-regulated unknown/unannotated
clones on the NIA arrays, when compared to normal controls. To confirm these original findings
independent Waptag1 samples were run on a different microarray platform (Affy).
Representatives from all classes of retrotransposons were up-regulated in early DCIS, advanced
DCIS, and papillary tumors when compared with normal C57BL/6J mammary glands (Figure
5.1.A). Using microarray data across multiple platforms and among several transgenic mammary
tumors, we discovered over expression of retrotransposons was not confined to Waptag1 or the
C57BL/6 genetic background (Figure 5.1). Rather, mice of a different genetic background and
transgenic for Neu, Int3, Myc, or Wnt1 showed up-regulation of multiple classes of
retrotransposons in their mammary tumors, compared with their appropriate normal FVB/NJ
mammary glands (Figure 5.1.B).
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Figure 5.1. Up-Regulation of Retrotransposons in Five Mouse Models of Mammary Cancer.
A) Expression of all classes of retrotransposons in Waptag 1 mammary glands increases with
tumor progression. Combined data from NIA 15K clone set cDNA arrays (NIA) and GeneChipR
Mouse Genome 430 2.0 Affymetrix Arrays (Affy) are shown. Representative retrotransposons
from: LTR Class I, three MuLV clones(NIA) & two Edv1(Affy); LTR Class II, two IAP(NIA); LTR
Class III, two MT clones(NIA); Non-LTR, two LINEs(NIA) & two SINEs(Affy). Legend: eDCIS,
early Ductal Carcinoma in situ; AdvDCIS, advanced DCIS; PapTumor, papillary adenocarcinoma
B) Over-expression of repetitive elements in mamamary carcinomas in FVB/NJ mice transgenic
for Neu, Int3, Myc, or Wnt1. Data from the 22K Compugen Mouse Release 2.0 oligonucleotide
probe microarrays was normalized due to spatial variation across some arrays. [All expression
values are relative to normal non-lactating mammary glands and are statistically significant
(ANOVA; p < 0.05). Error bars: standard deviation across clones of the same Class/Family.]

To determine whether retrotransposon over expression was contributed by the tumor cells or
the stroma, specific tumor cells in Waptag1 glands were investigated. Using laser capture
microdissection on frozen sections of mammary glands and tumors taken throughout the lifespan
of Waptag1, we collected pre-tumor cells of early DCIS and advanced DCIS, papillary tumor cells,
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solid, invasive tumor cells, and normal C57BL/6J control epithelial cells. After linear amplification
and subsequent microarray analysis, we found that indeed expression of retrotransposons occurs
within the tumor cells, specifically (Figure 5.2). Although only MaLR, MLT1K and MT-int LTR
Class III elements were found consistently up-regulated in both laser captured cells and whole
glands/tumors, we did find several LTR Class I and II as well as many LINEs and SINEs overexpressed compared with respective normal controls (Figure 5.2. and Table 5.4). This may
suggest that different retrotransposons may be expressed in tumor versus surrounding stromal
cells. Perhaps, in response to tumor cells, stromal cells likewise become aberrant.
Figure 5.2. Up-Regulation of Retrotransposons in Laser Capture Microdissected (LCM) Cells
Across Stages of Waptag1 Tumorigenesis. Log2 of the expression levels of LCM, linearly amplified
cells at each stage of Waptag1 tumor progression relative to LCM control C57BL/6J (B6) epithelial cells.
Data from Affy arrays. Representative LTR Class I and II retrotransposons: two probesets ETnERV;
three probesets each RLTR25A and RLTR9E; Legend: eDCIS, LCM early ductal carcinoma in situ cells;
DCIS, LCM advanced DCIS cells; PapT, LCM papillary adenocarcinoma cells; SolidT, LCM solid /
invasive tumor cells. [All expression values are statistically significant (ANOVA; q<0.05); Error bars:
standard deviation of several clones of the same Class/Family.]
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5.2. Retrotransposons are Abundant in Human Breast Cancer, DCIS, and Atypical Ductal
Hyperplasia
To determine whether retrotransposon expression is a general early feature of human breast
carcinogenesis, publicly available databases were searched for human breast tumor or DCIS (or
other early pre-tumor stage) data and queried for retrotransposon sequences (see methods).
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We initially found over-expression of multiple classes of retrotransposons in three different human
breast cancers, luminal, basal, and ERBB2-positive tumors4,5 when compared with normal breast
tissue (Table 5.1).
After manually surveying the results of two datasets, a few human breast cancer-specific
retrotransposons were found (Table 5.2). These preliminary results prompted us to investigate
whether retrotransposons found early in human carcinogenesis might be predictive of cancer
recurrence. Indeed, in atypical ductal hyperplasia (ADH) samples, from patients with a previous
cancer history, retrotransposons from several different classes was up-regulated (Table 5.3),
when compared to ADH samples from patients without former cancer incident.

Family / Class

(Range of Expression)

LTR

ERV1 / MER57

(9.0 – 31.2)

LTR

HERV-K / LTR5B

(2.2)

LTR

ERV-L / HERV-L
MaLR / MLT1

(2.1 – 2.6)
(1.4 – 3.5)

NonLTR

LINEs / L1, L2, L3, L4
SINEs / Alu

(1.5 – 5.6)
(1.8 - 8.2)

Table 5.1. Retrotransposon
Over-Expression in Three
Human Breast Cancer
Subtypes. Range of expression
shown is relative fold change,
tumors (luminal, basal or
ERBB2+) compared with normal
breast tissue4,5. If no range,
only one repeat was expressed.
All comparisons are significant
(two-tailed t-test as raw data
was unavailable; p≤0.05).

R/ MAANOVA analysis of human microarray data, from samples enriched in human DCIS
and IBC, invasive breast cancer (kindly provided by Drs. Li and Allred, Washington University, St.
Louis, MO) and normal breast controls (from public databases), was performed, as with the
mouse data. In both human DCIS and IBC, multiple probe sets exhibited over-expression of
several classes of retrotransposons, when compared with normal breast tissue (Figure 5.3). The
variety and level of over expression of retrotransposons in Waptag1 tumor progression (A) and in
human DCIS1 (B) is found in Table 5.4. These results suggest that retrotransposon activation
and expression early in the tumorigenic process may be a common feature to both mouse and
human mammary carcinogenesis.
As mentioned previously, chromatin maintenance and modification genes are also overexpressed early in tumor progression, suggesting that chromatin remodeling may be a common
underlying cause for this retrotransposon expression. Although yet unclear, the cause of
retrotransposon unsilencing, chromatin remodeling and aberrant gene expression in pre-tumor
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cells may be a response to stress, the result of epigenetic alterations, due to accumulation of unrepaired DNA double strand breaks, or a combination of these factors216-218.

Table 5.2. Over-expression of Retrotransposons in Human Breast Tumors. Results are combined
from two datasets: ‘dataset1’ compared/contrasted 32 luminal, 10 basal, 9 ERBB2+ tumors with 4
6
normal breast tissues4,5; ‘dataset2’ compared/contrasted 27 luminal, 16 basal, and 6 apocrine tumors .
Retrotransposon candidates as markers for specific tumor types as shown; tumors were compared with
normal glands (dataset1) or other tumor types (dataset2); a consensus of both comparisons is shown
for luminal and basal. [All comparisons are statistically significant (two-tailed t-test as the raw data was
not available; p≤0.05). Blank spaces indicate no elements could be found.]

ERBB2+
(dataset1 only)

Luminal

Basal

Apocrine
(dataset2 only)

ERV1 / LTR12C
& MER65B

LTR

ERV1 / MER57-int

LTR

ERVL / HERV-L
ERVK / LTR5B

MaLR /
MLT1K

Non
LTR

LINEs / L1M5
SINEs / AluJb, Jo
& AluSg/x

LINEs / CR1
L3/ L1MC5

LINE / L1ME3A
SINE / FLAM_A
SINE / Alu: FAM

ADH, with Cancer
Repeat family
LTR

Class I

LTR

Class II

Non
LTR

Retrotransposon

Fold change

ERV1

MER110
LTR19-int

2.65
2.16

HERV-K
HERV-L

LTR13A
LTR69

2.81
2.25

LINEs

L1MA6
L1MC4
L1PA5
AluSc
AluSg

Non-LTR
SINEs

2.83
2.06
2.58
2.1 – 2.58
1.9 - 2.38

Table 5.3. Retrotransposon Markers of Progression in Human Atypical Ductal Hyperplasia.
Retrotransposon overexpression was investigated in breast samples containing atypical ductal
hyperplasia (ADH); four samples from patients with a history of cancer and four from patients with
3
no history of cancer . [Fold change is: ADH, with cancer history compared to ADH, no cancer; a
range of fold changes reveals expression of multiple clones of the same retrotransposon (two-tailed
t-test as the raw data was unavailable; p≤0.05).]
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Figure 5.3. Retrotransposons Over-Expressed in Human Breast Carcinogenesis. Twentyseven samples enriched in ductal carcinoma in situ, DCIS, and twenty-four tumors of invasive breast
cancer, IBC (run on U95Av2 Affy Arrays) were compared to seven normal breast tissue samples (run
on U133plus2 Affy Arrays). Representative LTR Class I, II, III and non-LTR retrotransposons are
shown as log2 of the mean expression levels of human DCIS or IBC compared to normal breast;
three probesets each MER66A, LTR14B, and L1ME3; two, MER41B; four each, LTR16C and
L1MB5. [All expression values are statistically significant (ANOVA; q<0.01); Error bars: standard
deviation across clones of the same Class/Family after outliers were removed.]

5
humDCIS
humIDC

Relative Expression (log2)

4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
MER66A

MER41B

LTR Class I

LTR14B

LTR16C

LTR Class II & III

L1MB5

L1ME3

LINEs

5.3. Summary
Though many questions remain, regarding the cause of retrotransposon up-regulation early
in tumor progression, the findings presented here suggest that unsilencing of retrotransposons is
associated with the initial stages of cellular transformation. Across five different mouse models of
mammary cancer on two different genetic backgrounds, five human breast cancer subtypes,
human atypical hyperplasia, and DCIS in Waptag1 and human, retrotransposons were
consistently among the most differentially over expressed ‘genes’ in all comparisons. Indeed,
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these may be useful markers in the future for detection of early stages of human breast
carcinogenesis.
A
Array_ID

Repeat Class

Repeat Family

Strand

1425065_at
1428763_at
1424717_at
1424118_a_at
1435628_x_at
1456340_at
1446714_x_at
1459452_at
1433361_at
1455581_x_at
1434280_at
1434279_at
1454904_at
1457626_at
1419773_at
1450165_at
1422719_s_at
1446521_at
1432155_at
1419658_at
1442192_at
1450165_at
1417277_at
1421701_at
1451905_a_at
1428105_at
1455674_at
1456803_at
1435973_at
1430651_s_at
1450156_a_at
1427541_x_at
1452304_a_at
1434043_a_at
1439907_at
1457067_at
1430339_at
1436032_at
1458130_at
1458130_at
1428911_at
1444157_a_at
1456027_at
1444158_at
1454785_at
1459900_at
1459900_at
1437550_at
1437570_at
1423103_at
1436472_at
1440866_at
1442134_at
1457636_x_at

MER21B
MER21B
MER31A
MER34A1
RLTR1B
RLTR1C
ETnERV
ETnERV
MMERVK10C
MMERVK10C
MMETn-int
MMETn-int
MMETn-int
MYSERV6
RLTR10
RLTR13B4
RLTR25A
RLTR25A
RLTR25A
RLTR9B
RLTR9E
RLTR9E
RLTR9E
RLTR9E
RMER19A
RMER20A
RMER4A
RMER4A
RMER4A
MLT1K
MT-int
MT-int
L3
L3
L1MB4
L1MB4
L1MC3
L1MC3
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME1
L1ME3B
L1ME3B
Lx
Lx
FLAM_A
FLAM_A

LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/ERVK
LTR/MaLR
LTR/MaLR
LTR/MaLR
LINE/CR1
LINE/CR1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
SINE/Alu
SINE/Alu

+
+
C
+
+
C
+
+
+
+
+
+
+
+
+
+
C
+
C
+
C
+
+
+
C
+
C
+
+
+
C
C
+
C
C
C
+
C
C
C
+
C
+
C
C
C
C
C
+
C
+
+
+
+

Fold Change Fold Change Fold Change
Fold Change
BPs Left
Waptag1 LCM
Waptag1
Waptag1 LCM Waptag1 LCM
in Query
DCIS vs. wB6 wPapT-wB6 PapT-LCM B6 SolidT- LCM B6

-139
-211
0
-8
0
-38
-5
-5
-24
-309
0
0
0
-5
-137
-81
-344
-274
-168
-21
-149
-15
0
-41
0
-4
-271
-164
-186
-15
-13
-1
-45
-6
-11
0
-160
0
-236
-20
0
-39
-24
-214
-4
-262
-3
-31
-144
-63
0
0
0
-3

2.27
1.87
1.21
6.23
3.16
2.99
1.61
1.31
1.30
4.03
4.92
-1.31
-2.04
6.77
6.96
1.77
-1.22
3.07
1.32
7.31
2.01
1.77
2.25
1.27
4.44
2.31
1.09
1.48
3.32
4.06
5.06
3.53
1.84
3.03
2.11
5.24
2.35
2.79
4.41
4.41
2.89
2.14
1.92
2.36
1.78
2.04
2.04
2.08
4.47
2.50
1.67
-1.79
2.41
3.73

4.59
1.64
2.20
10.70
1.20
1.39
1.16
1.14
1.39
1.04
7.41
3.71
3.34
2.08
1.11
2.10
1.94
1.16
1.05
2.64
2.77
2.10
1.40
1.04
4.35
8.51
2.30
1.20
-1.07
1.72
13.00
4.89
2.75
1.23
1.39
1.04
3.46
1.64
2.39
2.39
1.66
1.60
1.38
1.27
1.22
1.15
1.15
1.03
2.57
-1.17
6.54
3.81
2.03
1.21

4.17
1.43
3.48
14.32
6.32
2.53
3.29
2.71
1.18
1.67
5.98
1.22
1.39
2.04
2.60
2.68
2.45
1.57
1.32
9.78
3.25
2.68
1.80
1.18
10.20
8.22
2.87
1.51
2.16
2.62
11.31
8.75
2.22
1.69
2.20
2.14
6.19
4.00
3.53
3.53
1.71
1.14
1.39
1.27
1.27
1.87
1.87
1.30
2.66
1.27
4.66
1.92
5.66
1.72

2.93
1.21
3.39
17.03
2.39
4.50
6.19
5.90
2.28
1.21
9.13
1.14
1.54
2.97
2.91
1.96
2.28
1.41
1.40
6.02
4.38
1.96
1.34
1.22
9.71
10.41
3.29
1.73
1.60
2.38
9.99
7.41
1.54
1.72
3.78
2.35
4.82
2.53
6.02
6.02
1.71
1.28
1.92
1.65
1.13
1.72
1.72
1.41
3.68
1.24
4.41
1.46
7.31
1.61

Table 5.4. Individual Clones Representing Retrotransposons Expressed during Tumorigenesis
in Waptag1 (A) or Human DCIS (B). Fold changes shown are significant (q<0.01). Multiple clone
target sequences align to the same retrotransposon, thereby supporting true over-expression of that
element. Repeat Class/Family as determined by RepeatMasker (see methods). (Any transposon
represented by multiple clones that showed equal over- and under-expression was removed from the
list.) [Abbreviations: DCIS, ductal carcinoma in situ; BPs, basepairs; LCM, laser capture
microdissection; wB6, whole C57BL/6J glands; PapT, papillary tumor; SolidT, solid tumor; Norm,
normal human breast.]
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B
Array_ID

34702_f_at, 34703_f_at, 34704_r_at
32250_at
1992_at
37709_at
40700_at
36105_at
34842_at
33983_at
1748_s_at
31442_at & 1582_at
33559_at
31324_at
37940_f_at
34429_at
41025_r_at & 41026_f_at
36105_at
35956_s_at
33503_at
36286_at
1391_s_at & 35412_at
35955_at
33453_at
35915_at
33453_at
39059_at
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39673_i_at
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40765_at
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1667_s_at & 34161_at
33568_at
1668_s_at
35602_at

Repeat Class

Repeat
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Strand

BPs Left in
Query

Fold Change Human
DCIS1 vs. Norm

HERVH
HUERS-P1
LTR26E
LTR37A
LTR48
LTR54B
LTR56
LTR72
LTR7B
MER31-int
MER34B-int
MER41B
MER49
MER4A1
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MER65-int
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MER89-int
LTR14B
LTR5B
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LTR40b
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L3
L3
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L1MB4
L1MB4
L1MB4
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L1MDa
L1ME3
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L1MEg
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L2a
L2b
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L2c
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LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
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LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERV1
LTR/ERVK
LTR/ERVK
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/ERVL
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LTR/MaLR
LINE/CR1
LINE/CR1
LINE/CR1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L1
LINE/L2
LINE/L2
LINE/L2
LINE/L2
LINE/L2
LINE/L2

+
+
+
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+
+
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+
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+
+
+
+
C
+
+
+
+
+
+
+
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+
C
C
+
C
C
C
+
C
+&C
C
C
+
+
+
C
C
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0
0
0
-64
-112
0
-60
-1
-328
0
-509
-100
0
0
-7 & 0
-255
-279
-79
-205
0 & -124
0
-338
-38
0
-11
-2
0
-213 & -445
-445
-14
-214
-1
-212
-52
-4
-61
-329
0 & -146
-66
0
-64 & 0
-11
-352
-151
-40
-201
-4 & 0
-191
-66
0
-66
0
0
-3
-457
-256
-109
-3 & 0
0
-126
-82
-238 & -226
-31, -1, -1
-201 & -57
-85
-335
-129

5.44, 3.14, 1.62
5.93
2.11
3.30
3.31
8.77
47.77
1.91
3.19
1.45 & 2.48
2.46
2.76
2.42
17.63
4.73 & 1.55
8.77
11.51
4.32
2.85
8.01 & 12.04
4.84
28.12
9.56
28.12
3.34
3.41
2.34
3.46 & 1.78
1.78
4.60
17.17
3.68
11.46, 4.72, 2.81
2.38
11.46, 4.72, 2.81
5.26
6.56
1.47 & 7.44
4.40
2.56
2.50 & 2.04
2.01
31.47
48.64
9.99
1.45
20.21 & 5.76
6.27
13.02
9.93
4.94
2.56
13.50
13.86
17.17
5.41
17.17
7.72 & 2.63
6.76 & 5.86
8.45
6.95
6.06 & 5.65
6.11, 5.96, 6.41
11.71 & 8.46
31.63
12.46
5.65

Table 5.4. Continued.
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Chapter 6
DISCUSSION AND CONCLUSIONS
Mouse models of human breast cancer remain important research tools: mouse models,
destined to develop cancer, provide samples throughout the tumorigenic process, from the
earliest changes through late stage progression; by utilizing different mouse models of mammary
tumorigenesis and combining their histological and genetic information with that of human,
progress can be made toward a more thorough understanding of mammary cancer; genetically
engineered mice that model important elements of human cancers facilitate the elucidation of the
molecules and pathways regulating normal development and disease, uncover de novo markers
for detection of early alterations to be used for earlier diagnosis, and expedite testing of new
therapeutic agents. Through comparison of mutual early mouse and human changes, predictive
of progression to invasion, new prognostic markers may be identified, to more clearly differentiate
the lesions of DCIS that will advance to invasive breast cancer from those that will not.
The research presented here directly compares global gene expression changes between a
mouse model of DCIS, Waptag1, and human DCIS. Among 6945 orthologous genes represented
on all microarrays, over two thousand genes were commonly differentially expressed in both
Waptag1 and human DCIS, when compared with species-specific controls. Microarray, ontology,
and pathway analyses revealed several novel findings characteristic of the early stages of
mammary tumor progression. First, at the cellular level, pre-tumor cells mirror the transcriptional
profile of advanced tumor cells, which implies that within lesions of DCIS, the surrounding tumor
microenvironment defines the stage of tumor progression. Second, down-regulation of metabolic
pathway genes involved in normal aerobic energy derivation supports the theory of an alternative
energy pathway utilized throughout tumorigenesis. Third, up-regulation of chromatin modification
genes and retrotransposons in DCIS in both species suggest that the epigenetic mechanisms that
silence retrotransposons are dysfunctional. In addition to these novel findings, DCIS samples in
human and Waptag1 exhibit uncontrolled cell growth, replication, and division as well as
deregulation of apoptosis, allowing damaged cells to cycle and divide without potential death,
thereby presenting several hallmarks of cancer at early stages of tumor progression.
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Dissection of tumor cell versus stromal changes during Waptag1 tumor progression revealed
the importance of identifying early pre-tumor cells amidst the overwhelming population of normal
cells. For earlier detection and treatment, it is critical to evaluate and target the early pre-tumor
cells, independently, especially if stromal changes are a secondary response due to cues from
nearby tumor cells. If Waptag1 early DCIS is any indication, the uninhibited growth, massive
down-regulation of normal aerobic respiration, and/or the bloom of retrotransposon expression
can best be detected and at the earliest possible stage without the excessive ‘noise’ found in the
surrounding cells of the mammary gland. Alternatively, stromal cell alterations are proving to be
important for tumor progression, as harbingers of transformation and invasion, such as those
characterized by epithelial to mesenchymal transitions during development and cancer219-224.
Breast cancer treatments to eliminate tumor cells simultaneously destroy normal, healthy
cells; thus, targeting only the tumor cells would be advantageous. Interestingly, an endogenous
photosensitizer, protoporphyrin IX, accumulates in pre-tumor and tumor cells of Waptag1 (and
other mouse and human tumors), especially after exongenous administration of a pre-cursor, 5aminolevulinic acid, one that appears to have no ill side effects. Upon accumulation of
protoporphyrin IX, pre-tumor cells can either be fluorescently detected at 380nm (for identification
of tumor margins during surgery, for example) or excited with 635nm wavelength of light, to
produce reactive oxygen species, ultimately resulting in cell death. Since a severe inhibition of
oxidative response and/or neutralization of reactive oxygen species has been detected through
analyses listed above and Waptag1 cells escape one apoptotic pathway, it would be interesting to
use the Waptag1 model to attempt excitation-induced early tumor cell death. The current
challenge is proximity of light source to the pre-tumor cells for excitation of the protoporphyrin IX;
635nm of light does not penetrate the skin. However, micro computed tomography (Micro CT),
capable of imaging in three dimensions and exciting cells of interest, may in the future enable
experiments such as these in mice. Interestingly, FVB/N-Tg(MMTVneu)202Mul/J mice which
harbor an inactivated form of rat Neu, a receptor tyrosine kinase in the epidermal growth factor
receptor family, under the control of the mouse mammary tumor virus (MMTV) promoter (MMTVNeu43) present opposing mitochondrial energetics from that of Waptag1 (or human). Moreover,
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MMTV-Neu mice may lend further insight into the mechanisms involved in mitochondrial changes,
such as oxidative stress, down-regulation of electron transport, or increased glycolysis.
What roles do mitochondrial bioenergetics play in tumorigenesis? A few studies have shown,
by combinatorial transforming manipulations in vitro, that from a single transforming ‘hit’ on
upward, pre-tumorigenic cells undergo an early switch in energy metabolism212,225. However, to
my knowledge, this phenomenon has not been described, as an entire process, throughout tumor
progression within a living system. Others have published data (in supplemental gene lists)
supporting the down-regulation of genes involved in normal aerobic respiration, similar to findings
discussed here, yet these changes were not mentioned, even in the discussion, within the text of
their publications61,78. Glycolysis is most likely the means of energy production in pre-tumor and
tumor cells18-21,211,213,214,226-228, when oxidative phosphorylation and generation of ATP via the
electron transport chain are predominantly inhibited. By switching to glycolysis, tumor cells would
gain several selective advantages: 1) energy independence, through utilization of an abundant
nutrient, glucose, to generate ATP with fewer limitations (no need for oxygen, for example); 2)
quicker energy, as the cancer cell produces more ATP through glycolysis than oxidative
phosphorylation, given the same amount of time229-231; 3) production of biosynthesis pathway
metabolites, via glucose breakdown, that are available for synthesis of nucleotides, lipids, etc. for
rapid growth. Thus, cancer cells gain increased invasive and metastatic potential.
Clearly, energy-related transcriptional changes are prevalent throughout all stages of tumor
progression in Waptag1 and human, but several questions still remain. Why are genes involved
in oxidative phosphorylation and mitochondrial respiration down-regulated? Wouldn’t it be more
efficient to supplement normal electron-transport-produced ATP thru glycolysis? Although
defects in mitochondrial energy metabolism have been associated with disease and cancer, (for
review211), these mutations usually result in generation of reactive oxygen species (ROS), though
there are exceptions. In Waptag1 and human tumorigenesis, either ROS are not being generated
or if present, they are not being dealt with through normal mechanisms. Could mutations in key
metabolic genes (or in their expression), as a result of un-repaired DNA breaks, improper joins,
chromosomal abnormalities, or altered epigenetic mechanisms be another means by which tumor
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cells promote tumorigenesis? In contrast to Waptag1 and human mammary cancer, the MMTVNeu mouse model seems to launch a full-blown oxidative response (transcriptionally), exhibiting
over-expression of lipid metabolism genes and cellular lipid metabolic processes, such as fatty
acid oxidation, whereas transcription of genes from these categories is down-regulated in
Waptag1 mouse or human samples (Fancher K et.al., future publication). Up-regulation of many
oxidative enzymes (Lao1, Ddo, Cox7a1 & 8b, Acox2, Suox, Noxo1, Loxl3, Aoc2 & Aof1, Duox1
and Duoxa1) suggests that ROS are being produced in Neu tumors; many of these genes were
down-regulated in Waptag1 and human. Expression of genes indicative of oxidative stress
response and/or neutralization of ROS: the antioxidant superoxide dismutase 3 (Sod3), ROS
storage and transport genes ceruloplasmin (Cp), and transferrin (Trf); oxidoreductase enzymes
(Txnip, Txndc1); and carbonic anhydrase genes (Car 9, an hypoxia-related gene, as well as Car2,
5b 6, 8, and 12), implies that cells are attempting to thwart ROS-induced cell injury, unlike
Waptag1 mouse or human cancer cells. Lastly, the cellular components over represented in
MMTV-Neu tumors are lysosome, endoplasmic retriculum, mitochondrion and peroxisome, all
membrane-bounded organelles with enzymes to oxidize molecules, produce ROS, and/or
neutralize ROS. These results are antithetical to those in Waptag1 and human. Further
comparison of mouse models with human tumors may offer new insight into the mitochondrial
bioenergetics of mammary carcinogenesis and identify how different cancers grow and invade
uniquely, seemingly with or without the stress response.
What initiates pre-tumor and tumor cells to make the glycolytic switch? Indeed, this is a
question over eight decades old214 and, to my knowledge, remains unresolved. Do all tumor cells
undergo this conversion? If Wallace and colleagues are correct and reactive oxygen species are
being produced, without neutralizing them, unscavenged free radicals could be the source of
initial or supplemental DNA-damage. For example, oxidative damage to DNA could be the
original early cause, initiating the cascade of secondary effects which enable and/or promote the
tumorigenic process. Alternatively, perhaps it is the dysfunction of the Trp53/TP53 tumor
suppressor that drives the shift in energy metabolism within tumor cells16,225,232-234. Studies of
Trp53 knockout mice and mouse or human cell lines confirmed that reduced oxygen
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consumption, higher levels of lactic acid, and increased production of ATP from glycolysis (versus
aerobic respiration) correlated with Trp53 deficiency225. Hypoxia-inducible factor, Hif1a/HIF1, can
increase glycolytic enzyme levels and therefore may be an initiating factor in the cancer cell’s
switch to glycolysis235,236. The phosphatidylinositol 3-kinase (PI3K) signaling pathway, primarily
through activation of Akt1/AKT1, increases glycolysis, independently of Hif1a/HIF1237 (for
review14,238). Additionally, crosstalk between Trp53 and Hif1 pathways complicates identification
of the origin of the metabolic switch239,240.
An early step in the malignant transformation of a cell involves deregulation of gene
expression. Given that gene expression is closely linked to chromatin organization and function,
it stands to reason that epigenetic changes, such as DNA methylation and histone modifications,
coincide with altered expression of many cellular genes and retrotransposons within the genome.
Retrotransposon expression may serve as an indicator of chromatin changes, rather than a
driver, based on the following three points: 1) the evidence that retrotransposons and repetitive
elements are normally silenced (for review120); 2) the multitude of seemingly redundant
mechanisms that maintain silencing, which are conserved across most organisms120,123-128,134136,241-248

; 3) deletion of key molecules involved in retrotransposon/heterochromatin silencing

results in dramatic results118,249-261. From rice to worms to mice to humans, transposons are
silenced through mechanisms such as cytosine methylation, epigenetic modifications to histone
tails, and/or via RNAi machinery. Thus, unsilencing of retrotransposons must occur as a result of
epigenetic changes favoring the expression of these elements. Although yet unclear, the
cause(s) of retrotransposon unsilencing, chromatin remodeling and aberrant gene expression
within early stages of tumor progression may be a response to stress, the result of epigenetic
alterations, due to accumulation of unrepaired DNA double strand breaks, or a combination of
these factors216-218.
What is the mechanism by which retrotransposon silencing is relieved? Whether genomic
changes that coincide with unsilencing of retrotransposons are local or global mechanisms, or a
combination thereof, remains uncertain. Certainly, genes expressed in one system may be
repressed in another, such as the estrogen receptor (Esr1) or Hoxd4 genes. These examples
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point out local active or inactive chromatin states129,130. Alternatively, others theorize that initially
global opening of chromatin occurs (i.e. within open chromatin fibers) and then local epigenetic
modifications, such as histone acetylation, are necessary for gene transcription131-133.
Additionally, it remains unresolved what cause initiates which effect in tumorigenesis. Does
global histone acetylation via aberrant activity of histone acetyltransferases alter chromatin
structure, which leads to subsequent, unrelated unsilencing of retrotransposons, or does the
unsilencing of retrotransposons occur first, locally, via a malfunction in the RNAi pathways during
tumorigenesis? Do kinases, like aurora B, phosphorylate serines and threonines locally at
heterochromatic regions, without neutralizing protein phosphatases due to their abnormal function
(globally), which consequently suppresses CBX5 chromobox protein binding as well as formation
of heterochromatin, leaving the associated DNA unsilenced? Are there alterations to (or switches
in) the histone code (locally) associated with retrotransposons, such as meH3K4, a hallmark of
active chromatin, instead of meH3K9? Finally, genomic instability, if it occurs early in the
tumorigenic process, may contribute to local (altered DNA sequence, for example) and global (i.e.
chromosomal gains, losses, or translocations) genome changes which either initiate or promote
mammary tumor progression in Waptag1 and human. (Certainly, the inhibition of Trp53/TP53
found in DCIS in both species supports the theory that genomic instability is an early occurrence.)
High-resolution array CGH analysis of DNA from laser-captured tumor cells throughout all stages
of Waptag1 tumor progression could help resolve questions regarding genomic stability changes
during tumorigenesis.
What transcriptional changes found early in Waptag1 tumor progression could aid the
understanding of a potential mechanism of aberrant expression of retrotransposons? Early in
tumor progression, a substantial down-regulation of stress responses and block of normal aerobic
respiration, lipid metabolism, and oxidoreductase activity occurs. The event(s) which initiate this
cascade of effects remain(s) largely unknown. However, speculation, based on available data
and the published literature may provide insight or offer hypotheses for future investigation of the
mechanisms underlying retrotransposon expression in early tumor progression.

91

DNA damage, specifically double-strand breaks that remain un-repaired, can instigate
expression and transposition of Short Interspersed Nuclear Elements (SINEs), which ultimately
results in genomic instability262. However, since SINEs have no reverse transcriptase enzymatic
activity, they depend upon Long Interspersed Nuclear Elements (LINEs) and/or other
autonomous retrotransposons for transposition. Indeed, results presented here demonstrate that
LTR and Non-LTR retrotransposons are actively transcribed. In addition, inhibition of Trp53/TP53
markedly accentuates this expression and transposition following DNA damage262. Our mouse
and human results both exhibit deregulated Trp53/TP53 activity. Furthermore, with over ten
percent of the human or mouse genomes composed of SINEs (at more than one million copies),
over 15% comprised of LINEs (at roughly 500,000 copies), alongside all the other
retrotransposons which, when combined constitute over one-third of the species DNA138,139,263,
perhaps it is a global mechanism by which SINEs are activated. Interestingly, a LINE1 element
knocked down in human melanoma cells showed subsequent down-regulation of human
endogenous retrovirus-K, implying that repetitive elements maintain a hierarchy, even during
tumorigenesis264. Finally, LINE1 retrotransposition flourishes in cancer cells, and others which
are dividing uncontrollably265. Hence, the up-regulation of cell cycle, DNA replication, etc. as well
as the loss of checkpoints provides an additional role in tumorigenesis by contributing to genomic
instability and LINE1 transposition. As shown in Table 5.4, LINE1 elements exhibit the highest
fold changes in Waptag1 mouse cells and human DCIS.
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3) genes
exhibit an inhibitory effect on mouse mammary tumor virus (MMTV) infection266, and therefore
their down-regulation may initiate or aid the unsilencing of retrotransposons. There are eight
members of the APOBEC3 human gene family (APOBEC3A-H), whereas mice only have one
gene (Apobec3). In mice, APOBEC3 (protein) binds to the MMTV capsid and is packaged into
virons; APOBEC3 decreases effective viral replication, largely through its cytidine deamination
activity266. In fact, Apobec3-/- mice show increased MMTV infection compared with littermates
harboring wild-type Apobec3266. In addition, work in HeLa and 293T cells showed that
APOBEC3A, 3B, 3F or 3G could inhibit LINE1 activity, including transposition267. At the transcript
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level, Apobec3 was up-regulated in samples throughout most stages of Waptag1 tumor
progression, as was APOBEC3B & 3C in the human samples. However, APOBEC3G was
substantially down-regulated in human DCIS as was APOBEC3F, to a lesser extent, compared
with normal breast tissue.
Adenosine deaminase enzymes are involved in gene silencing/unsilencing and function on
double stranded RNA structures. Abnormal RNA editing may contribute to alternative splicing
and subsequent multiple protein isoforms, increased variety of miRNAs, or suppression of RNAi
mechanisms and genomic instability268,269. Expression of the deaminase gene, Ada/ADA, is
significantly up-regulated within the specific cells of DCIS and tumors in Waptag1 and in human
DCIS1 and tumors. In fact, Ada/ADA is among the 63 genes predictive of poor prognosis in
human breast cancer (Table 4.3).
Alongside the retrotransposon transcriptional changes investigated at the global level here,
characterization of individual elements at the DNA level throughout all stages of tumor
progression would offer additional understanding of these elements. Specifically, is there new
transposition early in tumor progression that increases the level of retrotransposon gene
expression or is it simply an increase in the transcription of a finite number of elements within the
genome? Alternatively, it may be both. Since the copy number of Class I endogenous
retroviruses may be as low as a single genomic copy within the normal cell, quantitative
polymerase chain reaction (qPCR) probes and primers are being designed to investigate these
elements. Specifically, the copy number of Class I LTR elements MER34A1 and RLTR1C
retrotransposons will be analyzed by qPCR using DNA from tumor cells compared against that
from normal cells. A thorough quantitative analysis of the copy number changes of other classes
of retrotransposons, within cells of DCIS and tumors, compared against normal cells, will aid in
the understanding of these elements and help resolve these uncertainties.
In summary, besides putative retrotransposons (Table 5.4), several key genes, identified
through these analyses are significantly up-regulated in both species and may be suitable
candidates for future studies as early markers of DCIS, including the mitotic cell cycle/division
genes, Aurka/AURKA, Aurkb/AURKB, Bub1b/BUB1B, Cdc20/CDC20, and/or Kif11/KIF11, the
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DNA topoisomerase, Top2a/TOP2A, or the little known PCNA-associated factor,
2810417H13Rik/KIAA0101, the chromatin organization gene, Cenpa/CENPA, the ubiquitinconjugating enzyme, Ube2c/UBE2C, the receptor for hyaluronan-mediated motility,
Hmmr/HMMR, or the induced during growth factor-mediated cell survival gene, Spag5/SPAG5
(Table 4.3). Independent validation of these potential early markers, predictive of progression to
invasion, suggests that they are consistently up-regulated in human breast cancer and associated
with decreased survival (Figure 4.6). Since over two thousand transcriptional changes are
shared between human DCIS and the mouse model evaluated here, perhaps Waptag1 mice may
serve as an appropriate model for future studies aimed at detection of DCIS and/or therapeutic
intervention.
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Abstract
Epithelial to Mesenchymal Transition (EMT) is a common tumor phenotype in the FVB/NTg(WapMyc) 212Bri/J [Myc] mouse model of mammary carcinogenesis. In this study,
histopathology, immunohistochemistry and gene microarray analysis were used to characterize
EMT in this model. When compared with epithelial tumors exhibiting <1% EMT, genes overexpressed during early EMT (primary tumors with 13-50% EMT) showed significant enrichment in
cell-matrix adhesion molecules, extracellular matrix homeostasis, and angiogenesis, all classic
characteristics of EMT. Tumors with early EMT also exhibited decreased apoptosis, a feature
commonly associated with cancer; however, our findings of a cell cycle block and expression of
myoepithelial markers in early EMT are novel.
To better understand the transition toward an exclusively mesenchymal phenotype, in vivo
passage was used to generate epithelial cell-derived pure mesenchymal tumors. Analysis of
these spindle cell carcinomas (SCCs) confirmed an invasive molecular profile, including improved
vasculature and reduced apoptosis similar to early EMT. SCCs had a lower metastatic rate than
the epithelial carcinomas from which they were derived, a previously undescribed feature of EMT.
The reduced metastatic capability of SCC cells appears to result from their inability to access the
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blood stream since SCCs readily colonized the lungs when injected in the tail vein. Finally, SCCs
lacked expression of myoepithelial markers and the archetypal master regulators of EMT (Twist1,
Twist2, and Snai2), but had partially conquered the cell cycle block of early EMT, indicating that
early EMT and SCCs represent two distinct steps in cancer progression.

Introduction
Acquisition of the mesenchymal phenotype is a key stage in development and tumor
progression219,270,271. This process, termed epithelial to mesenchymal transition (EMT), is
coupled with invasion. Morphologic changes during EMT include loss of the cuboidal/polygonal
shaped epithelial cells and of cell-cell adhesions, gain of a spindloid morphology, and
transformation of the actin cytoskeleton and extracellular matrix (ECM) to enable motility.
Molecularly, EMT is associated with de novo expression of markers of mesenchymal cells such
as vimentin (Vim)272,273, markers of invasion such as S100a4, S100a6, and metalloproteinases274,
alongside concurrent loss of cell-cell adhesion markers such as Cdh1 (formerly E-cadherin)275,276.
Additional EMT-associated markers include members of the Snail, Twist, and Zeb families of
transcription factors, which directly inhibit Cdh1 transcription to promote EMT (reviewed in277).
At least three major signaling pathways have been implicated in EMT: the receptor tyrosine
kinase (RTK), transforming growth factor β (TGFB), and the WNT/β-catenin (CTNNB1) pathways
(reviewed in220,222). How these and other pathways may collaborate during EMT remains under
investigation276,277.
Transgenesis of the mammary gland–targeted myelocytomatosis oncogene (Myc) is amongst
the first and best described mouse models of carcinogenesis52,55,56, characterized by the
development of glandular and solid mammary adenocarcinomas. In recent years, tumors in this
model were found to be particularly prone to undergo EMT278,279. The value of Myc transgenic
models of mammary carcinogenesis is supported by the observation that human tumors with
EMT have genomic amplification of MYC58.
In the present study, Myc mammary carcinomas were examined using histology, microarrays,
and immunohistochemistry to characterize multiple stages of EMT. First, primary Myc tumors with
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EMT were compared to epithelial ones. Second, to further our knowledge of tumor progression
beyond EMT, in vivo passage was used to generate tumors comprised exclusively of either
mesenchymal cells (spindle cell carcinomas or SCCs), or pure epithelial tumors. Finally, tail vein
injection experiments evaluated the true metastatic ability of in-vivo passage tumors. Our results
indicate that tumorigenesis associated with EMT is a multistep process; several characteristic
markers of EMT are expressed only in early EMT but not in SCCs; and EMT hinders metastasis
in this model.

Methods
Primary Tumors. Hemizygous FVB/N-Tg(WapMyc)212Bri/J [Myc] mice55 were obtained
from The Jackson Laboratory (Bar Harbor, ME; stock #: 002677). Mice were aged (90-443 days)
until palpable mammary masses developed. Half of each tumor was collected in RNAlater
(Ambion, Austin, TX) and the remaining portion was fixed in Fekete’s acid-alcohol-formalin for
histology. The proportion of mesenchymal cells in 73 tumors from 41 mice was evaluated on
H&E stained sections using Photoshop 6.0 (Adobe, San Jose, CA). On the basis of
histopathology, three groups, each containing five carcinomas, were evaluated: the first group
contained neoplastic cells with an epithelial phenotype (5 tumors without EMT); the second group
featured <1% mesenchymal (spindloid) neoplastic cells (5 tumors); the third group, designated
“tumors with early EMT”, contained 13-50% neoplastic cells harboring a mesenchymal phenotype
(5 tumors with >12% EMT) in which four of these five tumors displayed large multifocal
coalescing areas of spindloid cells.
Mitotic rate was assessed in ten randomly-selected high power microscopic fields on whole
tumors and nucleolar size was estimated in 45-102 nuclei; in tumors with >12% EMT, spindloid
and epithelial portions were evaluated separately. Paraffin-embedded sections (5-6 μm thick)
were immunolabeled and graded for αSMA (Sigma, St. Louis, MO), COL4 (Chemicon,
Temecula, CA), K1, K5, K6, K10, K14 (BabCo, Richmond, CA), K17 (P. A. Coulombe, The Johns
Hopkins University, Baltimore, MD), K8/18 (Progen, Heidelberg, Germany), VIM (Biomeda, Foster
City, CA), cleaved caspase 3 (Cell Signaling Technology, Beverly, MA), and CCND1
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(Dakocytomation, Carpinteria, CA) as described previously278. A tumor was considered negative
for a marker if immunolabeling was detected in less than 10 cells within the tumor.
Generation of Tumors with a Pure Phenotype. Portions of tumors (n=18) arising from Myc
mice were collected aseptically to prepare cell suspensions while the remainder of the tumor and
the lungs were prepared for histology. For single cell suspensions, each tumor portion was finely
chopped in sterile phosphate buffered saline (PBS), incubated with 0.1% collagenase (Sigma, St.
Louis, MO) for 2-3 hours at room temperature, rinsed three times in PBS, and filtered through
Sefar Nitex 112 μm mesh (03-112/40; Sefar Holding, Rüschlikon, Switzerland). Single cell
suspensions (5,000-25,000 cells?) were injected in the gastrocnemius muscle of FVB.CgTg(ACTB-EGFP)B5Nagy/J (GFPU; The Jackson Laboratory; stock #: 003516) mice (n=2
mice/single cell suspension preparation) anesthetized with xylazine (19 mg/kg; Phoenix
Pharmaceutical Inc., St. Joseph, MO) and ketamine hydrochloride (95 mg/kg; Fort Dodge Animal
Health, Fort Dodge, IA). Mice were monitored bi-weekly until a tumor developed at the site of the
injection or for 2 months. Portions of these tumors were harvested, new single cell suspensions
prepared (as described above), and this process was repeated until three types of tumors with
pure phenotypes were obtained: glandular/trabecular, solid/comedo, and pure spindloid tumors
(designated as SCCs). Selected tumors were genotyped to ensure the passaged tissue
contained the Myc transgene. Tumor invasiveness was evaluated on H&E stained sections by
assessing entrapment of skeletal muscle fibers, nerves and adipocytes in randomly selected
SCCs (n=35) and solid/comedo carcinomas (n=35). Tumors selected for microarrays were
characterized by immunohistochemistry for the same markers as for primary tumors plus
tropomyosin (Chemicon).
In Vivo Tail Vein Metastasis Analysis. Single cell suspensions (5,000-25,000 cells) of
SCCs (n=58) and solid/comedo carcinomas (n=16; positive control) in a volume of 0.1 mL 0.9%
saline were injected intravenously (tail vein) or intra-muscularly (gastrocnemius muscle) into
anesthetized GFPU mice (2 mice for intravenous injections and 1 mouse for intramuscular
injections). The mice were monitored bi-weekly and euthanized when the mouse injected
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intramuscularly had a 10 mm in diameter tumor. Histology was performed on the intramuscular
tumor and on the lungs of all mice.
Microarrays. Treatment of tissue samples, RNA isolation, cDNA synthesis and labeling, and
hybridizations were performed as previously described187. Labeled samples were hybridized in
pairs, with the Universal Mouse Reference (Stratagene, La Jolla, CA), using a reference dyeswap method280 onto Compugen 22K mouse oligonucleotide microarrays. Mean intensity values
were used in subsequent statistical analysis. Microarrays were generated for 14 primary tumors
representing three phenotypes (4 without EMT, 5 with <1% EMT, and 5 with >12% EMT) and
separately for 15 tumors with a pure phenotype (5 glandular, 7 solid/comedo, 3 SCCs).
Microarray results for primary tumors were confirmed by quantitative reverse-transcriptase
polymerase chain reaction (QRT-PCR) for 12 genes representing various Gene Ontology (GO)
categories (Fig. 3C; Fig. 4).
Statistical Microarray Analysis. R/MAANOVA (http://research.jax.org/faculty/churchill/)
was used for analysis280. The mean channel intensities were imported into R and normalized
using lowess transformation. The Analysis of Variance (ANOVA) method was used to
decompose the channel intensities into an expression estimate for each tumor sample, after
accounting for Array and Dye effects280. For each experiment, differential expression among
tumor groups was tested by ANOVA using a fixed model. (For the in-vivo passage experiment,
pairwise contrasts were also performed to compare between any two groups.) For both
experiments, pooled permutation p-values of the Fs statistic were used176,281 to generate gene
lists using a false discovery rate (q≤0.05) adjustment for multiple testing and a fold change of ≥
1.2. Additionally, any gene with a relative fold change greater than 2.0 was included, regardless
of q-value193. Hierarchical clustering was carried out in JMP software (SAS Institute, Cary, NC).
Gene Ontology categories associated with significant genes were identified using Visual
Annotation Display (http://proto.informatics.jax.org/prototypes/vlad-1.0.3/). Pathway analyses
were performed using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA) or
GenMAPP 2.1 (Gladstone Institutes, San Francisco, CA). The data have been deposited in the
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Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/, under the accession GSE1498
(primary tumors) and GSE1533 (tumors with a pure phenotype).
Quantitative Reverse Transcriptase-Polymerase Chain Reaction (QRT-PCR). Total RNA
(the same RNA isolated and analyzed on the microarrays) from each sample was DNAse treated
(DNA-freeTM, Ambion) prior to cDNA synthesis. Using both random hexamers and oligo dT
primers, cDNA was synthesized from 1μg aliquots as described for First-Stand cDNA Synthesis
using random primers (SuperscriptTM III, Invitrogen Corp., Carlsbad, CA). A Ctnnb1 PCR (with
primers spanning intron/exon boundaries) was used to test for genomic contamination. For each
gene, Assays-on-DemandTM Gene Expression Products (Applied Biosystems, Foster City, CA)
were used to compare cDNA from tumors with >15% EMT (experimental) versus tumors without
EMT (control). For each QRT-PCR of each gene, cDNA from the equivalent of 2ng total RNA
(prior to DNAse treatment) was used. Accurate expression changes were determined using the
Δ, ΔCT method (User Bulletin #2, http://www.appliedbiosystems.com) and H3f3b as the
endogenous control (normalizer), which showed constant expression across all samples. (H3f3b
was not significant via microarray results either; in tumors with early EMT, H3f3b showed a fold
change of one, compared to tumors with no EMT.) Delta, ΔCT values were averaged from two
independent experiments (Figure A4), run on 7700 and 7500 Sequence Detection Systems, with
three replicates for each gene and each tumor per run.

Results
Histological and Immunohistochemical Characterization of Spindle Cells of Early EMT.
Acquisition of the mesenchymal phenotype was accompanied by the loss of glandular/trabecular
organization and the formation of bundles and fascicles (Fig. A1, D-F versus A-C). Tumor cells
with an epithelial phenotype were polygonal with a basophilic cytoplasm, with round nuclei
containing 1-5 large nucleoli. Tumor cells with a mesenchymal phenotype were spindloid with
acidophilic cytoplasm and their nuclei were oval to elongated containing 1-3 small nucleoli.
Spindloid cells accounted for 32% ± 19% of the five tumors studied (>12% EMT; Fig. A1D-F).
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Primary epithelial tumors expressed little or no markers of myoepithelial cells: keratin 5, K5 (0/4),
K6 (0/4), K8/18 (0/4), K14 (1/4), and K17 (0/4) (data not shown). In contrast, spindloid cells in
tumors with early EMT expressed keratins 5 (3/5), 6 (2/5), 8/18 (5/5), 14 (4/5), 17 (4/5), α-smooth
muscle actin (4/5), vimentin (4/5), and were surrounded by collagen type IV (Fig. A1G-M). Thus,
early EMT is associated with expression of terminal differentiation markers typical of
myoepithelial cells, de novo expression of vimentin, a hallmark of mesenchymal cells, and
increased ECM as assessed by collagen type IV.
In Vivo Selection Identifies Multistep Tumor Progression. To gain insight into tumor
progression changes following EMT, we generated tumors with a pure phenotype through intramuscular injection, serial passage and selection. Sequential morphologic steps of tumor
progression were represented: (1) glandular carcinomas, composed of epithelial cells that
formed trabeculae, cords and glands (Fig. A2A); (2) solid/comedo carcinomas, composed of
epithelial cells that formed large solid areas with central necrosis, which arose from glandular
carcinomas (Fig. A2B); (3) SCCs which arose from solid/comedo tumors and were composed of
spindloid cells of epithelial origin that formed bundles and fascicles (Fig. A2C). Unlike early EMT
tumors, neoplastic cells in SCCs showed no expression of epithelial or myoepithelial markers;
indeed, among these, only vimentin was expressed (immunohistochemistry data not shown).
Early EMT Tumors and SCCs Are Molecularly Distinct from Epithelial Tumors.
Hierarchical clustering of ANOVA expression estimates adequately identified the histological type
of all but two primary tumors, Samples 12 and 13 (Fig. A3A). Sample 12, with >12% EMT,
showed EMT in only one of its lobes and clustered with tumors without EMT, suggesting that an
epithelial portion of this tumor may have been processed for RNA; EMT was multifocal in the
other four tumors with >12% EMT. Similarly, Sample 13, without EMT, clustered with tumors
showing <1% EMT (Fig. A3A). In light of these findings, we classified tumors into two groups (5
with >12% EMT and 9 with <1% EMT); the pairwise comparison between these identified 526
unique genes of 536 clones differentially expressed (Fig. A3B; Table S12).
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Figure A1. Tumors Arising in Mice Transgenic for Myc generally have an epithelial phenotype
(A-C) but may also comprise large areas of spindloid neoplastic cells (D-F; hematoxylin & eosin).
The ratio of epithelial (red) and spindloid neoplastic cells (green) to stroma (yellow) and the areas of
necrosis (blue) was evaluated by image analysis (B, E). Compared to epithelial neoplastic cells (*),
spindloid neoplastic cells show stronger expression of: keratins 5 (G), 8/18 (H), 14 (I), and 17 (J);
α-smooth muscle actin (K); vimentin (L); and cyclin D1 (N). Areas composed of epithelial cells
contain less collagen type IV (M) and show more apoptosis (O) than the spindloid portions of the
tumors. Bar is 4.25 mm (A-B), 107 μm (C,F-N), 3.9 mm (D-E), and 215 μm (O).
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When compared with epithelial tumors, EMT tumors displayed over-expression of classical
markers of EMT: transcriptions factors Snai2, Twist1, Twist2, Zeb1 and Zeb2277; and Vim272,273
(Fig. A4; Table S12).

Figure A2. Tumors with a Pure Phenotype Generated Through Serial In Vivo Passage from
epithelial cell suspensions. Representative histological phenotypes for glandular (a), solid/comedo
(b), or spindloid (c) tumors are shown. [Hematoxylin & eosin stain; scale is 10x.]

In SCCs, 3,258 unique genes of 3,360 clones were differentially expressed in the pairwise
contrast with epithelial tumors (Table S42). Conventional markers of EMT (Snai1, Zeb1, Zeb2
and Vim) were abundantly over-expressed while Cdh1 was down-regulated, as expected (Table
S1, S42). However, some other classical EMT markers observed in early EMT were not
differentially expressed in SCCs, specifically Twist1, Twist2 and Snai2.
EMT is Associated with Altered Expression of Adhesion Molecules and ECM
Homeostasis Genes. Extracellular matrix production and remodeling are hallmark features of
EMT and suggest progression towards an invasive phenotype220,274,282-284. Indeed, the GO
categories related to cell adhesion, the ECM, basement membrane, actin cytoskeleton, and
collagen were enriched in early EMT tumors and SCCs (Fig. A3C; Fig. A4; Table S1, S2, S42).
Tumors with early EMT and SCCs over expressed genes with metalloproteinase activity (Mmp2,
3, 9, 13, and 14, and Bmp1) as well as Timp1, Timp2, Timp3, Fbln1, Fbln2, and Efemp2 (Fig. A4;
Table S1, S42), demonstrating the importance of maintaining homeostasis of the ECM; upregulation of some of these is associated with cell migration in EMT285. Contributing to cell
motility283,284, tumors with early EMT and SCCs over-expressed numerous ECM genes or proteins
and their cell surface receptor (Fig. A1M; Fig. A4; Table S12): membrane receptor nidogen 1 and
its ECM binding partners laminin 1 and collagen type IV286; ECM constituent fibronectin (FN1)
with its receptor the heterodimer ITGB1/ITGA5287; fibronectin, biglycan, and decorin, which may
bind collagen and/or thrombospondin; and Thbs1 and Thbs2, that are also markers of invasion287.
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Figure A3. Microarray Results Across 14 Early Epithelial to Mesenchymal Transition (EMT)
Myc Tumors. (A) Hierarchical clustering of ANOVA estimates. Tumors branched into three
clusters: one group was comprised of only tumors with >12% EMT (green highlight); light red
highlighting identifies exclusively epithelial cell tumors; no highlighting designates the tumors with
minimal EMT; (B) When organized into two groups (tumors with >12% EMT and tumors with <1%
EMT), 526 differentially expressed genes were identified (blue marks; q≤0.05); (C) Gene Ontology
analysis of Biological Process, Molecular Function, and Cellular Component categories over
represented in the 526 gene list compared to all genes in Mouse Genome Informatics
(www.informatics.org). [Darker color rectangles indicate greater significance. Shown in parenthesis:
p-value, # of genes analyzed this experiment, # of GO annotated genes background set. The
complete list of statistically significant GO categories is presented in Supplemental Table S22.]
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Other reported markers of cell motility/invasiveness, such as Cd97, Lox, Loxl1, Loxl2, Plaur,
S100a6, Tnc, and Sparc were up-regulated during early EMT and in SCCs (Fig. A4; Table S1,
S42). Additional GO categories significantly enriched in SCCs, when compared to pure epithelial
tumors, indicated increased invasiveness and ECM remodeling (Table S22). In SCCs only, the
epithelial adhesion molecules Cdh1 and claudins Cldn1, Cldn3, and Cldn7 were down-regulated
(Table S32), while mesenchymal adhesion molecules, such as Spp1, and a marker of invasion
S100a4, were up-regulated (Table S42).
Spindloid Cells are Less Proliferative than Epithelial Cells. Tumors with >12% EMT
showed a lower mitotic rate (116 ± 44 [average ± standard deviation] mitoses per 10 high power
fields) than tumors with <1% EMT (173 ± 62; t-test, p=0.03).
This difference in mitotic rate was directly attributable to a low mitotic rate in spindloid
neoplastic cells (9 ± 6) compared to the epithelial cells (190 ± 47; t-test, p<0.001). Consistent
with a higher mitotic rate288, epithelial neoplastic cells had a larger nucleolar area (8.3±1.9 μm2)
than spindloid neoplastic cells (3.7±1.2 μm2; t-test, p=0.03).
In total, 32 cell cycle genes were differentially expressed in early EMT tumors, thirteen of
which were negative regulators of the cell cycle (Fig. A3C; Fig. A4; Tables S1, S2 and S52).

Figure A4. Quantitative RT-PCR Expression Profile of Early EMT Tumors. Relative expression
differences [(-) Log2] in 12 genes across three tumors with epithelial to mesenchymal transition
(EMT; 15%, 60%, and 40%), compared to epithelial tumors (No EMT). [See methods for details.]
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Hspa8, Cdkn1a, Cdkn2a, Ccnd1, and Ccnd2, which control passage through G1289,290, were upregulated in early EMT tumors (Fig. A4; Table S12), and expression was confirmed at the protein
level (CCND1, Fig. A1N). The mRNA levels of S phase cyclin A were similar in tumors with and
without EMT. G2 or G2/M transition genes, such as Gadd45a (G2/M arrest), Plk3 (G2
progression), Cdkn2a, Cdkn1a, and/or transcriptional regulators, Usf1 and Elk3, were upregulated in early EMT compared to epithelial tumors, whereas Atm was under expressed (Fig.
A4; Tables S1, S52). These data and Ingenuity Pathway Analysis (Table S22) suggest that the cell
cycle block may occur in G2/M.
Spindloid cells in SCCs showed a higher mitotic rate (113 ± 35, n=11) than in early EMT
primary tumors (9 ± 6, n=5), but a lower rate than pure epithelial tumors (227 ± 43; t-test,
p<0.001). Molecularly, SCCs showed enrichment of genes involved in cell activation and cell
growth (Table S22) and Cdkn1a, a key cell-cycle progression regulator up-regulated in early EMT,
was not differentially expressed in SCCs (Table S42). Thus, the mechanism underlying cell cycle
arrest in early EMT was partly but not entirely abrogated in SCCs.
EMT is Associated with Increased Vascularization and Decreased Apoptosis. Large
areas of epithelial tumors are physiologically avascular due to a basement membrane separating
neoplastic cells from the stroma and the piling-up of tumor cells within comedo areas. Indeed,
tumors with early EMT and SCCs presented substantially better vascularization than epithelial
tumors, histologically and transcriptionally; genes involved in angiogenesis and vasculature
development were up-regulated (Fig. A3C; Table S1, S2, S42). Better vascularization in spindloid
areas may provide a less hypoxic environment than in epithelial areas, thereby limiting apoptosis
in spindloid regions. Histopathological analysis of H&E sections and cleaved caspase 3
expression identified more apoptosis in epithelial regions than spindloid areas of tumors with
early EMT (Fig. A1O). The following gene changes supported decreased apoptosis in early EMT:
Cycs, a caspase activator, was down-regulated, and Cdkn1a and Trp63, both negative regulators
of apoptosis, were up-regulated (Table S12). Additionally, regulation of apoptosis genes were
enriched in early EMT tumors and SCCs, when compared to epithelial tumors, and the GO term
positive regulation of apoptosis was significantly over-represented among genes up-regulated in
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SCCs (Table S1, S2, S42). Calcium ion-binding genes and the calcium-ion homeostasis gene
Cav1, which regulate apoptosis and angiogenesis291, may contribute to decreased apoptosis in
early EMT and SCCs (Fig. A3C; Fig. A4; Table S1, S2; S42).
TGFB and RTK pathway activation and signaling during EMT. GO, Ingenuity and
GenMAPP analyses identified features that were undetectable histologically. First, genes in the
TGFB pathway were enriched in SCCs and predominantly up-regulated compared with epithelial
tumors (Fig. A5). Over-expression of TGFB downstream targets (Snai1, Zeb1, Zeb2, Hmga2 and
Tgfbi) further supported this hypothesis (Table S42). Second, genes with receptor tyrosine
activity were over represented in SCCs, according to analysis by both Ingenuity and GO (Table
S2, S42). For example, transcription of Akt1, Angpt1, Epha2, Fgfr1, Lox, and Pdgfrb was
significantly up-regulated in SCCs versus epithelial tumors (Table S42). Additionally, Cdh1,
inhibited by the RTK and TGFB pathways during EMT, was down-regulated in SCCs (Table
S42)220I,292. Finally, lack of significant and critical WNT/CTNNB1 genes argued against
WNT/CTNNB1 signaling during EMT in Myc tumorigenesis (Fig. S1, Table S42).
Tumor Metabolism changes in early EMT and SCCs. A dramatic shift in the metabolism of
SCCs compared to pure epithelial tumors was identified through microarray analysis: compared
to epithelial tumors, genes involved in oxidative phosphorylation, electron carrier activity,
carboxylic acid metabolism, amino acid metabolism, ubiquinone biosynthesis and pyruvate
metabolism were down-regulated (Tables S2, S42). Some of these GO terms were significant in
early EMT as well (Tables S1, S22). Concurrently, there was down-regulation of mitochondrionrelated GO categories in SCCs and to a lesser degree in early EMT (Table S22). Taken together,
these changes suggest a shift from mitochondrial respiration to aerobic glycolysis.
Spindle Cell Carcinomas Are More Invasive But Less Metastatic Than Solid/Comedo
Carcinomas. SCCs were more invasive than solid/comedo carcinomas from which they were
derived, as assessed by entrapment of skeletal muscle fibers (32/35 versus 2/35; χ2 test,
p<0.001), nerves (20/35 vs. 10/35; p<0.05), and adipocytes (21/35 vs. 6/35; p<0.001; Fig. S22).
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Figure A5. GeneMAPP Visualization of the Transforming Growth Factor β (TGFB) Pathway. Genes
primarily up-regulated (red shading) in spindle cell carcinomas compared to epithelial tumors. (Blue
shading indicates down-regulation; green shading, genes not present on Compugen microarrays; no
shading, not significantly up- or down-regulated.)

However, SCCs (1/170) and glandular carcinomas (0/41) were less metastatic than solid/comedo
carcinomas (32/173) as assessed histologically by the presence of pulmonary metastases (or by
radiography 0/24; Supplemental Methods). Tail vein injections of single cell suspensions
demonstrated that the reduced metastatic rate in SCCs compared with solid/comedo tumors was
not due to the lack of metastatic capability, inability to survive in the blood, or failure to develop
tumors in the lungs. In fact, intravenous injections of single cell suspensions of SCCs caused the
development of tumors in the lungs more frequently (n=41/58) than that of solid/comedo
carcinomas (n=7/16, χ2 test, p<0.05).
Discussion
The aim of this study was to characterize EMT in a mouse model of mammary
carcinogenesis by assessing early EMT in primary Myc tumors and confirming our findings in
SCCs generated by serial in vivo passage. Two unanticipated phenomena were found in this
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model: first, early EMT is associated with cell cycle arrest; and second, spindle cell carcinomas
in late EMT had a lower incidence of metastases than less progressed solid/comedo (epithelial)
carcinomas.
Our observation that early EMT is associated with decreased cell cycling is paradoxical
because it implies that an important step in tumor progression is unfavorable to cell proliferation.
This observation is mirrored by in vitro studies where TGFB-induced EMT in human and mouse
epithelial cells induces growth arrest293,294. One major cause of cell cycle arrest is DNA damage.
However, karyotyping of SCCs failed to identify consistent, reproducible chromosomal
abnormalities in these tumors (data not shown). The dramatic reduction in cell cycling observed
in early EMT was partially overcome in SCCs. Importantly, Cdkn1a, a critical anti-proliferative
signal for cyclin dependent kinases, was abundantly over-expressed in early EMT but not
significant in SCCs, suggesting it may be a key molecule in recovery from this transitory cell cycle
block. Evaluation of other models of EMT is necessary to determine if decreased cell cycling is
unique to the model presented here.
SCCs were less metastatic than solid/comedo tumors from which they were derived, in spite
of increased vascularization, decreased expression of epithelial cell-cell adhesion genes, and
enhanced invasiveness. Tail vein injection experiments, however, established that SCC cells
could readily colonize the lungs. Therefore, the lack of metastatic spread in SCCs, growing in the
gastrocnemius muscle, is likely due to the inability of neoplastic spindloid cells to access the
vasculature and/or to embolize in spite of the rich vascularization of the skeletal muscle.
Additionally, an appropriate tumor-cell niche is critical for progression to metastatic invasion.
These observations, supported by others224,292, suggest that EMT and metastasis are uncoupled
tumorigenic processes.
Tumors with early EMT did not down-regulate epithelial adhesion molecules, with the
exception of Ceacam1, whilst SCCs did (Fig. A4; Table S32). Lack of down-regulation of the
prototypical epithelial marker Cdh1 in early EMT may be a limitation of the Compugen microarray
platform because Cdh1 was down-regulated in subsequent experiments using a different
platform295. Alternatively, a decrease of Cdh1 may have been obscured by the epithelial
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component of early EMT tumors or by high within-group variation. Indeed, raw ANOVA estimates
revealed that three of five primary tumors with >12% EMT showed down-regulation of Cdh1 when
compared to tumors without EMT.
Decreased apoptosis during early EMT and in SCCs was prominent histologically and
immunohistochemically. As one of Weinberg and Hanahan’s “Hallmarks of Cancer” diversion
from apoptotic mechanisms is necessary for successful tumor progression11. Increased
vasculature in early EMT and SCCs, identified histopathologically and transcriptionally, may limit
apoptosis. Additionally, regulation of apoptosis and calcium-ion binding genes were enriched in
early EMT and SCCs compared to epithelial tumors (Table S22); the latter group of genes my
enhance buffering to decrease calcium-ion mediated apoptosis291. Genes differentially expressed
and GO terms enriched in early EMT (Fig. A3C; Fig. A4; Table S12) and SCCs (Table S2 and
S42) support this hypothesis.
Transcriptional profiling identified striking metabolic differences for tumors with early EMT
and SCCs compared to epithelial tumors: genes involved in the generation of precursor
metabolites and energy and nuclear mitochondrial genes were down-regulated compared with
epithelial tumors. These previously undescribed findings for EMT may be the effect of increased
vascularization, a decrease in the number of mitochondria, or evidence of the Warburg effect, a
switch in the bioenergetics of tumor cells from normal mitochondrial respiration to aerobic
glycolysis/lactic acid fermentation213. This shift in energy production even in the presence of
oxygen is anticipated to provide a selective advantage to tumor progression12,211,213. Drugs which
exploit this phenomenon are currently in clinical trials (for review12,296).
The RTK, TGFB, and WNT/CTNNB1 pathways have been implicated in EMT. Data
presented here supports TGFB and RTK signaling pathways, at the transcriptional level, in SCCs.
Although the activation events remain unclear, post-transcriptional or post-translational
modifications, such as deregulated microRNAs no longer repressing their targets or epigenetic
alterations to histones, may alter master regulatory molecules, thereby initiating one or both of
these signal transduction pathways. Indeed, two independent labs recently showed in vitro how
the miR-200 family of microRNAs hinders TGFB-induced EMT through targeting Zeb1 and
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Zeb2297,298. In vitro exposure of SCC cells to drugs or siRNA, transfection with miRNAs, or in vivo
treatment with small molecule inhibitors targeting these pathways may uncouple the effects of
TGFB from those of RTK signaling to unravel the initiating events of signal transduction in EMT.
In summary, the findings presented here further our understanding of EMT during mammary
carcinogenesis in three important ways. First, EMT is a dynamic multi-step process: early EMT
is characterized by expression of myoepithelial markers, increased cell motility, invasiveness, and
vasculature, decreased apoptosis, and cell cycle arrest. Progression from early EMT to SCCs is
accompanied by the loss of myoepithelial markers, partial release from cell cycle block, significant
over-expression of cell growth and proliferation genes, enhanced invasion, and cooperation of
TGFB and RTK signal transduction. Second, classical markers of EMT may not represent late
EMT tumor progression: while over-expressed and highly significant in early EMT, Twist1,
Twist2, and Snai2 were not significant in SCCs. Third, in this model, metastasis was hindered by
EMT; tumor cell microenvironment and access to the blood stream substantially affected the
ability of neoplastic cells to metastasize. Evaluation of other models of EMT is needed to
determine whether these characteristics are universal or are unique to the multi-step model of
EMT tumorigenesis described herein.
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